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In	 2016,	 there	 were	 244	 new	 HIV	 infections	 in	 New	 Zealand;	 this	 is	 the	 fifth	
consecutive	 year	 of	 rising	 infection	 rates,	 and	 the	 largest	 number	 of	 new	 diagnoses	
reported	since	records	began	 in	1985.	 In	New	Zealand,	men	who	have	sex	with	men	
(MSM)	 can	 account	 for	 up	 to	 80%	 of	 new	 HIV	 diagnoses	 yearly.	 Until	 now,	 HIV	
prevention	has	focused	on	behavioural	methods,	such	as	condom	use,	abstinence,	and	
serosorting.	However,	recent	trials	show	that	a	new	biomedical	method,	pre-exposure	
prophylaxis	 (PrEP),	 is	more	 than	90%	effective	at	preventing	HIV	acquisition	among	
HIV-negative,	at-risk	individuals	when	taken	daily.	Unfortunately,	PrEP	is	not	a	silver	
bullet	 for	 HIV,	 as	 cited	 complexities	 associated	 with	 PrEP	 include	 potential	
antiretroviral	 resistance,	 side	 effects,	 cost,	 stigmatisation,	 and	 risk	 compensation.	
Therefore,	 this	 research	 aimed	 to	 answer	 the	 following	 questions:	 Do	 MSM	 from	
Canterbury	feel	that	PrEP	has	a	place	in	New	Zealand’s	public	health	system,	and	how	
could	 a	 policy	 be	 developed	 to	 minimise	 the	 difficulties	 regarding	 implementation	
faced	overseas?	Following	Carol	H.	Weiss’s	problem-solving	model,	 this	 thesis	uses	a	
multiple,	 mixed-methods	 approach	 to	 reduce	 uncertainty	 regarding	 HIV	 prevention	
and	treatment	attitudes	(specifically	regarding	PrEP)	among	a	particular	cohort	(MSM)	
and	 thus,	 informs	 more	 effective	 future	 policies.	 The	 methods	 used	 are	 a	 survey,	
interviews,	and	document	analysis.		
The	 first	 research	question	was	answered	using	an	anonymous,	online,	Likert	
scale	 survey.	 Participants	 were	 recruited	 using	 non-probability	 purposive	 sampling.	
42	MSM	from	the	Canterbury	region	were	surveyed	to	measure	their	attitudes	towards	
HIV,	PrEP	and	condom	use.	100%	of	participants	agreed	that	taking	PrEP	is	a	good	way	
to	 reduce	 their	 chances	of	HIV	 infection,	 100%	of	participants	 agreed	 that	PrEP	 is	 a	




This	 policy	 is	 designed	 specifically	 to	 fit	within	New	 Zealand’s	 public	 health	 system	
and	 is	 informed	 by	 the	 grassroots	 input	 and	 empirical	 evidence	 collected	 through	
interviews	with	 HIV	 experts,	 survey	 data,	 and	 document	 analysis.	 PrEPared	 Against	
HIV:	2.0	pays	specific	attention	to	 ‘PrEP	problem	areas’	such	as	developing	adequate	
clinical	 guidelines,	 ensuring	 PrEP	 providers	 receive	 adequate	 support,	 encouraging	
adherence,	and	reducing	stigmatisation	linked	to	PrEP	use.	This	research	shows	there	
is	a	need	 for	greater	 investment	 in	HIV	prevention	rather	 than	costly	HIV	treatment.	
PrEP	 can	 reduce	 future	 HIV	 infections	 and	 there	 is	 obvious	 support	 from	 both	 HIV	
experts	 and	MSM	 for	a	PrEP	policy	 in	New	Zealand.	However,	PrEP	needs	 to	be	one	




























































































































that	 has	 the	 potential	 to	 alter	 the	 course	 of	 the…	 HIV	 epidemic	 today.”	 –	 Jonathan	
Mermin,	Center	for	Disease	Control	and	Prevention.1	
	
2016	 saw	 record	 levels	 of	 new	HIV	 infections	 in	New	Zealand	 since	 epidemiologists	
began	 tracking	 the	 virus	 in	 1985.	 New	 Zealand’s	 current	 and	 past	 HIV	 prevention	
strategy	 has	 relied	 solely	 on	 behavioural	 methods,	 however,	 recent	 scientific	 trials	
have	 shown	 that	 pre-exposure	 prophylaxis	 (PrEP)	 is	 effective	 at	 preventing	 the	
transmission	 of	 HIV.	 The	World	 Health	 Organization	 (WHO)	 has	 recommended	 that	




policy	 solution.	 Multiple,	 mixed-methods	 were	 used	 to	 gain	 an	 understanding	 of	
attitudes	 towards	 PrEP,	 and	 explore	whether	 the	medication	 could	 be	 implemented	
effectively	while	managing	the	complications	that	have	occurred	overseas.		
Chapter	 1	 surveys	 the	 known	 science	 on	 HIV	 and	 discusses	 a	 brief	 political	





cells	 in	 the	body’s	 immune	system.	Once	an	 individual	 is	 infected	with	HIV,	 they	will	
remain	infected	for	the	rest	of	their	life.	HIV	specifically	attacks	the	CD4	lymphocyte	T	
cells	 (also	known	as	T-helper	cells,	CD4	cells	or	T4	cells),	which	 the	 immune	system	
uses	 to	 fight	 off	 infections.2	HIV	 uses	 ribonucleic	 acid,	 RNA,	 as	 genetic	 material	 to	
overcome	the	CD4	cells.	A	simplified	definition	of	the	early	stages	of	HIV	states:	
	
CD4	 T	 cells	 are	 pivotal	 to	 generating	 effective	 immunity	 against	 invading	





This	 transition	 signals	 that	 HIV	 has	 turned	 into	 AIDS,	 Acquired	 Immune	 Deficiency	


















or	 groups	 (M,	 N,	 and	 O);	 there	 are	 eleven	 subtypes	 of	 the	 virus	 (A-K,	 and	 U	
(unclassified))	 in	 group	M	of	HIV-1.10	There	 are	 eight	 groups	of	HIV-2	 (A-H).11	All	 of	
the	subtypes	of	the	HIV-1	virus	can	share	genetic	information	with	one	another,	thus	
resulting	 in	 a	 continually	 increasing	 number	 of	 HIV-1	 combinations.12,	13	Therefore,	
HIV	 is	 considered	 much	 more	 complex	 than	 other	 common	 viruses	 that	 infect	 the	
human	body.	Furthermore,	HIV	is	more	lethal	because	according	to	Crawford,	
	
It	works	 by	 stealth,	 silently	 entering	 the	 body	 and	wiping	 out	 the	 very	 immune	
defences	 that	 have	 specifically	 evolved	 to	 fight	 such	 invaders.	 Without	 modern	





	 HIV	 is	 spread	 person-to-person	 through	 blood,	 pre-seminal	 fluid,	 semen,	
vaginal	 fluid,	 rectal	 fluid,	 and	 breast	milk.15,	16,	17	However,	 for	 transmission	 to	 occur	
these	body	fluids	must	come	into	contact	with	a	mucous	membrane	or	damaged	tissue,	



























the	 nose,	 mouth,	 genital	 areas	 and	 anus.	 The	 most	 common	 method	 of	 HIV	
transmission	is	through	vaginal	or	anal	sexual	intercourse,	and	the	chances	of	infection	
increases	 with	 unprotected	 sexual	 intercourse.	 Sharing	 or	 reusing	 needles	 used	 to	
inject	 drugs	 and	 needle-stick	 injuries	 can	 also	 spread	 HIV.	 Due	 to	 the	 numerous	
methods	of	 transmission,	HIV/AIDS	can	affect	multiple	groups	 in	society.	Those	who	
have	a	higher	risk	of	contracting	HIV/AIDS	are:	gay	and	bisexual	men/men	who	have	






virus.	 During	 this	 period,	 the	 virus	 is	 produced	 in	 large	 quantities	within	 the	 body,	
which	 causes	 the	 CD4	 cell	 count	 to	 drop	 dramatically.20	HIV-positive	 individuals	 are	
most	 infectious	during	 the	 acute	HIV	 infection.	Once	 these	 symptoms	disappear,	 the	
infection	has	progressed	to	the	clinical	latency	stage.	HIV-positive	individuals	may	feel	
and	 look	 healthy	 for	 many	 years	 without	 symptoms	 or	 realising	 their	 HIV-positive	
status.21,	22,	23	The	virus	still	 replicates	within	 the	body	but	at	much	 lower	 levels.	HIV	
can	remain	at	this	stage	with	antiretroviral	therapy	(ARTs),	which	keeps	HIV-positive	
individuals	 healthy	 and	 lowers	 their	 chances	 of	 spreading	 the	 virus	 to	 others.24	
Furthermore,	 an	 HIV	 diagnosis	 is	 no	 longer	 a	 death	 sentence,	 as	 an	 HIV-positive	
individual	 has	 a	 high	 chance	 of	 living	 just	 as	 long	 as	HIV-negative	 individuals	when	
following	 the	 correct	 ART	 schedule.25	As	 a	 result,	 there	 has	 been	 an	 increase	 of	HIV	
infections	 worldwide	 but	 a	 decrease	 in	 the	 number	 of	 AIDS-related	 deaths.26,	27	The	
final	 stage	 of	 HIV	 is	 AIDS,	 where	 the	 CD4	 cells	 are	 significantly	 lowered	 or	 the	
individual	has	one	or	more	opportunistic	infections	or	cancers.		
	 Due	to	HIV’s	ability	to	continually	mutate	the	possibility	of	an	effective	vaccine	























Until	 more	 advanced	 medical	 treatments	 are	 developed	 to	 eradicate	 HIV/AIDS,	
education	 and	 prevention	 campaigns	 remain	 the	 best	 approaches	 of	 reducing	 this	
pandemic.			
HIV/AIDS	and	MSM	
MSM	 is	 one	 of	 the	most	 common	 terms	 used	 in	HIV/AIDS	 literature	 since	 the	 early	
1990s.30	While	 labels	 such	 as	 homosexual,	 gay,	 bisexual,	 queer,	 and	 transgender	 can	
carry	a	stigma	in	the	broader	society,	MSM	attempts	to	cover	a	range	of	individuals	by	
only	 categorising	 their	 sexual	 behaviour.31 ,	 32 	For	 example,	 ‘gay/homosexual	 and	
bisexual	men’	does	not	include	men	who	are	not	open	about	their	sexuality	or	have	to	




HIV	 infection	 transmission	 is	 not	 equal,	 as	 some	 behaviour	 is	 more	 likely	 to	
pass	on	the	virus	than	others.	In	every	area	where	HIV	statistics	are	available,	MSM	are	
overrepresented	 compared	 to	 the	 rest	 of	 the	 population.35	For	 example,	 studies	 of	
sexual	health	clinics	have	shown	that	MSM	are	40	times	more	likely	to	have	HIV	than	
heterosexual	 men	 and	 women	 in	 New	 Zealand.36	MSM	 accounted	 for	 80%	 of	 HIV	
diagnoses	 in	2014,	despite	making	up	only	2.5%	of	New	Zealand’s	population.37	The	
incidence	 of	 HIV	 infections	 in	 MSM	 is	 “not	 an	 accident	 of	 history,	 but	 a	 real	
phenomenon”	 and	 there	 are	 multiple	 reasons	 for	 this	 higher	 prevalence	 of	 HIV.38	

























transmitted	 infections	 (STIs)	 are	 likely	 to	 spread	 faster	 than	among	heterosexuals.39	
Thirdly,	male	 homosexual	 relationships	 allow	 both	men	 to	 partake	 in	 receptive	 and	
insertive	 sexual	 intercourse.	 In	 the	 2002-2006	 Gay	 Auckland	 Periodic	 Sex	 Surveys	
(GAPSS),	 more	 than	 50%	 of	 males	 reported	 both	 insertive	 and	 receptive	 anal	
intercourse	with	a	regular	partner	or	casual	partner	in	the	past	six	months.40	Thus,	the	
flexible	 nature	 of	 anal	 sexual	 intercourse	 between	 men	 increases	 the	 chances	 of	
becoming	infected	and	subsequently	passing	HIV	onto	other	sexual	partners.41	Finally,	
MSM	 continue	 to	 report	 high	 numbers	 of	 casual	 sexual	 partners.42,	43 ,	44,	45	While	
reports	of	more	 than	10	 sexual	partners	 in	 six	months	 are	 generally	decreasing,	 the	
2002-2014	 GAPSS	 shows	 that	 more	 than	 one	 in	 five	 men	 have	 at	 least	 11	 sexual	
partners	in	six	months.	46	It	is	argued	that	if	the	unprotected	anal	intercourse	between	






was	 a	 link	 between	 HIV	 and	 AIDS	 because	 of	 the	 long	 period	 between	 the	 initial	
infection	and	when	the	virus	manages	to	deplete	the	body	of	enough	CD4	cells	or	cause	
an	opportunistic	infection.	As	a	result,	the	history	of	HIV	is	complicated.	The	following	




























epidemiological	 publication	 for	 health	 professionals	 around	 the	 USA.48	At	 this	 stage,	




and	 in	 night	 clubs).50	It	was	 also	 initially	 thought	 to	 be	 a	 sexually	 transmitted	 virus	
among	homosexual	men.51		
It	 was	 not	 until	 doctors	 in	 Africa,	 London,	 Paris,	 Copenhagen	 and	 other	
European	nations	 found	patients	with	 similar	 symptoms	 that	 the	 extent	 of	 the	AIDS	
disease	 became	 known.	 It	 became	 clear	 that	 AIDS	 was	 a	 “new,	 inexplicable	
epidemic.”52	As	with	the	Spanish	flu,	poliomyelitis	virus,	and	severe	acute	respiratory	
syndrome	 (SARS),	 the	 spread	 of	 HIV/AIDS	 was	 greatly	 facilitated	 by	 access	 to	 air	
travel.53,	54	Gaëtan	 Dugas,	 also	 known	 as	 Patient	 Zero,	 a	 Canadian	 air	 steward,	 was	
originally	 linked	 to	 the	 initial	 spread	 of	 HIV	 around	 America	 after	 reporting	 an	
estimated	2,500	 sexual	partners	 in	 ten	years.55	In	March	2016,	 researchers	 from	 the	
University	of	Arizona	argued	that	Dugas	was	not	the	“index	patient”	of	AIDS	in	America	
based	on	the	sequences	of	HIV	that	were	around	at	 that	 time.56	However,	 it	 is	highly	
likely	 that	 Dugas	 would	 have	 helped	 spread	 HIV/AIDS	 given	 the	 number	 of	 sexual	
contacts	and	his	occupation.		
By	 January	 1982,	 multiple	 names	 emerged	 for	 AIDS,	 including	 Gay-Related	
Immune	Deficiency	(GRID).57	AIDS	was	then	associated	with	the	‘4-H	club,’	which	was	
the	 infection	 of	 “homosexuals,	 haemophiliacs,	 heroin	 addicts,	 and	 Haitians.” 58	
However,	it	was	not	until	September	1982	that	the	CDC	named	AIDS	officially.	By	late-
1982,	reports	emerged	of	AIDS	in	a	child	who	had	numerous	blood	transfusions	as	a	
baby,	 and	 women	 who	 had	 sex	 with	 bisexual	 men.	 Within	 a	 week	 of	 this	
announcement,	the	CDC	reported	22	cases	of	“unexplained	cellular	immunodeficiency	
and	opportunistic	infections”	in	the	weekly	MMWR.59	






















AIDS	 patient,	 which	 they	 called	 Lymphadenopathy-Associated	 Virus	 (LAC).	 Further	
crucial	 discoveries	 were	 made,	 including	 reports	 that	 AIDS	 was	 present	 in	
heterosexual	 women	 and	 the	 CDC	 established	 that	 AIDS	 could	 be	 spread	 via	 sexual	
activity	or	blood.	60	In	April	1984,	 the	American	National	Cancer	 Institute	 claimed	 to	





virus	 that	 causes	 AIDS	 was	 to	 be	 called	 Human	 Immunodeficiency	 Virus	 and	
abbreviated	 to	 HIV.	 HIV	 replaced	 LAV,	 HTLV-III,	 AIDS-associated	 virus	 (ARV),	 and	
immunodeficiency-associated	virus	 (IDAV).62	By	 the	end	of	 the	1980s	 celebrities	 like	
Rock	Hudson	had	died	of	AIDS,	a	teenager	from	Indiana	was	excluded	from	school	due	
to	 his	 AIDS	 infection,	 and	 AIDS	 had	 been	 reported	 in	 every	 region	 in	 the	 world.63	











severity	 of	 the	 pandemic.	 In	 1992,	 AIDS	 became	 the	 number	 one	 cause	 of	 death	 for	





















Nations	 Programme	 on	 HIV/AIDS	 to	 combine	 global	 efforts	 to	 fight	 against	 the	
HIV/AIDS	 epidemic.	 By	 this	 stage,	 “over	 four	 million	 people	 had	 died	 from	 AIDS,	
several	million	were	living	with	HIV	and	future	predictions	were	dire.”68		
At	 the	 end	 of	 the	 20th	 century,	 multiple	 highly	 active	 antiretroviral	 therapy	
(HAART)	drugs	had	been	approved,	the	first	HIV	vaccines	were	explored,	and	the	first	
significant	decline	in	AIDS-related	deaths	occurred.69	Furthermore,	compensation	was	
given	 to	haemophiliacs	who	were	 infected	with	HIV	between	1982	and	1987	by	 the	
America’s	Blood	Centers	as	instructed	by	the	Ricky	Ray	Hemophilia	Relief	Act	of	1998.70		
2000s:	The	end	in	sight?	
In	 September	2000,	 the	UN	 included	a	 target	 to	 reduce	HIV/AIDS	 in	 the	Millennium	
Development	Goals	(MDG	6).71	By	2001,	a	number	of	large	pharmaceutical	companies	
that	produced	generic	HAART	drugs	offered	their	products	 to	developing	nations	 for	
lower	 prices	 after	 pressure	 from	 UNAIDS.72	A	 “rapid	 HIV	 test”	 was	 developed	 and	
approved	 in	 the	 USA,	 which	 produced	 a	 result	 within	 20	 minutes	 with	 99.6%	
accuracy.73	In	 2003,	 the	 WHO	 promoted	 their	 ‘3	 by	 5’	 policy	 to	 ensure	 that	 HIV	




infections	 worldwide,	 providing	 greater	 access	 to	 HAART,	 and	 promoting	 new	
prevention	 methods.	 By	 2013,	 “AIDS-related	 deaths”	 had	 decreased	 by	 nearly	 one-
third	 since	 the	 peak	 of	 the	 pandemic	 in	 2005,	 but	 there	were	 still	 an	 estimated	 35	
million	 people	 living	with	HIV	 around	 the	world.76	In	 2014,	UNAIDS	 introduced	 two	
important	 programmes:	 Fast	 Track,	 and	90-90-90.	 Fast	 Track	 focuses	 on	 ending	 the	
AIDS	epidemic	by	2030,	 so	 “that	 the	spread	of	HIV	has	been	controlled	or	contained	

























people	 with	 diagnosed	 HIV	 infection	 will	 receive	 sustained	 antiretroviral	




been	achieved	six	months	earlier	 than	 the	deadline,	with	HAART	given	 to	15	million	
people.	The	UN’s	Sustainable	Development	Goals	(SDGs)	now	focus	on	HIV	action	plans	
and	prevention	policies.	The	SDG	3	fosters	“healthy	lives	and	promote[s]	well-being	for	





The	 first	 cases	 of	 HIV	 did	 not	 occur	 in	 New	 Zealand	 until	 late	 1983,	 when	 Bruce	
Burnett	and	Ray	Taylor	returned	home	after	contracting	the	virus	overseas.	Until	then,	
AIDS	 was	 seen	 to	 be	 a	 distant	 threat	 localised	 in	 bigger	 cities	 or	 “something	
manufactured	by	people	who	opposed	the	gay	community.”80	However,	 in	1984,	New	
Plymouth	became	 the	 first	 city	with	 a	 case	of	 transmitted	AIDS	 and	an	AIDS-related	




HIV	 tests	 were	 available,	 gay	 and	 bisexual	 men	 were	 dissuaded	 from	 giving	 blood	



















illegal	 and	 could	 result	 in	 a	 maximum	 prison	 sentence	 of	 14	 years.83	The	 NZAF	
(formerly	 AIDS	 Support	 Network	 and	 AIDS	 Support	 Network	 Trust)	 realised	 that	
without	decriminalising	homosexual	activity,	“we	couldn’t	tell	gay	men	to	use	condoms	
because	 they	 weren’t	 supposed	 to	 be”	 having	 sex.84	The	 HLRB	 aimed	 to	 legalise	
homosexual	 behaviour	 between	 two	 or	 more	 consenting	 men	 and	 remove	
discrimination	 based	 on	 sexuality.85,	86	The	 opposition	 for	 the	HLRB	was	 strong,	 and	
included	 National	 MP	 Norman	 Jones,	 the	 Coalition	 of	 Concerned	 Citizens	 and	
fundamentalist	 churches	 like	 the	 Salvation	 Army.	 However,	 public	 support	 for	 the	
HLRB	was	partly	due	to	the	gay	community’s	positive	and	proactive	response	to	HIV.87	







healthcare	 and	 remove	 stigmatisations	 against	 certain	 groups.89,	90,	91,	92,	93,	94	Since	 it	
became	clear	 that	 the	unprotected	anal	 intercourse	was	one	of	 the	main	methods	of	

































reduction	 in	 HIV	 infection[s]”	 through	 successful	 health	 policies. 99 	In	 1997	 HIV	
diagnoses	were	at	an	all	time	low	since	they	were	first	recorded	in	1985	(see	Figure	1).	






of	 contracting	 HIV	 based	 on	 statistical	 profiles.	 The	 2003	 Strategy’s	 goals	 included	
improved	 social	 attitudes	 towards	 HIV/AIDS,	 increasing	 prevention	 education,	
establishing	 specialist	 services	 and	 policies	 around	 the	 country,	 and	 creating	 a	
database	to	track	the	epidemiology	of	the	virus.102	
More	 recent	 HIV	 campaigns	 included	 the	 use	 of	 social	 media	 to	 promote	
condom	 use.	 The	 NZAF’s	 Love	 Your	 Condom	 (LYC)	 brand	 had	 a	 large	 social	 media	
presence	 targeted	 to	 young	MSM	 in	New	 Zealand.	 LYC	was	 a	 frank,	 explicit	website	
that	 encouraged	 people	 to	 feel	 comfortable	 talking	 about	 condom	 use	 and	 safe	 sex,	
particularly	 those	 at-risk	 of	 HIV.103 	Through	 a	 combination	 of	 mass,	 social,	 and	
guerrilla	marketing,	 and	 community	 engagement	methods,	 LYC	was	 able	 to	 reach	 a	
large	audience.104,	105	The	LYC	brand	was	discontinued	 in	 January	2017	 to	make	way	
for	a	new	campaign,	Ending	HIV.		
However,	national	HIV	 infections	have	begun	 to	 rise	again.	 In	2017,	 there	are	
around	3200	people	living	with	HIV	in	New	Zealand.106	Figure	1	depicts	the	number	of	























with	 the	 increase	 in	 total	 diagnoses	 suggests	 a	 true	 rise	 in	 incidence	 in	 recent	
years.”107	The	NZAF	also	notes	that	the	large	increases	in	HIV	infections	seen	in	Figure	
1	 between	 2002-2004	 is	 linked	 to	 more	 refugees	 and	 immigrants	 moving	 to	 New	
Zealand	before	HIV	tests	were	compulsory	prior	to	arrival.108	
Figure	 2	 shows	 the	 number	 of	 MSM	 diagnosed	 with	 HIV	 between	 1984	 and	
2016	 in	 New	 Zealand.	 Yearly	 MSM	 HIV	 infections	 between	 1984-1990	 were	 not	
available.	These	graphs	show	that	53%	of	the	4,438	HIV	infections	between	1984	and	
2016	 occurred	 between	 MSM	 in	 New	 Zealand.109 	Figure	 2	 also	 shows	 how	 HIV	
infection	rates	for	MSM	have	fluctuated	between	1990	and	2016	in	New	Zealand.	The	
AIDS	 Epidemiology	 Group	 originally	 argued	 that	 despite	 the	 clear	 increase	 in	 HIV	
infections	 between	 2001	 and	 2005,	 infection	 rates	 from	 2006	 until	 2015	 show	 no	
specific	 trend	of	 increasing	or	decreasing.110	However,	2016	saw	the	highest	number	
of	HIV	 infections	 of	MSM	 recorded	 in	New	Zealand.	 It	 appears	 that	 this	 trend	 is	 not	
unique	to	New	Zealand;	reports	have	shown	that	in	many	developed	nations	there	are	
“re-emergent	 epidemics”	 of	 HIV	 between	 MSM	 despite	 greater	 overall	 access	 to	
ARTs.111	
The	 AIDS	 Epidemiology	 Group	 Leader	 Sue	 McAllister	 granted	 the	 researcher	
































by	 individuals	 who	 are	 not	 infected	 by	 HIV	 but	 have	 a	 high	 risk	 of	 contracting	 the	
virus.114,	115,	116,	117,	118,	119,	120,	121	A	prophylactic	drug	is	designed	to	“prevent	or	control”	
an	infection	or	disease.122	Therefore,	if	an	individual	engages	in	risky	behaviour	that	is	
linked	 to	 HIV	 transmission,	 PrEP	 minimises	 the	 likelihood	 of	 the	 virus	 creating	 a	
permanent	 infection	 in	 the	 body. 123 	PrEP	 is	 the	 first	 successful	 biomedical	 HIV	
prevention	method,	which	signals	a	new	era	of	HIV	prevention	and	policy.		
PrEP	is	an	oral,	once-daily	pill.	The	antiretroviral	drug	currently	comes	in	two	
forms:	 tenofovir	disoproxil	 fumarate	(TDF),	or	a	 tenofovir	disoproxil	 fumarate	(TDF)	
and	emtricitabine	(FTC)	combination	called	Truvada.124,	125,	126,	127	Truvada	is	made	by	
Gilead	 Sciences,	 Incorporated.	 PrEP	 reached	 the	 market	 in	 2012	 when	 the	 United	
State’s	FDA	approved	Truvada	for	prophylactic	prevention	of	HIV.	However,	Truvada	






























































risk	 of	HIV	 on	 a	 single	 occasion	 can	 use	 post-exposure	 prophylaxis	 (PEP)	within	 72	
hours	of	the	event.135	In	2014,	the	WHO	recommended	that	PrEP	was	made	accessible	
to	all	MSM	to	reduce	global	HIV	infections.	In	November	2015,	the	WHO	extended	this	
recommendation	 to	 all	 groups	 around	 the	world	 that	 are	 at	 a	 significant	 risk	of	HIV	
infection.136	In	 February	 2017,	 New	 Zealand’s	Medicines	 and	Medical	 Devices	 Safety	





























the	 first	month	 of	 treatment.	 These	 include	 loss	 of	 appetite,	 headaches,	 nausea,	 and	









men	and	women.	Greater	detail	 about	 the	 trials	of	PrEP	 is	 in	Chapter	2.	PROUD	and	



































environments,	 labels	 and	 stigmatisation,	 adherence	 issues,	 potential	 risky	 behaviour	
while	 using	 PrEP,	 ensuring	 regular	 HIV	 and	 STI	 tests,	 and	 the	 cost	 of	 PrEP.	 These	
challenges	associated	with	PrEP	are	discussed	in	further	detail	in	Chapter	2,	however,	
it	 is	 important	 to	mention	 these	 themes	 to	 provide	 a	 sufficient	 introduction	 to	 this	
subject.		
Medical	environments	
Sexual	 behaviour	 is	 a	 private,	 intimate	 topic	 that	 can	 be	 uncomfortable	 to	 discuss,	
which	is	why	it	is	often	dismissed	by	patients	and	doctors.150	However,	if	patients	and	
clinicians	are	unable	to	discuss	sexual	behaviour	together,	the	clinician	cannot	provide	
the	 necessary	 medical	 care.	 In	 the	 2014	 GAPSS	 and	 Gay	 men’s	 Online	 Sex	 Survey	
(GOSS),	one	third	of	participants	said	their	doctor	did	not	know	their	sexuality.151,	152	
Results	 also	 show	 that	 respondents	who	 identify	 as	bisexual,	were	younger,	were	of	
“Asian	 or	 other	 non-European/Māori/Pacific	 ethnicity,”	 or	 had	 a	 small	 number	 of	
same-sex	 relationships	 believed	 their	 doctor	 was	 less	 likely	 to	 know	 of	 their	
sexuality.153	Without	adequate	and	relevant	healthcare,	nearly	half	of	HIV	infections	of	





Despite	 claims	 that	 PrEP	may	 reduce	 fear	 of	 HIV,155	a	 number	 of	 studies	 have	 cited	
stigmatisation	as	a	deterrent	to	using	PrEP.	This	negative	reaction	towards	PrEP	is	not	


















stigmatisation	 includes	 negative	 attitudes	 towards	 “homosexuality,	 so-called	
‘promiscuity’,	 sex	work,	 and	 injecting	 drug	 use.”156	PrEP-users	 have	 also	 been	 called	
‘Truvada	whores’	 for	 taking	 the	 drug	 so	 they	 can	 engage	 in	 risky	 behaviour	 by	 the	
American	 AIDS	 Healthcare	 Foundation	 President	 Michael	 Weinstein.157 ,	158 	If	 the	






































because	 the	 drug	 is	 not	 as	 cheap	 as	 condoms	 and	 cannot	 prevent	 STIs.166	With	
biomedical	HIV	prevention	methods,	condoms	can	be	seen	as	out-dated,	which	has	the	
potential	 to	 “undercut	 programmes	 to	 keep	 [HIV]	 negative	 people	 negative	 that	 are	
based	on	behaviour	change.”167	Research	shows	inconsistent	results	of	the	impact	that	











about	 regular	HIV	 and	 STI	 tests.	 If	 individuals	 become	HIV-positive	 and	 continue	 to	
take	PrEP,	they	risk	becoming	resistant	to	the	active	components	of	PrEP.171,	172,	173,	174	
Antiretroviral	 resistance	 occurs	 because	 HIV-positive	 individuals	 are	 treated	 with	 a	
combination	of	 two	or	 three	antiretroviral	drugs	 (polypharmacy)	 that	 limit	different	
phases	of	 the	virus’s	replication	because	the	virus	mutates	too	fast	 for	monotherapy.	
Therefore,	 if	 an	 individual	 becomes	 HIV-positive	 and	 continues	 to	 use	 PrEP,	 the	
monotherapy	components	in	PrEP	will	not	provide	enough	protection	against	HIV	and	
there	is	a	high	risk	of	antiretroviral	resistance.	As	a	result,	it	is	imperative	that	PrEP-





















compared	 to	 generic	 PrEP.	 Truvada	 costs	 NZ	 $900-1,200	 per	 month175,	176,	177	and	
generic	 PrEP	 costs	 between	 $60-100	 per	month.	The	 cost	 of	 branded	 PrEP	 is	 out	 of	
most	people’s	budgets,	which	 is	why	individuals	would	need	to	rely	on	subsidisation	





economic	 analysis	 aims	 “to	bring	 greater	 rationality	 to	 often	 complex	decisions,	 and	
shed	 light	on	 the	 logic	behind	choices.”178	The	cost	of	PrEP	 is	a	clear	barrier	 to	PrEP	
use	and	will	be	discussed	further	in	Chapter	2.		
These	 challenges	 of	 PrEP	mentioned	 above	 simply	 skim	 the	 surface.	 A	 more	




the	 implementation	 of	 PrEP	 for	 MSM.	 Email	 correspondence	 with	 the	 MOH	 has	
indicated	that	as	at	March	2017,	the	MOH	was	developing	a	policy	framework	for	PrEP.	
The	researcher	also	acknowledges	the	occurrence	of	a	PrEP	demonstration	project	led	
by	 the	 Auckland	 Sexual	 Health	 Service	 and	 Auckland	 District	 Health	 Board	 (ADHB),	
and	 partnered	 by	 the	 NZAF,	 Body	 Positive,	 and	 the	 University	 of	 Auckland.	 As	 at	
August	 2016,	 there	 were	 over	 250	 people	 who	 had	 registered	 their	 interest	 in	 the	
project,	 but	 current	 funding	was	 only	 available	 for	 150	 individuals.179	As	mentioned	
throughout	 this	 chapter,	 there	 are	 four	 recommended	 groups	 that	 can	 benefit	 from	




The	 thesis	 is	divided	 into	six	chapters,	 the	 first	being	 this	chapter,	Setting	 the	












Chapter	 2,	 Understanding	 the	 Complexities	 of	 PrEP,	 is	 a	 literature	 review	 of	 the	
relevant	 scholarly	 information	 on	 PrEP.	 Chapter	 2	 is	 split	 into	 three	 key	 review	
sections:	 the	 first-generation	 RCTs	 of	 PrEP,	 clinicians’	 opinions	 of	 PrEP,	 and	 the	
attitudes	 that	 MSM	 have	 towards	 PrEP.	 Many	 of	 the	 challenges	 of	 PrEP	 that	 were	
briefly	discussed	in	this	chapter	are	explored	in	greater	depth	in	Chapter	2.	Chapter	3,	
Methodology,	 discusses	 and	 justifies	 the	 methods	 used	 for	 this	 thesis.	 The	 thesis	
follows	 Carol	 H.	Weiss’s	 problem-solving	model	 that	 uses	 research	methods	 to	 help	
reduce	 uncertainty	 regarding	 a	 problem	 and	 inform	 a	 policy	 recommendation.	 This	
research	 uses	 a	 multiple,	 mixed-methods	 approach	 for	 primary	 research.	 These	
methods	are	an	attitude	scaling	survey,	interviews,	and	document	analysis.	Chapter	4,	
Canterbury	 MSM	 and	 their	 attitudes	 towards	 PrEP,	 presents	 the	 results	 from	 the	
online,	anonymous,	attitude	scaling	survey	of	MSM	that	took	place	in	March	and	April	
2017.	Chapter	5,	PrEPared	Against	HIV:	2.0,	is	the	champion	of	the	thesis;	this	chapter	








A	 literature	 review	 of	 first-generation	 randomised	 controlled	 trials,	 providers,	 and	
MSM	patients.	
	
This	 chapter	 presents	 a	 comprehensive	 literature	 review	 of	 PrEP	 in	 three	 major	






the	 fight	against	HIV.	However,	since	the	approval	of	Truvada	 in	 July	2012,	PrEP	has	
not	 been	 received	 in	 the	way	 that	many	 of	 its	 supporters	 imagined.	 For	 example,	 a	
2013	survey	of	 infectious	disease	 specialists	 in	America	and	Canada	 found	 that	one-
third	 of	 practitioners	 did	 not	 think	 PrEP	 was	 “relevant	 to	 their	 practice.” 180	
Furthermore,	while	three	out	of	four	doctors	surveyed	said	they	supported	the	use	of	
PrEP	 for	high-risk	 individuals,	only	9%	had	prescribed	PrEP.181	Similarly,	 there	have	










However,	 ‘An	 Open	 Letter	 to	 the	 CDC	 on	 PrEP’	 (Centers	 for	 Disease	 Control	 and	
Prevention)	 from	 the	 US	 AIDS	 Healthcare	 Foundation	 states	 that	 Truvada	




















though	 the	 raw	 numbers	 tell	 another	 story.”	 The	 AIDS	 Healthcare	 Foundation	
estimates	that	as	at	June	2016,	less	than	0.04%	of	American	MSM	were	using	PrEP.186	
	 It	 is	 clear	 that	while	PrEP	may	be	a	good	option	 for	HIV	prevention,	 its	entry	
into	the	HIV	circuit	has	been	complicated.	The	purpose	of	 this	 literature	review	is	 to	
explore	 the	 various	 issues	 surrounding	PrEP.	This	 literature	 review	will	 cover	 three	
crucial	topics:	first-generation	randomised	control	trials	(RCTs),	provider	opinions	of	
PrEP,	 and	 potential	 patient	 reactions	 to	 PrEP.	 These	 three	 themes	 have	 all	 been	
purposefully	picked.	The	first-generation	RCTs	are	essential	because	these	six	studies	
proved	the	efficacy	of	PrEP	to	prevent	HIV.	Without	the	results	from	these	trials,	PrEP	
would	 not	 be	 available	 for	 HIV	 prevention.	 The	 second	 and	 third	 topics	 for	 this	
literature	 review	 are	 necessary	 because	 they	 move	 PrEP	 away	 from	 the	 controlled	
environment	of	a	clinical	trial	and	into	the	‘real	world,’	where	daily	life	has	an	impact	
on	 the	 drug.	 Provider	 opinions	 of	 PrEP	 are	 crucial	 to	 understand	 because	 without	
doctors,	the	target	populations	of	PrEP	would	not	have	access	to	the	drug.	And	finally,	
the	third	section	focuses	on	the	responses	MSM	have	toward	PrEP.	The	uptake	of	PrEP	
ultimately	 relies	 on	 whether	 patients	 see	 PrEP	 as	 a	 worthwhile	 HIV	 prevention	
technology.	The	 literature	 review	will	 conclude	by	placing	 this	 thesis	 in	 the	broader	
scope	of	research	that	has	already	been	undertaken	regarding	PrEP.			
First-generation	randomised	control	trials	of	PrEP	
There	 are	 six	 first-generation	 PrEP	 trials:	 iPrEx,	 Partners	 PrEP,	 TDF2,	 VOICE,	 FEM-
PrEP,	 and	 the	 Bangkok	 Tenofovir	 Study.	 These	 six	 trials	 all	 aimed	 to	 determine	
whether	 PrEP	 stops	 the	 transmission	 of	 HIV	 infection	 among	 high-risk	 groups.	 The	
results	from	these	RCTs	were	deemed	to	provide	sufficient	evidence	in	favour	of	using	
PrEP	as	an	HIV	prevention	method.		
There	were	 a	 total	 of	 18,019	 participants	 in	 the	 six	 RCTs,	 although	 all	 of	 the	
trials	 lost	participants.	 iPrEx187	had	2,499	MSM	and	transgender	women	(TGW)	from	
Brazil,	 United	 States,	 Thailand,	 Ecuador,	 Peru,	 and	 South	 Africa.	 FEM-PrEP188	had	
2,120	 HIV-negative	 women	 from	 Kenya,	 South	 Africa,	 and	 Tanzania.	 VOICE189	had	
5,029	HIV-negative	female	participants	from	South	Africa,	Uganda,	and	Zimbabwe.	The	
TDF2190	trial	 used	 1,200	 high-risk	 heterosexual	 men	 and	 women	 in	 Botswana	 aged	














PrEP191	had	 4,758	 serodiscordant	 couples	 from	 Kenya	 and	 Uganda.	 The	 Bangkok	
Tenofovir	Study192	used	2,413	injecting	drug	users	(IDUs)	from	Bangkok,	Thailand.	All	
of	 the	 trials	 had	 one	 or	 more	 placebos.	 iPrEx,	 FEM-PrEP,	 TDF2	 and	 the	 Bangkok	
Tenofovir	Study	had	two	arms	with	a	50%	chance	of	a	placebo	drug.	Partners	PrEP	had	
three	arms	with	a	33%	chance	of	placebo,	and	VOICE	had	five	arms	with	a	20%	chance	







75.0%.	 Unadjusted	 efficacy	 levels	 of	 TDF	 preventing	 HIV	 infections	 were	 -49.0%	 in	
VOICE,	 48.9%	 in	 the	 Bangkok	 Tenofovir	 Study,	 and	 67.0%	 in	 Partners	 PrEP.	
Unadjusted	efficacy	levels	of	TDF+FTC	preventing	HIV	infections	were	-4.4%	in	VOICE,	
6.0%	 in	 the	 FEM-PrEP	 trial,	 44.0%	 in	 iPrEx,	 62.2%	 in	 TDF2,	 and	 75.0%	 in	 Partners	
PrEP.	 These	 results	 determine	 that	 iPrEx,	 Partners	 PrEP,	 TDF2,	 and	 the	 Bangkok	
Tenofovir	Study	RCTs	all	prove	that	PrEP	(in	either	form)	can	effectively	prevent	HIV	
infection	 among	 high-risk	 groups.	 As	 a	 contrast,	 the	 FEM-PrEP	 and	 VOICE	 results	
showed	that	PrEP	did	not	prevent	HIV	infections.	The	varying	levels	of	PrEP’s	efficacy	
and	 overall	 results	 of	 PrEP’s	 ability	 to	 limit	 HIV	 infections	 have	 been	 linked	 to	
adherence	levels	(discussed	below).	
	 The	 number	 of	 participants	 who	 underwent	 seroconversion	 (changing	 from	
HIV-negative	to	HIV-positive)	during	the	RCTs	was	significantly	small	compared	to	the	
total	 number	 of	 trial	 subjects.	 Ranked	 smallest	 to	 largest,	 the	 proportion	 of	 HIV	
infections	out	of	the	total	trial	participants	were	0.017%	in	Partners	PrEP,	0.021%	in	




Bangkok	 Tenofovir	 Study)	 and	 two	 unsuccessful	 RCTs	 (FEM-PrEP	 and	 VOICE)	 has	
been	 linked	 to	 the	 rates	 of	 adherence	 of	 trial	 subjects.	 These	 trials	 measured	












among	 subjects	 with	 detectable	 levels	 of	 PrEP	 in	 their	 bloodstream.	 The	 Bangkok	










40%	of	participants	had	active	 components	of	TDF+FTC	 in	 their	bloodstream.	These	
results	show	how	obvious	the	link	between	adherence	and	efficacy	for	PrEP	is.		
Antiretroviral	resistance	
A	 major	 concern	 with	 PrEP	 is	 that	 individuals	 can	 contract	 a	 virus	 that	 becomes	
resistant	 to	 the	 active	 components	 in	 PrEP	 if	 it	 is	 still	 taken	 after	 seroconversion.	
There	were	only	10	cases	of	resistance	to	PrEP	active	drug	components	out	of	a	total	of	
509	HIV	 infections	 from	 the	 six	 RCTs	 oral	 PrEP	 arms.	 There	was	 1	 instance	 of	 TDF	
resistance	 in	 the	 TDF	 arm	 and	 1	 instance	 of	 FTC	 resistance	 in	 the	 TDF+FTC	 arm	 of	
Partners	PrEP.	There	was	1	case	of	FTC	resistance	in	the	TDF+FTC	arm	of	the	VOICE	
RCT.	 There	 were	 5	 and	 2	 confirmed	 cases	 of	 PrEP	 resistance	 in	 the	 FEM-PrEP	 and	




and	 the	 drug	 that	was	 taken	 (TDF	 or	 TDF+FTC).	 TDF	 side	 effects	 include	 grade	 1-4	
neutropenia,	 nausea	 and/or	 vomiting,	 and	 liver	 issues.	 The	 nausea	 and	 vomiting	
decreased	 over	 time	whereas	 the	 liver	 issues	 did	 not.	 TDF+FTC	 side	 effects	 include	
nausea,	vomiting,	unintentional	weight	 loss,	 gastrointestinal	 side	effects,	 fatigue,	 and	




modes	 of	 HIV	 prevention.	 The	 RCTs	 offered	 participants	 HIV	 tests,	 risk-reduction	
counselling	 and	 condoms.	Partners	PrEP,	 iPrEx,	 and	TDF2	also	offered	STI	 tests	 and	





The	next	 section	of	 the	 literature	 review	will	 explore	 the	 second	of	 the	 three	




to	 providers.	 The	 majority	 of	 the	 literature	 reviewed	 in	 this	 section	 focuses	 on	
clinicians	 and	 their	 opinions	 and	 attitudes	 towards	 PrEP.	 Overall,	 this	 literature	
explored	the	factors	that	would	persuade	or	dissuade	a	doctor	to	offer	their	patients	
PrEP.	 It	 is	 crucial	 to	 look	 at	 these	 factors	 because	without	 the	 support	 of	 clinicians,	
potential	PrEP-users	will	struggle	to	gain	access	to	this	HIV	prevention	method.		
The	literature	on	physicians’	opinions	regarding	PrEP	had	a	combined	total	of	
2,678	 participants,	 which	 took	 place	 between	 2006	 and	 2015.	 The	 studies	 were	
conducted	 in	 the	United	 States,	 Canada,	 Italy	 and	 Peru.	 The	 sampling	methods	 used	
include	 snowball	 sampling,	 convenience	 sampling,	 and	 purposive	 sampling.	 The	
studies	used	surveys,	pilot	surveys,	focus	groups,	and	interviews.		
Knowledge,	support,	and	previous	prescription	patterns	of	PrEP	before	the	studies	
Knowledge	of,	 support	 for,	 and	previous	prescription	patterns	of	PrEP	varied	across	
the	 literature,	 although	 this	 seems	 logical	 depending	 on	 when	 the	 research	 was	





in	 2012	 and	 2013,	 found	 physicians	 were	 97%195	and	 95%196	supportive	 of	 PrEP	
under	the	condition	that	more	research	was	conducted	into	the	drug’s	efficacy.	Results	





















100%.202	Some	 of	 the	 higher	 recorded	 support	 for	 PrEP	 was	 linked	 to	 previous	
knowledge	 or	 prescriptions	 given.203,	204	By	 contrast,	 opposition	 towards	 PrEP	 also	
varied.	 The	 proportion	 of	 physicians	 that	 were	 unwilling	 to	 prescribe	 PrEP	 was	
3.1%,205 	4.7%,206 	12%,207 	and	 30%.208 	One	 study	 did	 not	 give	 a	 final	 figure,	 but	
reported	 that	 the	 majority	 of	 general	 practitioners	 were	 unwilling	 to	 prescribe	
PrEP.209	
	 Prescriptions	 of	 PrEP	 prior	 to	 the	 research	 fluctuated	 over	 the	 years	 but	
generally	 increased	over	 time.	The	proportions	of	 doctors	who	had	prescribed	PrEP	














































The	majority	 of	 the	 literature	 about	 provider	 opinions	 of	 PrEP	 focuses	 on	 concerns	




drug;	 the	 higher	 the	 efficacy,	 the	 more	 support	 was	 reported	 for	 PrEP.	 An	 average	
efficacy	 level	 of	 71%	 was	 considered	 sufficient	 enough	 to	 prescribe	 to	 high-risk	
individuals.219	One	 study	 reported	 that	 94%	 of	 physicians	 believe	 that	 PrEP	 is	 an	
effective	HIV	prevention	method.220	However,	another	study	in	2013	found	only	13%	





Herd	 immunity	 provides	 a	 community	 with	 greater	 immunity	 against	 infectious	
diseases.	When	 there	 are	 high	 levels	 of	 immune	 community	members	 the	 spread	 of	
infectious	 diseases	 is	much	 lower,	 which	 protects	 individuals	 who	 are	 not	 immune.	
Although	herd	immunity	is	not	directly	linked	to	HIV,	one	study	of	American	clinicians	
did	 claim	 that	 PrEP	 could	 have	 a	 similar	 impact	 at	 the	 community	 level.	 Multiple	
participants	 in	 the	study	supported	PrEP	as	a	method	 for	herd	 immunity	because	“if	
you	could	get	enough	of	just	that	one	population	protected,	then	you	could	break	that	
cycle	 within	 the	 community.”223	As	 the	 number	 of	 high-risk	 individuals	 using	 PrEP	
increases,	 there	 is	 a	 greater	 chance	 that	 the	 transmission	 of	 HIV	 could	 decline	 in	 a	
particular	community.		
Barriers	to	PrEP	implementation	
Despite	 most	 of	 the	 literature	 focusing	 on	 physicians	 and	 PrEP	 to	 uncover	 their	
attitudes	and	opinions	towards	the	drug,	further	analysis	shows	that	there	was	more	














Provider	 concerns	 are	 defined	 as	 concerns	 that	 primarily	 come	 from	 the	 doctors	
themselves	 and	 are	 linked	 to	 their	 role	 in	 regards	 to	 PrEP.	 There	 are	 six	 identified	
provider	 concerns:	 antiretroviral	 resistance,	 adherence,	 biomedicalised	 prevention,	
efficacy-effectiveness	gap,	lack	of	guidelines,	and	time	and	resources.		
Antiretroviral	resistance	
The	most	 cited	 issue	with	PrEP	 according	 to	 surveyed	doctors	 and	 specialists	 is	 the	
potential	for	antiretroviral	resistance.	To	reiterate,	HIV	is	treated	using	polypharmacy	
because	when	only	one	ART	is	used	the	virus	can	mutate	and	become	resistant	to	that	
particular	drug.	As	 a	 result,	 individuals	 can	develop	an	HIV	virus	 that	 is	 resistant	 to	
PrEP	 if	 they	seroconvert	while	 continuing	 to	 take	PrEP.	Of	 the	studies	 that	provided	
proportions,	the	percentage	of	doctors	concerned	about	antiretroviral	resistance	was	
32%,224	41.9%,225	77%,226	88%,227	94%,228	and	 >40%.229	Another	 six	 articles	 did	 note	
antiretroviral	resistance	as	a	concern	but	did	not	cite	an	exact	figure.	
Adherence	




studies	 that	did	not	disclose	the	proportion	of	doctors	 that	 identified	adherence	as	a	
barrier	to	PrEP	implementation.233,	234,	235	
Biomedical	prevention	
Some	 providers	 did	 not	 support	 PrEP	 as	 it	 gives	 drugs	 to	 otherwise	 healthy	
individuals.	 One	 provider	 argued	 against	 Truvada	 for	 prevention	 of	 HIV	 because	
























disease”	 is	 not	 recommended.236	Three-quarters	of	 the	 literature	 cited	 toxicities	 as	 a	
deterrent	 to	 PrEP,	 particularly	 as	 the	 long-term	 side	 effects	 of	 PrEP	 are	 currently	
uncertain.	The	reported	proportions	of	doctors	concerned	with	the	biomedicalisation	
of	HIV	prevention	and	potential	 long-term	side	 effects	were	41%,237	53%,238	62%,239	
91%,240	and	 >40%.241	Those	 who	 do	 not	 support	 biomedicalised	 HIV	 prevention	
favour	 behavioural	 methods	 like	 condoms,	 serosorting,	 and	 abstinence.242	74%	 of	




and	 results	 of	 the	 drug	 when	 it	 is	 implemented	 in	 the	 ‘real	 world.’244	The	 poor	
adherence-related	 results	 of	 the	 FEM-PrEP	 and	 VOICE	 trials	 show	 how	 the	 efficacy-
effectiveness	 gap	 can	 occur.	 Physicians	 from	 Boston	 hypothesised	 that	 the	 efficacy-
effectiveness	 gap	 would	 decrease	 adherence	 to	 PrEP’s	 once-daily	 regime,	 as	 it	 was	
likely	 to	 be	 lower	 in	 the	 real-world	 compared	 to	 the	 first-generation	RCTs.245	If	 this	




on	 the	 necessary	 medical	 care	 for	 patients	 using	 PrEP.	 Prior	 to	 these	 national	
guidelines	 for	American	doctors,	 the	 lack	of	guidelines	was	cited	as	a	concern	by	the	
surveyed	physicians.246,	247	However,	 even	after	 the	Guidelines	were	 released,	58%	of	
American	doctors	saw	the	Guidelines	as	a	major	or	moderate	barrier	to	effective	PrEP	




























Any	new	policy	 requires	 additional	 time	 and	 resources	 to	 ensure	 that	 it	 is	 effective,	
and	 the	 implementation	 of	 PrEP	 is	 no	 different.	 The	 application	 of	 PrEP	 must	 be	
carefully	 planned	 to	 ensure	 that	 other	 health	 programmes	 are	 not	 disadvantaged.	
Time	 and	 resources	 were	 a	 common	 concern	 raised	 by	 almost	 half	 of	 the	 studies	
focused	 on	 doctors.	 PrEP	 is	 a	 complex	 medication	 so	 whoever	 prescribes	 PrEP	
(general	practitioners,	sexual	health	doctors,	and/or	STI	and	HIV	clinics)	must	provide	
additional	medical	support	for	PrEP-users.	Doctors	stated	that	this	extra	support	could	
negatively	 impact	 time	and	 resources	because	 it	may	 require	 clinics	 to	 expand	 their	
capabilities, 250 	increase	 monitoring	 of	 patients, 251 ,	 252 	and	 put	 extra	 pressure	 on	










was	mentioned	 in	 all	 but	 two	 of	 the	 studies	 regarding	 clinician-reported	 barriers	 to	
PrEP.	The	 common	 theme	was	 that	 the	high	 cost	 of	Truvada	would	 cause	 inequities	



























of	 clinicians	 had	 concerns	 about	whether	 insurance	 companies	would	 pay	 for	 PrEP:	
26%	saw	it	as	a	minor	barrier,	31%	a	moderate	barrier,	and	32%	a	major	barrier.270	






Risk	 compensation	 is	 the	 theory	 that	 individuals	 will	 engage	 in	 increased	 risky	
behaviour	when	they	believe	there	is	a	decreased	perceived	risk.	Risk	compensation	is	
a	 common	 issue	 since	 new	 HIV	 prevention	 methods	 such	 as	 serosorting,	 male	




to	 use	 condoms.	 All	 but	 one	 study	 in	 provider-focused	 literature	 mentioned	 risk	
compensation	 as	 a	 strong	 barrier	 to	 PrEP.	 Of	 the	 studies	 that	 provided	 figures,	 the	
percentages	of	doctors	concerned	about	PrEP-related	risk	compensation	were	22%,272	





























judgemental	 about	 patients’	 personal	 lives.277	Interestingly,	 the	 study	 that	 tracked	





The	 final	 section	 of	 this	 literature	 review	 will	 examine	 the	 third	 theme:	
potential	 PrEP-users’	 opinions	 of	 the	 medication	 as	 a	 biomedical	 HIV	 prevention	





as	MSM.	Given	the	research’s	 focus	on	MSM	for	 the	PrEP	health	policy,	 the	 literature	
review	only	explores	studies	with	MSM.	The	majority	of	the	academic	literature	on	the	
subject	 of	 PrEP	 focuses	 on	 MSM’s	 self-reported	 willingness	 to	 use	 PrEP,	 attitudes	
towards	PrEP,	and	patterns	of	use.		
The	literature	on	MSM	and	their	attitudes	towards	PrEP	features	11,475	MSM	
and	 TGW	 participants	 that	 took	 place	 between	 January	 2007	 and	 July	 2015.	 The	
participants	were	 from	America,	Australia,	Peru,	 South	Africa,	 India,	Canada,	Britain,	
Thailand,	 Taiwan,	 and	 China.	 The	 sampling	 methods	 included	 respondent-driven	
sampling,	 random	 sampling,	 convenience	 sampling,	 purposive	 sampling,	 online	




and	 again	 in	 August-November	 2011	 in	 Canada.279	The	 second	 cross-sectional	 study	
was	part	of	an	ongoing	longitudinal	cohort	study	on	young	MSM	(YMSM),	and	data	was	




















Generally,	 the	more	 recent	 studies	 of	MSM	 report	 higher	 levels	 of	 awareness	 about	
PrEP.	The	earliest	study	took	place	 in	2007	and	19%	of	MSM	reported	some	 level	of	
knowledge	about	PrEP.284	The	most	recent	study	reported	74.5%	of	MSM	were	aware	

















































subjects	 reported	 being	 aware	 of	 PrEP,	 compared	 to	 28%	 in	 2011.298	The	 study	





The	 reported	 percentages	 of	 MSM	 using	 PrEP	 were	 0.004%,301	0.5%,302 	1.5%,303	
2.2%,304	2.7%,305	6.8%,306	and	 11.9%.307	Two	 studies	 reported	 no	 respondents	 that	
had	 used	 PrEP	 for	 HIV	 prevention.308,	309	One	 of	 the	 cross-sectional	 studies	 reported	
that	 the	number	of	MSM	who	had	used	PrEP	 increased	 from	5%	 in	2012	 to	21%	 in	




































Willingness	 to	 use	 PrEP	 is	 discussed	 in	 the	majority	 of	 this	 literature.	 The	 reported	
figures	 of	 MSM	 willing	 to	 adopt	 PrEP	 was	 28.2%,311 	46.1%,312 	47.8%,313 	50%,314	
50.2%,315	51%,316	54.3%,317	55.4%,318	56%,319	56.7%,320	60.3%,321	67.8%,322	74%,323	




were	 willing	 to	 use	 PrEP	 compared	 to	 37%	 of	 TGW.327	A	 third	 study	 did	 not	 use	
quantitative	 research	methods	 but	 stated	 that	 the	majority	 of	 the	MSM	 in	 the	 focus	













































in	 one	 study	 dropped	 considerably	 when	 participants	 had	 to	 pay	 for	 their	 PrEP	
prescription.	 56%	 of	 MSM	 were	 interested	 in	 PrEP	 initially	 but	 this	 proportion	




as	 an	HIV	prevention	method.	The	 final	portion	of	 this	 literature	 review	 is	 split	 into	















This	 disparity	 could	 have	 impacted	 the	 proportion	 of	 MSM	 who	 reported	 concerns	
about	PrEP’s	side	effects.	Three	qualitative	studies	analysed	how	MSM	viewed	PrEP’s	
side	 effects.	 The	 first	 study	 reported	 that	 side	 effects	 played	 a	 role	 in	 the	 MSM’s	
willingness	to	use	PrEP	because	if	side	effects	were	mild	or	lessened	over	a	period	of	
time,	MSM	were	more	likely	to	consider	adopting	PrEP.336	However	a	select	few	MSM	
from	 the	 same	 sample	 were	 less	 deterred	 by	 potential	 side	 effects,	 arguing	 that	
“there’s	gonna	be	side	effects	to	everything,	no	matter	what	you	do.”	The	second	study	














number	 of	MSM	 argued	 that	 every	 drug	 had	 associated	 side	 effects.337	A	 third	 study	
reported	that	a	 large	majority	of	MSM	cited	vomiting,	dizziness,	and	a	change	in	skin	
colour	induced	by	PrEP	as	concerning.338	
Two	 studies	 presented	 data	 regarding	 side	 effects	 and	 MSM	 categorised	 by	
their	ethnicity.	One	study	found	that	Indian	MSM	were	considerably	 less	deterred	by	
potential	 side	 effects	 of	 PrEP	 compared	 to	 MSM	 from	 Peru	 and	 South	 Africa.339	A	








about	side	effects).	There	were	 two	qualitative	studies	 that	discussed	 long-term	side	
effects	with	MSM.	The	first	study	found	that	MSM	were	less	willing	to	consider	using	
PrEP	 if	 the	 side	effects	were	 severe	or	did	not	 fade	over	 time.342	Furthermore,	 these	





A	number	of	 studies	 revealed	 that	MSM	were	uncertain	about	using	PrEP	 if	 the	 side	
effects	 could	 negatively	 impact	 their	 lifestyle.	 One	 study	 cited	 concerns	 about	
complications	 of	 PrEP	with	 existing	 health	 conditions,	 such	 as	 diabetes.345	A	 second	
study	reported	that	MSM	believe	there	 is	always	a	 ‘down’	when	taking	medicine	and	






















the	 side	 effects	 from	 PrEP,	 and	 44.7%	 were	 concerned	 that	 PrEP	 would	 have	 a	
negative	impact	on	their	diet	and	sleep.347	
Efficacy	and	adherence	







PrEP	 if	 it	 was	 not	 100%	 effective. 353 	One	 cross-sectional	 study	 measured	 the	
percentage	of	MSM	who	were	not	willing	to	use	PrEP	at	50%	and	75%	efficacy	in	2008	




All	 potential	 PrEP-users	 should	 be	 provided	with	 accurate	 information	 about	
the	 link	 between	 PrEP’s	 efficacy	 and	 adherence.	 Many	 ongoing	 or	 planned	
demonstration	studies	 focus	on	more	complex	 factors,	 such	as	 “adherence	education	
and/or	counselling”	using	community-focused	campaigns	and	technology	approaches,	
such	as	text	reminders	to	take	PrEP.355	The	general	consensus	between	academia	and	

























Only	 two	 studies	 of	 MSM	 discussed	 antiretroviral	 resistance.	 21.7%	 of	 MSM	 in	
Beijing 357 	and	 64.7%	 of	 MSM	 from	 New	 York	 City 358 	expressed	 anxiety	 about	
antiretroviral	 resistance	 from	 PrEP.	 It	 is	 interesting	 to	 compare	 the	 emphasis	 that	
physicians	 and	MSM	put	 on	 antiretroviral	 resistance.	Overall,	 physicians	were	much	





MSM	 perceive	 using	 PrEP	 in	 relation	 to	 themselves.	 The	 three	 concerns	 are	
embarrassment,	self-perceived	HIV	risk,	and	a	lack	of	interest	in	PrEP.		
Embarrassment	about	PrEP		
Given	 the	politically	 turbulent	history	of	HIV,	 it	 is	not	surprising	 that	some	MSM	are	
anxious	 about	 a	 new	 prevention	 technique.	 However,	 the	 proportion	 of	 MSM	 who	
reported	feeling	embarrassed	about	using	PrEP	appears	to	be	relatively	low.	One	study	
found	 that	 fewer	 than	 25%	 of	 all	 MSM	 surveyed	 in	 India,	 Peru,	 and	 South	 Africa	
reported	 using	 PrEP	 as	 ‘fairly’	 or	 ‘very	 embarrassing.’359	While	 a	 study	 of	 MSM	 in	
Thailand	found	that	only	8.5%	saw	PrEP	as	‘fairly’	or	‘very	embarrassing,’	38.1%	were	
‘fairly’	 or	 ‘very	 anxious’	 to	 use	 PrEP.	360	One	 qualitative	 study	 of	MSM	 found	 that	 an	
undisclosed	number	of	MSM	would	not	use	PrEP	because	there	was	a	potential	to	feel	
embarrassed.361	These	MSM	may	have	been	concerned	with	outsiders	who	judge	PrEP-
users	and	make	assumptions	that	 the	MSM	engaged	 in	high-risk	activities.	 It	 is	 likely	
that	 the	 small	 portion	 of	 MSM	 that	 felt	 embarrassed	 or	 anxious	 to	 use	 PrEP	 are	
concerned	with	PrEP-associated	stigmatisation,	which	will	be	discussed	later.		
Self-perceived	HIV	risk	
Health	 professionals	 give	 patients	 a	 risk-level	 regarding	 a	 certain	 illness,	 and	















far	 less	 likely	 to	 consider	 using	 PrEP.	 The	 literature	 cites	 two	main	 reasons	 for	 low	
self-perceived	HIV	 risk,	 stating	 that	 the	MSM	may	 not	 engage	 in	 risky	 behaviour	 as	




of	MSM	 in	 Canada	 found	 that	 85.3%	 claimed	 it	 was	 ‘very	 unlikely’	 that	 they	would	
contract	 HIV,	 despite	 27.7%	 stating	 they	 do	 not	 always	 use	 condoms	 when	 having	




One	 Australian	 study	 found	 that	 the	 majority	 of	 MSM	were	 not	 interested	 in	 using	
PrEP.368	A	study	of	MSM	from	Rhode	 Island	 found	that	10.7%	were	not	 interested	 in	
PrEP	 at	 all	 (compared	 to	 89.3%	who	 ranged	 between	 ‘a	 little	 interested’	 and	 ‘very	






linked	 to	behaviour,	which	can	be	 reduced	depending	on	how	MSM	act.	This	 section	
discusses	risk	compensation,	and	a	lack	of	information.		
Risk	compensation	
As	 discussed	 in	 the	 previous	 section,	 risk	 compensation	 is	 a	 common	 concern	
associated	 with	 PrEP	 because	 it	 can	 reduce	 the	 drug’s	 efficacy	 and	 encourage	 the	























study	 found	that	41.1%	of	MSM	were	not	 likely	 to	use	condoms	with	PrEP,	however	
this	figure	dropped	to	26.3%	when	the	MSM	who	were	not	willing	to	pay	for	their	own	
prescription	were	removed.373	10.4%	of	Thai	MSM	were	not	willing	to	take	PrEP	if	 it	
meant	having	 to	use	 condoms	at	 the	 same	 time,374	compared	 to	43.7%	of	MSM	 from	
America.375	Risk	compensation	was	also	discussed	in	the	qualitative	research	studies.	
A	 small	 proportion	 of	 MSM	 from	 two	 focus	 groups	 states	 that	 predicted	 risk	
compensation	 was	 a	 reason	 not	 to	 take	 PrEP,	 as	 they	 would	 be	 less	 likely	 to	 use	








a	 portion	of	MSM	 in	California	were	 concerned	 that	PrEP	may	be	more	 effective	 for	
some	 people	 compared	 to	 others	 and	 thought	 that	 the	 efficacy	 could	 decline	 over	
time.380	A	number	of	American	MSM	brought	up	the	efficacy-effectiveness	gap,	stating	
that	 the	 promise	 of	 100%	 efficacy	 is	 not	 translated	 to	 total	 protection	 against	 HIV	




























The	 final	 section	 of	 concerns	 collates	 together	 the	 issues	 that	 are	 out	 the	 control	 of	
MSM.	These	examples	are	barriers	to	PrEP	uptake	that	MSM	cannot	solely	minimise	or	




of	 branded	 PrEP	 will	 continue	 to	 exclude	 the	 majority	 of	 MSM	 from	 accessing	 the	
drug.382,	383	The	 general	 trend	 shows	 that	 PrEP	 would	 be	 more	 popular	 if	 it	 was	
cheaper	because	 the	 cost	 is	 a	deterrent,384,	385	and	 the	higher	 the	 cost	of	PrEP,	 fewer	
MSM	will	be	able	to	afford	the	drug.386	The	percentages	of	MSM	who	were	concerned	
about	 the	 cost	 of	 PrEP	 or	 could	 not	 afford	 to	 pay	 for	 it	 were	 11.8%,387	23.6%,388	
61.2%,389	and	 77%.390	The	majority	 of	MSM	were	 happy	 to	 pay	 around	 $20-$25	 per	
month	in	their	local	currency	for	a	prescription	of	PrEP.391,	392,	393,	394	One	study	found	
that	MSM	 from	Peru	 and	 South	Africa	were	 less	 likely	 to	 be	willing	 to	 pay	 for	 PrEP	
compared	to	MSM	from	India.395	Given	the	results	of	this	literature,	it	can	be	assumed	












































The	 final	 concern	 is	 the	 negative	 impact	 that	 PrEP	 could	 have	 on	 personal	














PrEP,	 and	 the	 Bangkok	 Tenofovir	 Study.	 This	 section	 was	 crucial	 because	 without	
these	six	RCTs,	PrEP	would	not	be	an	approved	option	for	HIV	prevention.	The	level	of	
unadjusted-efficacy	of	PrEP	varied	hugely	from	-49.0%	to	75.0%,	and	thus,	four	of	the	
six	 studies	 found	 that	 PrEP	 was	 effective	 at	 preventing	 HIV	 transmission.	 The	

















attitudes	 towards	 PrEP.	 This	 section	 was	 important	 because	 without	 doctors	
prescribing	 PrEP,	 MSM	 cannot	 access	 this	 new	 technology.	 It	 is	 crucial	 that	 the	
concerns	doctors	have	with	PrEP	are	explored	so	they	can	be	minimised	and	managed	
to	make	future	PrEP	implementation	as	successful	as	possible.	There	were	more	than	
2,000	doctors	and	medical	specialists	 involved	 in	 these	studies.	This	review	grouped	
concerns	 into	 two	 categories:	 provider	 concerns,	 and	 social	 concerns.	 The	 provider	




because	 if	PrEP	 is	going	 to	be	a	successful	HIV	prevention	method,	 it	 is	necessary	 to	
have	a	good	understanding	of	MSM’s	attitudes	 towards	PrEP.	There	were	more	 than	
19,000	 MSM	 and	 TGW	 used	 in	 a	 mixture	 of	 studies.	 The	 literature	 focused	 on	
awareness	 and	willingness	 to	 use	 PrEP	 for	 HIV	 prevention,	 and	 barriers	 associated	
















Empirical	 social	 science	 research	 to	 better	 understand	 how	
users/consumers/patients	 and	 providers/scientists/producers	 engage	 new	




Optimisation	 is	 generally	 used	 when	 discussing	 human	 enhancement	 technologies,	
however,	it	can	also	be	discussed	when	examining	PrEP.	PrEP	prevents	the	occurrence	

















Do	MSM	 from	 Canterbury	 feel	 that	 PrEP	 has	 a	 place	 in	 New	 Zealand’s	 public	 health	









previously	 mentioned,	 PrEP	 can	 reduce	 HIV	 infections	 by	 over	 92%	 when	 taken	
consistently	and	combined	with	additional	prevention	methods.405,	406,	407,	408	However,	
PrEP	uptake	has	been	slow	worldwide,	and	Chapter	2	discussed	concerns	patients	and	
providers	 have	with	PrEP.	This	 thesis	 explores	 the	 opinions	 and	 attitudes	 regarding	
PrEP	to	gain	an	understanding	of	community	reactions	to	the	drug.	The	thesis	research	











In	 order	 to	 achieve	 the	 research	 aims,	 the	 thesis	 follows	 the	 problem-solving	
model,	 as	 originated	by	Carol	H.	Weiss.	 This	model	 uses	 a	 combination	of	 “evidence	
and	 conclusions”	 to	 find	 solutions	 to	 a	 particular	 policy	 problem	 that	 currently	


















application	 of	 research,”	 and	 high-quality	 research	 is	 required	 to	 fill	 the	 gaps	 in	 the	
knowledge.411,	412	The	type	of	research	conducted	does	not	matter	so	long	as	it	reduces	
the	uncertainty	regarding	the	problem	and	provides	clear	policy	options.413,	414	In	this	
case,	 the	 policy	 problem	 is	 the	 successful	 implementation	 of	 PrEP,	 taking	 into	
consideration	 the	 uncertainties	 linked	 to	 the	 complexities	 of	 the	 drug	 and	 that	 no	
PrEP-focused	 studies	 have	 been	 undertaken	 in	 New	 Zealand	 prior	 to	 this	 research.	
(However,	 in	 the	 course	 of	 this	 research,	 the	 researcher	 was	 made	 aware	 that	 the	
Ministry	 of	Health	 (MOH)	 is	 currently	 developing	 a	 policy	 for	 PrEP	 in	New	Zealand.	
The	 researcher	 has	 limited	 information	 about	 the	 scope	 of	 MOH’s	 policy,	 but	 this	
research	may	be	able	to	contribute	to	the	MOH’s	policy.)	Therefore,	this	thesis	follows	
the	 problem-solving	 method	 by	 using	 multiple	 research	 methods	 to	 reduce	
uncertainty	 regarding	 PrEP,	 allowing	 for	 the	 development	 a	 successful	 PrEP	 policy	
designed	for	MSM	in	New	Zealand.	This	research	consists	of	one	quantitative	method	
and	 two	 qualitative	methods.	 The	 quantitative	method	 is	 an	 attitude	 scaling	 survey,	
and	 the	 qualitative	 methods	 are	 interviews,	 and	 document	 analysis.	 Qualitative	
methods	provide	a	rich415	context	to	a	policy	problem,	while	quantitative	methods	fill	
in	 the	 contextual	 blanks	 that	 occur	 in	 qualitative	 research.416	Subsequently,	 mixed-
methods	 research	 design	 produces	 arguably	 better	 quality417 	and	 more	 targeted	
results.	 Furthermore,	 using	 multiple	 methods	 gives	 the	 researcher	 a	 sense	 of	
confidence:	 if	one	method	falls	short	or	does	not	produce	adequate	results,	 there	are	
additional	methods	that	can	still	fulfil	the	research	aims.		










































enough	 LGBTI	 participants.	 As	 a	 result,	 this	 research	 used	 non-probability	 sampling	
methods	 to	 gain	 enough	 participants.418	Non-probability	 sampling	 methods	 are	 a	
collection	 of	 “sampling	 technique[s]	 for	 which	 the	 probability	 of	 a	 person	 being	
selected	 into	 the	 sample	 is	 unknown.”419	The	 biases	 of	 non-probability	 sampling	 are	
well-known	 and	 will	 be	 discussed	 in	 further	 detail	 in	 the	 Ethical	 Considerations	
section,	 but	 it	 is	 important	 to	 recognise	 that	 non-probability	 sampling	 methods	
provide	 a	 good	 option	 when	 there	 is	 no	 requirement	 to	 assess	 the	 particular	
population	prevalence	of	a	variable.420	Participants	for	the	online	survey	were	targeted	
using	 purposive	 sampling	 where	 subjects	 are	 carefully	 selected	 based	 on	
characteristics	 that	are	of	 interest	 to	 the	 researcher.421,	422,	423,	424	Participants	 for	 this	
survey	were	targeted	based	on	their	self-identification	as	MSM	and	their	potential	 to	
have	 an	 opinion	 about	 PrEP	 for	 HIV	 prevention.	 The	 survey	 was	 voluntary	 so	 if	
potential	subjects	did	not	identify	as	MSM	they	did	not	have	to	participate.			
The	 survey	 was	 hosted	 on	 Qualtrics	 using	 the	 University	 of	 Canterbury’s	
license.	The	decision	to	post	the	survey	online	was	based	on	three	key	factors.	Firstly,	
an	 online	 survey	makes	 it	 easier	 to	 ensure	 that	 the	 participants	 remain	 anonymous	
and	their	associated	answers	cannot	be	 identified425	compared	to	paper	surveys	 that	
participants	complete	in	front	of	the	researcher.	This	guarantee	of	anonymity	is	more	























the	 Internet	 for	 social	 and	 dating	 purposes,	 which	 contributes	 to	 their	 large	 online	









the	 advertisement	 of	 the	 survey	 before	 it	 was	 posted	 online	 (see	 Appendix	 2).	 The	
survey	was	 promoted	 using	 open	 access	 so	 participants	 did	 not	 need	 to	 contact	 the	
researcher	 to	 get	 a	 link	 for	 the	 study,	 which	 is	 useful	 for	 promoting	 a	 “sense	 of	










was	 on	March	 1	 2017.	 These	 groups	were	 all	 sent	 the	 same	 advert	 and	 link	 to	 the	
survey.	A	second	batch	of	survey	advertising	was	sent	on	March	6	2017.	These	groups	
were	 sent	 the	 same	 advert	 as	 the	 first	 release,	 but	 the	 researcher	 did	 not	 post	 the	
advert	on	 this	occasion	due	 to	 the	group’s	privacy	settings.	The	second	round	of	 the	
survey	was	advertised	on	March	22	and	March	27	2017,	exactly	three	weeks	after	the	
adverts	were	 initially	posted.	The	researcher	posted	all	of	 these	advertisements.	The	
final	 round	of	 the	 survey	 advertisements	were	 posted	 on	 the	April	 12	 and	April	 17,	
another	three	weeks	after	the	second	round.	The	survey	was	active	online	for	7	weeks	
and	closed	on	the	April	20.	Given	the	format	of	the	survey’s	sampling	and	advertising	



















The	 introduction	 provided	 background	 information	 to	 PrEP,	 including	 its	
highest	recorded	efficacy	level,	associated	side	effects,	the	average	cost	of	PrEP	in	NZ	$	
per	month,	 and	 an	 example	 of	 the	 survey	 questions.	 It	 had	 a	 clause	 stating	 that	 the	
results	 from	 the	 survey	were	 anonymous	 but	would	 be	 used	 for	 data	 analysis	 for	 a	
Master’s	thesis.	Respondents	were	required	to	give	consent	to	participate	in	the	survey	
as	 a	 requirement	 of	 the	 University’s	 HEC.	 Only	 participants	 that	 ticked	 ‘yes’	 to	 this	







openly	 provide	 their	 sexual	 identification	 without	 the	 researcher	 assuming	 that	
participants	would	only	fit	into	a	certain	number	of	options.		









it	 is	 considered	 the	most	 useful	 of	 the	 various	 scales	 for	 behavioural	 research.431	A	
Likert	 scale	 compromises	of	 a	 statement	 that	 the	participant	 is	 required	 to	 agree	or	
disagree	 with.	 Attitude	 scaling	 surveys	 simply	 portion	 respondents	 into	 broad	
categories	based	on	their	perceived	attitude	towards	a	statement	but	do	not	provide	
robust	statistical	insights.432	An	example	of	the	Likert	scale	questions	used	was	“I	don’t	








survey	 had	 four	 pre-fixed	 attitude	 answers:	 strongly	 agree,	 agree,	 disagree,	 and	
strongly	disagree.	A	Likert	scale	typically	has	five	options	for	an	answer,	as	it	includes	
a	neutral	choice,	however	it	is	not	uncommon	to	change	the	number	of	responses.433,	
434	Upon	 the	 development	 of	 the	 survey	 it	 was	 decided	 that	 removing	 the	 neutral	







Zealand.	 The	 purpose	 of	 the	 semi-structured	 interviews	 was	 to	 gain	 a	 better	
understanding	 of	 the	 current	 HIV	 infection	 trends.	 Interviews	 are	 a	 well-known	
qualitative	 method	 that	 uncovers	 experts’	 thoughts	 “on	 events,	 processes,	 and	
perceptions”	 of	 trends.435	Interviews	were	 used	 to	 fulfil	 the	 second	 research	 aim	 to	
gain	 a	 greater	 understanding	 of	 current	 HIV	 trends	 in	 New	 Zealand.	 Potential	
interviewees	were	picked	using	purposive	sampling,	as	their	expertise	in	HIV	provided	
a	 meaningful	 contribution	 to	 this	 research.	 Some	 potential	 interviewees	 that	 were	
identified	 prior	 to	 the	 interviews	 included	 New	 Zealand	 AIDS	 Foundation	 staff	
members,	 researchers,	 epidemiologists,	 community	workers	 specialising	 in	HIV,	 and	
health	 professionals.	 A	 specific	 number	 of	 interviews	 were	 not	 required	 but	 it	 was	
assumed	that	there	would	be	between	five	and	eight	interviewees	to	gain	a	rich	insight	
into	 HIV	 in	 New	 Zealand.	 All	 potential	 interviewees	 were	 invited	 to	 participate	 via	
email	correspondence.	The	email	contained	an	information	sheet	and	consent	form	as	
required	by	the	University’s	HEC	(see	Appendix	4).		
Interviewees	were	 encouraged	 to	 talk	 in	 a	 free	 and	 frank	manner	 during	 the	
interviews.	 All	 interviewees	 chose	 how	 to	 be	 identified	 in	 the	 research,	 but	 it	 was	
presumed	 that	 interviewees	would	 remain	 confidential	 unless	 stated	 otherwise.	 The	
following	individuals	took	part	in	the	interviews:	
	
• Sean	 Kelly,	 Manager	 Health	 Services,	 New	 Zealand	 AIDS	 Foundation,	
Christchurch;	














• Dr	 Nigel	 Raymond,	 Infectious	 Disease	 Specialist,	 Capital	 and	 Coast	 District	
Health	Board,	Wellington.	
	
It	 is	 important	 to	 note	 that	 only	 two	 interviewees	 acknowledged	 that	 they	 were	
authorised	to	speak	on	behalf	of	their	institution	(Dr	Nigel	Raymond,	Capital	and	Coast	





topics.	 The	 interviewer	 used	 open	 questions	 so	 the	 respondent	 had	 the	 ability	 to	
provide	 as	 much	 detail	 as	 desired436	and	 could	 freely	 bounce	 between	 topics.	 The	
majority	 of	 the	 questions	 asked	 were	 the	 same	 throughout	 the	 interviews,	 though	
there	 were	 additional	 questions	 based	 on	 the	 interviewees’	 specialisations.	 This	
flexible	 format	 ensured	 that	 ‘off-topic’	 conversations	 could	 still	 offer	 important	
insights437	needed	 to	 answer	 the	 research	 aims.	 Some	 examples	 of	 the	 consistent	
questions	asked	include:	
	









researcher	 to	 facilitate	 discussion	 with	 the	 interviewee	 instead	 of	 concentrating	 on	
transcribing	 the	 conversation	 accurately.	 Interviews	 were	 transcribed	 in	 full	 and	
emailed	 to	 the	 interviewee	 to	 confirm	 within	 five	 working	 days.	 The	 researcher	
assumed	that	if	there	was	no	response,	the	interviewee	was	happy	with	the	transcript.	












papers,	 and	 legislation.	 Document	 analysis	 was	 chosen	 as	 the	 final	 method	 for	 this	
research	 because	 it	 provides	 supplementary	 information	 that	 is	 highly	 valuable	 to	
achieving	the	second	research	aim	and	the	overall	study.	In	addition,	when	combined	
with	 further	 methods,	 document	 analysis	 validates	 common	 trends,	 minimises	
potential	 biases	 that	 could	 occur,	 and	 increases	 the	 integrity	 of	 findings.439 	For	
example,	the	majority	of	the	information	that	was	examined	in	Chapters	1	and	2	was	










research	method	 for	 future	development	of	PrEP	policies	 in	New	Zealand.	While	 the	
focus	group	did	not	ultimately	occur,	the	use	of	the	three	other	methods	ensured	the	









mind,	 the	 researcher	 consulted	with	 a	 statistician	 to	 ensure	 that	 the	 analysis	 of	 the	
results	would	 be	 adequate.	 It	was	 agreed	 that	 given	 the	 use	 of	 the	 Likert	 scale,	 the	
relatively	 small	 sample	 (although	 considered	 large	 in	 statistical	 terms),	 and	 the	
research	aims,	it	would	be	acceptable	to	present	the	data	in	its	raw	form.	The	rationale	
behind	 this	 decision	 was	 that	 the	 data	 was	 exploratory	 and	 there	 was	 no	 need	 to	










attitudes	 towards	 the	 survey	 topics.	 Furthermore,	 the	 results	 from	 the	 survey	 are	
complimented	by	the	additional	research	methods.	Therefore,	there	was	no	statistical	
analysis	 of	 the	 survey;	 Chapter	 4	 simply	 presents	 the	 spread	 of	 attitudes	 to	 each	
question.		
Interviews	
The	 data	 processing	 for	 the	 interviews	 is	 the	 transcript;	 the	 transcripts	 were	
completed	 within	 five	 working	 days	 of	 the	 interview	 to	 ensure	 that	 what	 was	
discussed	was	still	fresh	in	the	interviewee’s	mind.	The	analysis	of	the	interviews	was	
conducted	 using	 NVivo	 11.4.0	 for	 Mac.	 The	 interviews	 were	 coded	 using	 NVivo	 to	
highlight	 themes	 that	were	 shared	 between	 the	 interviewees	 on	 specific	 topics.	 The	
coding	also	showed	the	discrepancies	between	what	interviewees	said.	The	analysis	of	
the	 interviews	 is	not	presented	 in	a	 subsequent	 chapter,	but	 the	 trends	and	 insights	
that	 were	 revealed	 through	 NVivo	 coding	 are	 used	 to	 complement	 the	 policy	
recommendation	for	PrEP	that	is	presented	in	Chapter	5.	
Ethical	considerations	
As	with	all	 research,	 there	are	ethical	 considerations	 that	must	be	 factored	 in	 to	 the	
overall	 project.	 Every	methodological	decision	 that	was	made	needed	 to	 ensure	 that	
the	participants	who	volunteered	their	time	were	treated	respectfully.	This	section	will	
discuss	 three	 ethical	 considerations	 that	 occurred	 throughout	 the	 research:	 LGBTI	
subjects,	 discussing	 sexual	 behaviour	 and	 HIV,	 and	 Human	 Ethics	 approval.	 This	
comprehensive	 discussion	 of	 research	 ethics,	 given	 both	 the	 sensitive	 nature	 of	 the	
research	 topic	 and	 the	 fact	 that	 this	 thesis	 constituted	 a	 valuable	 learning-by-doing	
experience,	may	inform	future	work	on	PrEP	and	HIV	prevention	in	New	Zealand.	
Research	focusing	on	LGBTI	
The	methodological	 difficulties	 of	 studying	 LGBTI	 populations	 are	well	 documented:	
identifying	LGBTI	populations	that	are	easily	defined,	gaining	ethics	approval,	reaching	
the	 population	 to	 advertise	 the	 research,	 getting	 enough	 participants	 for	 a	 credible	
sample	 size,	 and	 avoiding	 any	discrimination	 or	 offence.443,	444,	445	As	mentioned,	 it	 is	
almost	 impossible	 to	 use	 probability	 sampling	 for	 LGBTI	 groups	 because	 they	 are	 a	
minority	of	 the	wider	population,	 so	 the	 chance	of	 finding	a	 representative	group	 in	
the	sample	is	highly	unlikely.	The	population	is	even	smaller	when	researching	specific	
groups	within	the	LGBTI	community,	such	as	MSM,	which	makes	the	sample	harder	to	
















LGBTI	 community.	 This	 decision	 limits	 the	 generalisability	 of	 the	 findings	 and	 the	
sample	cannot	be	considered	representative,	but	it	was	the	best	choice	to	ensure	that	
the	 sample	 size	 was	 large	 enough	 to	 provide	 meaningful	 results.	 Despite	 these	
methodological	 challenges,	 purposive	 sampling	 using	 LGBTI	 groups	 in	 Christchurch	
still	ensures	that	the	participants	recruited	for	the	survey	made	a	credible	sample	to	
fulfil	the	research	objectives.455	
	 One	 ethical	 consideration	 raised	 by	 a	member	 of	 an	 online	 LGBTI	 group	was	
that	 the	 survey	needed	 to	 include	more	 trans-	 and	 gender-diverse	 terms.	This	point	









had	been	 live	 for	 nearly	 one	week	 so	 any	 changes	 to	 the	 survey	while	 it	was	 active	




were	 released	 for	 a	 second	 time.	 This	 valuable	 input	 also	 seems	 to	 reflect	 the	






















marked	as	U	 for	sex	on	their	health	card	 in	 July	2017).	Future	research	on	PrEP	and	
health	 issues	 more	 broadly	 will	 need	 to	 incorporate	 this	 feedback	 and	 the	 author	
appreciated	the	opportunity	to	learn	from	the	study	community.		
Research	focusing	on	sexual	behaviour	and	HIV	
Further	 to	 the	 complications	 regarding	LGBTI	 respondents,	 the	 research	design	 also	
needed	to	consider	the	sensitivity	of	exploring	sexual	behaviour	and	attitudes	towards	
HIV.	Sensitive	 research	 is	defined	by	asking	questions	about	a	 topic	 that	 is	normally	
considered	 personal	 and	 may	 cause	 the	 respondent	 to	 feel	 offended	 or	
uncomfortable.456	Of	the	three	methods	used	for	this	research,	the	survey	is	most	likely	
to	 be	 considered	 sensitive	 research	 given	 the	 frank	 nature	 of	 the	 questions,	 which	
could	 elicit	 a	 negative	 reaction	 (see	 Appendix	 3).	 However,	 a	 meta-analysis	 of	 sex	
research	 has	 found	 that	 the	 anonymity	 of	 online	 research	 methods	 can	 encourage	
participants	to	share	‘frowned	upon’	behaviour,	such	as	risky	or	illegal	activities.457	In	
order	to	make	the	potential	respondents	feel	as	comfortable	as	possible	answering	the	






As	 a	 requirement	 of	 the	 University	 of	 Canterbury,	 any	 research	 involving	 human	
participants	must	be	approved	by	the	HEC.	The	first	application	for	this	research	was	




Gay/Bi/MSM	have	multiple	 partners,	 and	 have	 anal	 intercourse.	 However,	 some	
gay	 couples	 show	 exclusive	 fidelity	 and	may	 be	 offended	 by	 the	 suggestion	 that	
they	 should	 take	 PrEP.	 There	 are	 also	 people	who	 identify	 as	 Gay	 or	 Bi	 but	 are	
celibate	 for	 religious	 or	 other	 reasons.	 It	 would	 be	 worth	 considering	 these	





researcher	 cited	 statistics	 from	 the	 2002-2014	 Gay	 Auckland	 Periodic	 Sex	 Surveys	










76.9%	of	 respondents	had	between	2	and	over	50	sexual	partners	 in	 the	six	months	
prior	to	the	surveys,	respectively.459	More	than	80%	of	MSM	from	both	the	GAPSS	and	
GOSS	 engaged	 in	 anal	 intercourse	with	 a	 regular	 and	 irregular	 sexual	 partner.460,	461	
The	 researcher	 justified	 their	 thesis,	 stating	 that	 it	 does	 not	 intend	 to	 make	
assumptions	about	the	sexual	behavior	of	MSM,	but	is	simply	based	on	recent	statistics	
of	MSM	from	New	Zealand.			
	 The	researcher	also	 responded	 to	 the	HEC’s	 concern	 that	 there	are	MSM	who	
remain	celibate	for	personal	reasons	and	may	take	offence	to	the	suggestion	that	they	
should	 use	 PrEP.	 It	was	 argued	 that	MSM	who	 are	monogamous,	 celibate	 or	 do	 not	
engage	in	anal	intercourse	are	unlikely	to	need	PrEP	given	their	low	HIV-risk.	Higher-
risk	 MSM	 that	 may	 benefit	 from	 using	 PrEP	 include	 members	 of	 serodiscordant	
couples,	 MSM	 with	 multiple	 sexual	 partners,	 and	 MSM	 that	 do	 not	 regularly	 use	
condoms.	 Therefore,	 there	 should	 be	 no	 need	 for	 MSM	 who	 have	 a	 low-risk	 of	
contracting	HIV	to	feel	offended	by	the	research,	as	they	are	not	the	target	population	
for	PrEP.	The	researcher	also	stated	that	if	individuals	feel	that	they	are	not	high-risk	





in	 place	 to	 deal	with	 potentially	 offended	 individuals,	 as	 it	was	 not	 the	 researcher’s	
intent	to	generalise	all	MSM	into	a	one-size-fits-all	category.	The	researcher	provided	
contact	 details	 so	 participants	 could	 get	 in	 touch	 if	 they	 did	 take	 offence	 to	 the	
research.		




of	 the	 2017	 university	 year	 to	 ensure	 that	 more	 potential	 participants	 could	 be	
captured	in	the	online	groups.	However,	in	late-February	2017,	it	was	discovered	that	





27	 2017.	 The	 HEC’s	 acceptance	 of	 the	 new	 sampling	 method	 was	 approved	 on	 the	













end	 of	 the	 survey.	 Interviewees	 were	 required	 to	 sign	 the	 interview	 consent	 form	
before	 it	 took	place	 (see	Appendix	4).	This	 form	also	 informed	 the	researcher	of	 the	
interviewee’s	ability	to	talk	on	behalf	of	their	institution.		
Validity	
Validity	 is	 a	 crucial	 aspect	 of	 research	 because	 it	 ensures	 that	 the	 findings	 are	
“plausible,	 credible,	 trustworthy,	 and,	 therefore,	 defensible.”462	Donald	 T.	 Campbell	
and	Julian	C.	Stanley	claimed	that	there	are	two	types	of	validities	in	primary	research:	
internal	validity,	and	external	validity.	Internal	validity	is	the	level	“with	which	we	can	
infer	 that	 a	 relationship	 between	 two	 variables	 is	 casual	 or	 that	 the	 absence	 of	 a	
relationship”	 shows	 limited	 causality.463	External	 validity	 focuses	 on	 the	 level	 of	
generalisability	 that	 occurs	 from	 the	 research	 results,464	and	 “the	 extent	 to	 which	
conclusions	can	be	applied	across	different	populations	or	situations.”465		
	 This	 research	 is	 high	 in	 internal	 validity,	 as	 none	 of	 the	 eight	 elements	 of	
internal	 validity	 as	 identified	 by	 Campbell	 and	 Stanley	 were	 jeopardised.	 This	
conclusion	 is	 based	 on	 the	 fact	 that	 all	 of	 the	 chosen	 research	 methods	 were	 only	







triangulation,	which	occurs	when	a	 research	project	uses	multiple	methods	 to	 test	 a	
hypothesis	 or	 subject. 467 	Triangulation	 can	 be	 used	 numerous	 ways,	 such	 as	
“measuring	 variables	 in	 more	 than	 one	 way	 or	 addressing	 hypotheses/research	




















This	 study	 used	 ‘between	 methods'	 triangulation,	 which	 occurs	 when	 the	
researcher	 uses	 a	 variety	 of	 differing	 methods	 to	 achieve	 a	 shared	 research	
objective.471As	 briefly	 discussed	 in	 the	 Research	 Design	 section,	 multiple	 mixed-
methods	 were	 chosen	 because	 if	 one	 method	 fell	 through,	 the	 triangulation	 of	 the	
other	methods	ensured	the	research	aims	could	still	be	achieved.	This	occurred	when	
the	 focus	 group	was	 cancelled	 but	 the	 researcher	 could	 still	 rely	 on	 the	 other	 three	
methods	 to	 answer	 the	 research	 questions.	 Furthermore,	 triangulation	 was	 picked	
because	 it	 ensures	 that	 the	 weaknesses	 of	 one	 method	 are	 compensated	 by	 the	
strengths	 of	 the	 other	 chosen	 methods.472 ,	473 	As	 a	 result,	 the	 researcher’s	 work	
benefitted	 from	 the	 statistical	 data	 collected	 through	 the	 survey	 and	 the	 rich	
qualitative	data	that	was	drawn	out	by	exploring	opinions,	ideas,	and	attitudes	through	
interviews	 and	 document	 analysis.	 When	 the	 results	 from	 the	 research	 were	
reinforced	through	triangulation,	the	findings	of	this	study	gained	validity.474		
However,	 it	 is	 worthwhile	 to	 note	 that	 replicating	 studies	 to	 ensure	 external	
validity	 is	 much	 harder	 when	 the	 studies	 use	 triangulation.475	Likewise,	 qualitative	
methods	 are	more	difficult	 to	 replicate	 than	quantitative	 research.476	Therefore,	 it	 is	





























uncertainty	 and	 provide	 a	 policy	 recommendation.	 The	 thesis	 uses	multiple,	mixed-
methods	 to	 achieve	 these	 aims	 and	 answer	 the	 overall	 research	 questions.	 The	
quantitative	online	 survey	using	 the	Likert	 scale	was	used	 to	 fulfil	 the	 first	 research	
aim.	 Participants	 were	 recruited	 using	 non-probability	 purposive	 sampling	 and	 the	
survey	was	 hosted	 on	Qualtrics.	 The	 second	 research	 aim	was	 achieved	 through	 in-
depth	 Skype	 or	 face-to-face	 interviews	 with	 HIV/AIDS	 experts	 from	 around	 New	
Zealand.	 Interviewees	 were	 invited	 to	 participate	 via	 email	 and	 recruited	 using	
purposive	sampling.	There	were	6	 interviews	and	7	 interviewees.	The	research	aims	
were	complimented	by	the	use	of	document	analysis.		
	 The	 analysis	 of	 each	 research	 methods	 differed.	 The	 results	 from	 the	 online	
survey	were	not	statistically	analysed,	but	have	been	presented	in	a	raw	form	due	to	





account	 throughout	 the	 thesis.	 Firstly,	 there	 were	 methodological	 challenges	 that	
needed	 to	 be	 overcome	 due	 to	 the	 complexities	 of	 researching	 LGBTI	 populations.	
Similarly,	 topics	 such	as	 sexual	behaviour	and	HIV	are	 sensitive	 to	 those	 involved	 in	
the	research.	As	a	result,	the	researcher	had	to	be	very	careful	about	dealing	with	the	
participants	 to	 ensure	 they	were	 respected	 and	 felt	 comfortable	 to	 participate.	 As	 a	
requirement	of	the	HEC,	all	of	the	research	methods	and	sampling	methods	had	to	be	





note	 the	 triangulation	 of	 research	 methods,	 which	 can	 validate	 the	 results	 of	 the	
research	further	despite	the	lack	of	external	validity.	
	 The	 next	 chapter,	 Chapter	 4,	 will	 display	 the	 exploratory	 results	 from	 the	





100%	 of	 participants	 ‘strongly	 agree’	 or	 ‘agree’	 that	 PrEP	 is	 a	 worthwhile	 HIV	





that	was	conducted	 in	March	and	April	2017.	 It	 is	 important	 to	note	 that	 the	sample	
size	 is	 small	 compared	 to	 other	 behavioural	 surveys	 and	 the	 generalisability	 of	 the	
results	must	be	viewed	carefully.		
Introduction	
As	discussed	 in	Chapter	3,	 the	aim	of	 this	 thesis	 is	 to	design	a	health	policy	 for	PrEP	
implementation	for	MSM	in	New	Zealand.	The	overall	research	questions	are:	Do	MSM	
from	Canterbury	feel	that	PrEP	has	a	place	in	New	Zealand’s	public	health	system,	and	
how	 could	 a	 policy	 be	 developed	 to	 minimise	 the	 difficulties	 faced	 overseas?	 The	
objective	 of	 the	 anonymous,	 online	 attitude	 scaling	 survey	 is	 to	 accomplish	 the	 first	
research	aim,	which	is	to	uncover	and	analyse	the	attitudes	of	MSM	towards	PrEP	and	
HIV	in	the	Canterbury	region.	
	 The	 researcher	 based	 the	 frank	 questions	 of	 the	 survey	 on	 the	Gay	Auckland	
Periodic	Sex	Survey	(GAPSS)	and	Gay	men’s	Online	Sex	Survey	(GOSS).	The	GAPSS	has	




the	 opportunity	 to	 create	 evidence-based	 and	 scientific	 HIV/AIDS	 campaigns.478	The	
GAPSS/GOSS	 were	 initially	 conducted	 biannually,	 but	 the	 cycle	 recently	 changed	 to	




























This	 survey	 primarily	 measured	 attitudes	 through	 the	 use	 of	 a	 Likert	 scale,	
however,	it	also	features	three	yes/no	questions	based	on	previous	behaviour.	Just	as	
large-scale	nationwide	surveys	 like	GAPSS	and	GOSS	direct	 future	HIV	policymaking,	
the	 researcher’s	 small-scale	 survey	 of	 MSM	 aims	 to	 achieve	 the	 overall	 research	





The	 methods	 used	 for	 the	 online	 survey	 are	 presented	 in	 detail	 in	 Chapter	 3.	 To	
summarise,	the	participants	were	asked	to	complete	a	self-administered,	online	survey	
via	 Facebook	 groups,	 Facebook	 pages,	 and	 email	 databases	 of	 LGBTI	 groups.	 The	
survey	used	non-probability	purposive	sampling,	as	participants	were	invited	to	take	
the	survey	based	on	characteristics	that	were	of	interest	to	the	researcher.484,	485,	486,	487	
The	 researcher	was	 interested	 in	 individuals	 that	 self-identified	 as	MSM	and	had	 an	
opinion	on	PrEP.	The	survey	was	open	access,	which	meant	 that	any	 individual	with	
the	URL	link	could	participate.	Participation	in	the	survey	was	voluntary.	Due	to	a	lack	
of	 funding,	 the	 researcher	 was	 limited	 to	 promoting	 the	 survey	 for	 free	 and	 no	
compensation	was	offered.	There	was	no	pilot	 testing	undertaken	before	 the	 survey	

















four	 sections:	 an	 introduction;	 a	 demographics	 section;	 an	 HIV	 and	 condom	 use	
section;	 and	 a	 section	 on	 attitudes	 towards	 PrEP.	 To	 reiterate,	 the	 introduction	
provided	 background	 information	 for	 the	 survey,	 including	 important	 information	
about	PrEP	such	as	efficacy,	cost,	side	effects,	and	an	example	of	the	survey	questions.	
The	introduction	also	had	a	consent	question	as	required	by	the	University’s	HEC.	The	
demographic	 section	 gathered	 data	 on	 age,	 gender,	 ethnicity,	 and	 sexuality.	 This	
section	contained	the	only	two	questions	that	were	compulsory	(age,	presented	in	age	
brackets,	and	gender,	which	also	included	a	‘prefer	not	to	disclose’	option).	The	third	
section,	 HIV	 and	 condom	 use,	measured	 attitudes	 towards	 condoms	 during	 sex	 and	
HIV.	The	majority	of	section	three’s	questions	were	presented	using	the	4-point	Likert	
scale.	 There	 were	 three	 questions	 in	 section	 three	 that	 were	 yes/no	 behavioural	
questions.	 The	 final	 section	 measured	 attitudes	 towards	 PrEP	 and	 all	 of	 these	
questions	were	presented	using	the	Likert	scale.	While	most	typical	Likert	scales	use	
5-points	 (strongly	 agree,	 agree,	 neutral,	 disagree,	 strongly	 disagree),	 a	 decision	was	
made	 to	 remove	 the	 neutral	 option	 and	 use	 a	 4-point	 scale.	 The	 researcher	
acknowledges	 that	 Likert	 scales	measure	 broad	 attitudes	 but	 do	 not	 provide	 results	
that	 can	 be	 used	 to	 make	 generalisations	 or	 future	 predictions	 about	 the	
participants.488	
Results	
Between	 March	 1	 2017	 and	 April	 20	 2017,	 forty-two	 participants	 took	 part	 in	 the	
attitude	 scaling	 survey	 of	 Canterbury	 MSM.	 Given	 the	 voluntary	 nature	 of	 the	
questions,	 there	 was	 a	 mix	 of	 38	 to	 42	 respondents	 for	 each	 question.	 The	 mean	
number	 of	 respondents	 was	 39,	 excluding	 the	 questions	 where	 participants	 were	
asked	to	write	 their	sexuality	and	ethnicity.	No	participants	were	excluded	 from	this	
study,	as	it	was	voluntary	to	complete	the	survey.		
	 After	 discussion	 with	 the	 Statistics	 Consulting	 Group	 at	 the	 University	 of	
Canterbury,	the	researcher	made	the	decision	to	present	the	following	results	in	their	
raw	form	because	the	data	is	exploratory.	There	has	been	no	statistical	analysis	for	the	









The	 spread	 of	 the	 respondents’	 ages	 were	 as	 follows:	 18-24	 years,	 51.22%;	 25-34	
years,	19.51%;	35-44	years,	14.63%;	45-54	years,	12.2%;	and	55-64	years,	2.44%.	39	
respondents	identified	as	male	(95.12%),	one	participant	identified	as	female	(2.44%)	
and	one	participant	 chose	 the	option	 ‘other/prefer	not	 to	 answer’	 (2.44%).	Figure	4	
present	the	distribution	of	the	participants’	ages	and	genders.		
30	 participants	 provided	 their	 ethnicity.	 Of	 these,	 twenty-three	 (76%)	 identified	 as	
Pākehā/New	Zealand	European/New	Zealand	Caucasian/white,	four	(12%)	identified	
as	Māori	or	Māori	and	another	ethnicity,	 two	(6%)	 identified	as	Asian	or	Asian	with	
another	 ethnicity,	 and	 one	 (3%)	 identified	 as	 British.	 35	 participants	 provided	 their	
sexual	 orientation.	Of	 these,	 twenty-five	 (71%)	 identified	 as	 gay/homosexual/queer,	
two	 (5%)	 as	 bisexual,	 two	 (5%)	 as	 pansexual,	 and	 six	 (17%)	 as	 other.	 ‘Other’	























Likewise,	 the	 majority	 of	 the	 respondents	 also	 shared	 similar	 attitudes	 towards	
sharing	 one’s	 HIV	 status	 with	 sexual	 partners.	 Figure	 8	 displays	 that	 90%	 of	
participants	 ‘agreed’	 or	 ‘strongly	 agreed’	 that	 it	 is	 important	 to	 tell	 their	 sexual	
partners	 about	 their	 HIV	 status.	 4	 participants	 ‘disagreed’	 with	 this	 statement.	 The	
results	 from	Figure	9	 show	a	 similar	 attitude	 to	 the	 importance	of	 knowing	 the	HIV	
status	of	one’s	sexual	partners.	Only	three	participants	‘agreed’	that	they	did	not	care	







	 Figures	10	and	11	did	not	 follow	the	Likert	scale	 format	 that	was	used	 in	 the	
majority	of	the	survey;	these	two	statements	were	the	second	and	third	of	the	yes/no	
questions	 (the	 first	was	 the	whether	 participants	 knew	 their	 HIV	 status).	 Figure	 10	
shows	the	proportion	of	respondents	who	had	engaged	in	anal	sexual	intercourse	with	
another	male	with	 a	 condom	 in	 the	 last	 twelve	months.	 This	 statement	was	used	 to	
provide	a	comparison	to	Figure	11,	which	depicts	the	proportion	of	participants	who	
had	engaged	 in	anal	 sexual	 intercourse	with	another	male	 in	 the	 last	 twelve	months	
without	a	condom.	
Figures	12	and	13	were	also	designed	for	comparison.	Figure	12	shows	the	spread	of	
attitudes	 when	 asking	 an	 irregular	 sexual	 partner	 to	 use	 a	 condom	 for	 anal	 sex.	
87.18%	of	participants	felt	comfortable	asking	a	one	night	stand,	friend	with	benefits,	
or	new	sexual	partner	to	use	a	condom.	The	proportion	of	participants	who	‘disagreed’	
or	 ‘strongly	 disagreed’	 with	 this	 statement	 was	 less	 than	 Figure	 13	 where	 the	
respondent	 was	 engaging	 in	 anal	 sex	 with	 a	 regular	 partner.	 Nearly	 85%	 of	













The	 distribution	 of	 the	 participants’	 answers	 in	 Figures	 12	 and	 13	 was	
unexpected.	 Figure	 12	 showed	 a	 large	 skew	 of	 subjects	 stating	 that	 they	 ‘strongly	
agreed’	 about	 feeling	 comfortable	when	 asking	 an	 irregular	 partner	 to	 use	 condoms	
and	 there	 was	 a	 large	 difference	 between	 the	 distribution	 of	 ‘strongly	 agreed’	 and	
‘agreed’	 responses.	 By	 contrast,	 Figure	 13	 shows	 the	 majority	 of	 participants	 were	
comfortable	asking	a	regular	partner	to	use	a	condom	and	there	was	 little	difference	











necessary	 for	 safe	 anal	 sexual	 intercourse	 between	 two	men.	 71.8%	 of	 participants	













did	 not	 have	 condoms	 handy,	 they	 would	 still	 have	 anal	 sex.	 Over	 two-thirds	 of	






The	 questions	 in	 the	 following	 section	were	 purposefully	 picked	 to	 address	 specific	
complications	 that	have	arisen	since	 the	emergence	of	PrEP.	Some	of	 these	concerns	
include	 embarrassment	 associated	 with	 using	 PrEP,	 cost,	 the	 claim	 that	 PrEP	
encourages	promiscuity,	and	adherence	to	the	daily	drug	regimen	and	regular	testing.		
	 100%	 of	 participants	 shared	 a	 positive	 attitude	 towards	 the	 statement	 that	








Figures	 18	 and	19	 show	 the	 attitudes	 towards	 discussing	 sexuality	 and	PrEP	with	 a	
general	practitioner	or	doctor.	As	shown	in	Figure	18,	87.5%	of	participants	‘strongly	
agreed’	or	‘agreed’	that	they	feel	comfortable	talking	to	their	doctor	about	their	sexual	
orientation.	 3	 participants	 ‘disagreed’	 and	 two	participants	 ‘strongly	 disagreed’	with	
this	 statement.	 Figure	 19	 shows	 the	 results	 for	 the	 statement	 that	 respondents	 felt	
comfortable	 asking	 their	 doctor	 for	 PrEP.	 82.5%	 of	 participants	 ‘strongly	 agreed’	 or	
‘agreed’	 with	 this	 comment.	 The	 number	 of	 subjects	 that	 had	 a	 negative	 attitude	
towards	 asking	 their	 doctor	 for	 PrEP	 was	 slightly	 higher	 than	 the	 statement	 about	
discussing	sexuality	with	a	doctor.	
The	 vast	majority	 of	 the	 respondents	 shared	 a	 similar	 attitude	 towards	 taking	 PrEP	
everyday,	 as	 shown	 in	 Figure	 20.	 85%	 of	 respondents	 ‘disagreed’	 or	 ‘strongly	




Figure	 21	 shows	 the	 results	 for	 the	 statement	 that	 the	 requirement	 for	 regular	HIV	




































less	 likely	 to	use	 condoms.	The	majority	of	 the	 respondents	held	 a	negative	 attitude	
towards	 this	 statement.	3	participants	 ‘strongly	agreed’	 (7.69%),	 twelve	participants	




Figure	25	 shows	 the	 levels	of	 embarrassment	 the	participants	 associated	with	using	
PrEP.		A	minority	(12.5%)	of	participants	‘agreed’	or	‘strongly	agreed’	that	they	would	




for	 MSM/gay	 and	 bisexual	 men	 in	 New	 Zealand	 for	 HIV	 prevention.	 1	 participant	
‘disagreed’	(2.5%),	while	97.5%	of	respondents	‘strongly	agreed’	or	‘agreed’	that	PrEP	
should	be	subsidised	for	MSM/gay	and	bisexual	men.		
The	 final	question	 in	 the	PrEP	section	measured	whether	participants	believe	
that	PrEP	is	a	worthwhile	method	of	HIV	prevention	for	MSM/gay	and	bisexual	men	in	







towards	 HIV,	 condom	 use,	 and	 PrEP	 using	 a	 4-point	 Likert	 scale.	 The	 following	
discussion	of	 the	results	 is	split	 into	 the	 two	sections	of	 the	survey.	The	trends	 from	
the	HIV	and	condom	usage	section	have	been	 linked	back	 to	 the	GAPSS/GOSS	 tables	





The	 results	 are	discussed	 in	 a	 similar	order	 to	how	 they	are	presented	above	 in	 the	
Results	 section	 for	ease.	However,	 it	 is	 important	 to	note	 that	some	of	 the	questions	
are	not	exactly	 the	same	as	the	GAPSS/GOSS	questions,	so	any	conclusions	that	have	
been	drawn	by	the	researcher	are	not	entirely	concrete.		
Overall,	 it	 appeared	 that	 the	 participants	 generally	 shared	 similar	 attitudes	





HIV	 in	 New	 Zealand	 and	 that	 up	 to	 80%	 of	 new	 infections	 can	 occur	 in	 the	 MSM	


















	 Knowing	 one’s	 HIV	 status	 and	 the	 status	 of	 a	 sexual	 partner	 is	 important	 to	
ensure	 that	all	appropriate	steps	can	be	 taken	 to	prevent	 the	spread	of	HIV.	Overall,	
survey	 participants	 had	 a	 common	 attitude	 that	 it	 is	 important	 to	 share	 their	 HIV	
status	with	a	sexual	partner	and	visa	versa.	However,	10%	of	respondents	‘disagreed’	
that	 it	 was	 important	 to	 tell	 their	 partners	 about	 their	 HIV	 status	 and	 7.5%	 of	
participants	 ‘agreed’	 that	 they	 did	 not	 care	 about	 their	 sexual	 partner’s	 HIV	 status.	
These	 results	 show	 that	 future	 HIV	 prevention	 programmes	 may	 need	 to	 place	 a	
higher	 priority	 on	 the	 importance	 of	 sharing	 HIV	 statuses	 with	 sexual	 partners	 to	
ensure	 that	 both	parties	 can	 avoid	passing	on	 the	 virus.	However,	 it	 is	 important	 to	
consider	 that	 the	 proportion	 of	 participants	 who	 had	 alternate	 attitudes	 towards	
sharing	 HIV	 statuses	 was	 much	 smaller	 in	 this	 survey	 than	 the	 GAPSS/GOSS.	 The	
GAPSS	showed	 that	42.2%	of	participants	 ‘disagreed’	and	24.8%	 ‘strongly	disagreed’	
that	 an	 HIV-positive	man	would	 tell	 them	 his	 status	 before	 they	 had	 sex.	 Similarly,	
58.7%	 ‘disagreed’	 or	 ‘strongly	disagreed’	with	 this	 statement	 in	 the	GOSS.492	Despite	
the	small	sample	size	of	this	survey,	it	is	important	to	recognise	that	a	small	minority	




simply	 not	 engaged	 in	 anal	 sexual	 intercourse	 with	 another	 male	 within	 that	 time	
period,	 or	 they	 do	 not	 use	 condoms	 at	 all.	 However,	 it	 is	 more	 important	 to	
acknowledge	that	more	than	half	of	the	respondents	did	engage	in	condomless	sex	in	
the	last	twelve	months.	The	researcher	cannot	assume	whether	this	result	is	because	
the	 two	 partners	 were	 both	 HIV-negative,	 an	 exclusive	 couple,	 or	 considered	
undetectable	 and	 uninfectious	 (U=U)493	because	 there	 were	 no	 further	 questions	 to	
discuss	 the	 background	 information	 behind	 these	 occasions.	 However,	 these	 results	
are	not	surprising	when	compared	 to	self-reported	condom	use	with	boyfriends	and	
casual	partners	 in	 the	GAPSS	and	GOSS.	Only	26.5%	and	23.6%	of	participants	 from	
the	 GAPSS	 and	 GOSS	 always	 used	 condoms	 with	 a	 boyfriend,	 respectively. 494	
Unsurprisingly,	 self-reported	condom	use	was	higher	among	 irregular	partners,	with	
















partner	 to	 use	 a	 condom.	 Both	 of	 these	 statements	 generated	 a	 similar	 number	 of	
negative	responses.	However,	10%	of	 the	participants	 ‘disagreed’	and	2.5%	 ‘strongly	
disagreed’	 that	 they	were	 comfortable	 asking	 an	 irregular	 partner	 to	 use	 a	 condom.	
This	surprised	the	researcher	given	the	results	discussed	above	from	the	GAPSS/GOSS	
where	condom	use	between	irregular	partners	was	much	higher	than	between	regular	
partners.	 Despite	 the	 negative	 responses	making	 up	 a	 small	 proportion	 of	 the	 final	
answers,	 more	 effort	 may	 need	 to	 be	 made	 to	 promote	 the	 importance	 of	 being	
confident	and	comfortable	when	asking	any	sexual	partner	to	use	a	condom	to	prevent	
HIV.		
	 One-third	of	 the	participants	reported	that	they	would	still	engage	 in	anal	sex	
even	 if	 the	 partner	 refused	 to	 wear	 a	 condom.	 Similarly,	 30.77%	 of	 participants	
‘strongly	 agreed’	 or	 ‘agreed’	 that	 they	would	 still	 have	 sex	 even	 if	 they	did	not	have	
condoms	 with	 them.	 These	 results	 seem	 quite	 high	 given	 the	 importance	 of	 using	
condoms	to	prevent	HIV,	particularly	when	compared	to	related	attitudinal	questions	
from	 GAPSS	 and	 GOSS.	 These	 studies	 showed	 that	 in	 general,	 attitudes	 towards	






and	GOSS	 	 ‘strongly	agreed’	or	 ‘agreed’	 that	 they	would	not	use	 condoms	 if	 a	 sexual	
partner	 didn’t	 want	 to	 use	 them,	 respectively.498	Combining	 the	 results	 from	 this	
GAPSS/GOSS	question	and	the	respondents	from	the	Canterbury	survey,	between	one	
in	three	and	one	 in	 five	participants	are	happy	to	engage	 in	sex	even	 if	 their	partner	
does	not	want	 to	use	a	condom.	Despite	 the	NZAF’s	claims	that	around	20%	of	MSM	
will	 not	 use	 condoms	 at	 all	 (these	 MSM	 are	 the	 ideal	 candidates	 for	 PrEP)	 ,499	the	
figures	from	this	survey	seem	to	be	much	higher	than	they	should	be.	It	is	possible	that	
those	participants	who	would	 still	 engage	 in	anal	 sex	 if	 the	partner	 refused	 to	use	a	











	 More	 than	 one	 in	 four	 participants	 ‘agreed’	 or	 ‘strongly	 agreed’	 with	 the	
statement	that	condoms	are	not	necessary	for	safe	sex.	This	proportion	is	higher	than	
expected	and		is	worrying	given	that	condoms	have	been	the	primary	HIV	prevention	
method	 since	 the	 1980s.	 New	 Zealand’s	 condom	 culture	 between	MSM	 is	 extremely	
important,500	and	 self-reported	knowledge	of	 condoms	 is	 very	high	between	MSM	 in	
the	 GAPSS/GOSS.	 Results	 from	 2006	 and	 2008	 surveys	 show	 that	 98.4%	 of	 GAPSS	
participants	and	96%	of	GOSS	participants	knew	that	anal	sex	without	a	condom	has	a	
high	 risk	 of	 HIV	 transmission. 501 	Given	 that	 the	 vast	 majority	 of	 GAPSS/GOSS	
participants	 have	 knowledge	 about	 the	 importance	of	 condoms,	 it	 is	 very	 surprising	
that	 28.2%	of	 the	 Canterbury	MSM	believe	 that	 condoms	 are	 not	 necessary	 for	 safe	
anal	sex	between	two	men.	Once	again,	it	is	possible	that	there	is	context	behind	these	
answers	 that	 the	researcher	cannot	assume	 to	know.	Furthermore,	 there	 is	a	chance	
that	participants	were	thinking	of	PrEP	as	an	option	for	safe	sex	instead	of	condoms,	
due	to	the	topic	of	the	survey.	The	finer	details	of	this	result	are	not	known,	and	it	is	
not	possible	 for	 the	 researcher	 to	make	 sweeping	 generalisations	due	 to	 the	 limited	
external	validity.	Condom	usage	will	never	be	at	100%,	though	there	may	need	to	be	




and	PrEP,	which	was	 presented	 in	 Chapter	 2.	 As	 above,	 the	 results	 are	 discussed	 in	
relatively	the	same	order	as	they	were	shown	in	the	Results	section,	but	are	grouped	
by	the	related	concerns	that	were	discussed	in	the	literature	review.	
	 Most	 importantly,	 the	 overall	 attitudes	 of	 the	 participants	 towards	 PrEP	 are	
positive	and	generally	shared.	100%	of	participants	were	supportive	of	the	statement	
that	taking	PrEP	is	a	good	way	to	reduce	one’s	chance	of	HIV	infection.	Furthermore,	
100%	 of	 MSM	 surveyed	 responded	 positively	 that	 PrEP	 is	 a	 worthwhile	 HIV	
prevention	method	for	MSM/gay	and	bisexual	men.	This	is	the	most	important	result	
from	the	survey	because	despite	the	small	sample	size	compared	to	the	GAPSS/GOSS	
or	 studies	 presented	 in	 Chapter	 2,	 it	 cannot	 be	 denied	 that	 Canterbury	 MSM	 are	
interested	in	and	supportive	of	PrEP	as	a	new	HIV	biomedical	prevention	technology.	
Given	that	this	is	the	first	study	measuring	attitudes	towards	PrEP	in	New	Zealand,	the	
researcher	 is	unable	 to	 compare	 these	 results	 to	other	 studies.	However,	 it	 is	worth	
noting	 that	 other	 studies	 around	 the	world	 reported	MSM’s	willingness	 to	 use	 PrEP	














increased	 dramatically	 since	 then.	 Regardless,	 it	 is	 crucial	 to	 note	 the	 total	 support	
from	all	of	the	Canterbury	MSM	for	PrEP.		
	 However,	 PrEP	 will	 not	 be	 successful	 if	 potential	 PrEP-users	 are	 not	
comfortable	 talking	 with	 their	 doctor	 about	 the	 drug.	 87.5%	 of	 participants	 were	
comfortable	discussing	their	sexual	orientation	with	their	doctor,	which	is	imperative	
if	 patients	 are	 to	 receive	 adequate	 healthcare	 and	 relevant	 advice	 about	 preventing	
HIV.	 However,	 it	 is	 important	 to	 note	 that	 these	 figures	 are	 higher	 than	 the	 2014	
GAPSS/GOSS.	 Only	 60.4%	 and	 42.8%	 of	 GAPSS	 and	 GOSS	 participants,	 respectively,	
had	told	their	regular	doctor	about	their	sexuality.504	82.5%	of	MSM	were	comfortable	
asking	 their	 doctor	 for	 PrEP.	 Furthermore,	 87.5%	 of	 respondents	 would	 not	 be	
embarrassed	if	people	knew	they	took	PrEP,	compared	to	12.5%	of	participants	who	
would	 be.	 When	 paralleled	 to	 other	 studies,	 the	 17.5%	 of	 MSM	 who	 were	 not	
comfortable	 asking	 their	 doctor	 for	 PrEP	 and	 12.5%	 of	 MSM	 who	 would	 be	
embarrassed	 that	 others	 knew	 they	 used	 PrEP	 is	 in	 the	middle	 of	 the	 range;	 other	





technique	 either,	 due	 to	 embarrassment	 about	 their	 sexual	 practices.	 Despite	 the	
relatively	 low	 levels	of	embarrassment	about	discussing	one’s	 sexuality	 (12.5%)	and	























transmission	 and	 can	prevent	 antiretroviral	 resistance.	 Thus,	 the	high	percentage	 of	
MSM	 from	Canterbury	who	do	not	believe	 that	 the	daily	 regime	of	PrEP	 is	 a	burden	
shows	great	promise	when	implementing	the	drug	in	New	Zealand.			
	 PrEP	 is	 often	 targeted	 at	 the	 high-risk	 MSM	 that	 do	 not	 use	 condoms	
regularly508,	509	but	continuing	to	still	use	condoms	is	an	important	part	of	using	PrEP	
because	they	prevent	STIs.	A	drop	in	condom	use	while	taking	PrEP	is	known	as	risk	
compensation.	 Of	 the	 MSM	 surveyed,	 only	 10%	 of	 participants	 ‘agreed’	 and	 2.5%	
‘strongly	agreed’	taking	PrEP	means	individuals	do	not	need	to	use	condoms.	However,	





use	 additional	 protection.	 Overseas	 studies	 showed	 self-reported	 predicted	 risk	





despite	 the	majority	acknowledging	 the	 importance	of	wearing	condoms	when	using	




just	 to	 ensure	 that	 STI	 rates	 do	 not	 increase	 dramatically,	 but	 also	 to	maximise	 the	
number	of	potential	HIV	infections	prevented.	The	MSM	from	Canterbury	showed	that	






























at	 how	 stigma	 and	 labels	 impacted	 potential	 users.	 28.8%	of	MSM	 surveyed	 in	New	
York	City	 had	 concerns	 that	 if	 they	were	 seen	 taking	PrEP,	 others	would	 think	 they	
were	HIV-positive.518	African-American	MSM	iterated	the	same	concerns	in	a	different	
study.	519	There	were	also	concerns	that	outsiders	might	assume	individuals	took	PrEP	
to	 engage	 in	 risky	 behaviour	 regularly,	 particularly	 if	 there	 was	 a	 lot	 of	 HIV	
stigmatisation	 in	 the	 community.520,	521	In	 order	 to	 support	 potential	 PrEP-users	 and	
dispel	 stigma	and	 labels,	 future	policy	programmes	must	 include	accurate	 education	
about	 the	 medication.	 Furthermore,	 PrEP-users	 should	 feel	 comfortable	 taking	 the	
drug	 without	 backlash	 or	 judgement	 about	 their	 actions	 from	 others.	 Thus,	 more	
emphasis	 needs	 to	 be	 placed	 on	 the	 fact	 that	 while	 PrEP	 does	 allow	 for	 safer	 sex	
between	men,	it	does	not	promote	promiscuity	any	more	than	condoms.		
	 The	cost	of	PrEP	is	a	commonly	cited	barrier	to	uptake,	and	has	been	discussed	
in-depth	 in	 both	 Chapters	 1	 and	 2.	 97.5%	 of	 the	 MSM	 surveyed	 were	 in	 favour	 of	
subsidised	PrEP	for	MSM	in	New	Zealand.	The	question	did	not	state	whether	 it	was	
generic	 or	 branded	 PrEP,	 yet	 it	 is	 clear	 that	 MSM	 see	 PrEP	 as	 a	 key	 role	 in	 HIV	























to	 know	 how	 much	 the	 Canterbury	 MSM	 would	 be	 willing	 to	 pay	 for	 a	 monthly	
prescription	 of	 PrEP,	 a	 decrease	 in	 the	 price	 of	 generic	 PrEP	 would	 undoubtedly	
increase	 access	 for	 more	 potential	 users.	 Making	 PrEP	 cheaper	 is	 imperative,	
especially	 in	 regards	 to	 minimising	 all	 potential	 inequalities	 that	 can	 occur	 in	
healthcare.529,	530	However,	 as	 with	 everything	 in	 public	 health,	 there	 is	 always	 a	
winner	and	a	loser:	when	funding	is	given	to	one	healthcare	initiative,	it	is	often	taken	
from	 another.	 Any	 subsidies	 would	 be	 examined	 as	 a	 part	 of	 an	 in-depth	 economic	
analysis	by	PHARMAC.	Therefore,	it	is	fundamental	that	future	PrEP	policies	take	into	





point	 Likert	 scale	 to	 measure	 attitudes,	 and	 despite	 the	 exploratory	 nature	 of	 the	
results,	 they	provide	a	 good	 starting	point	 for	PrEP	policy.	The	 survey	of	MSM	 from	
Canterbury	 found	 that	 100%	 of	 participants	 agreed	 that	 PrEP	 is	 a	 worthwhile	 HIV	
prevention	method	 for	MSM,	 100%	agreed	 that	 PrEP	 is	 a	 good	way	 to	 reduce	 one’s	
chances	 of	HIV	 infection,	 and	 97.5%	believe	 that	 PrEP	 should	 be	 subsidised	 in	New	
Zealand.	However,	future	policy	recommendations	need	to	take	into	consideration	the	
following	factors:	adherence	to	the	daily	regime;	embarrassment	about	one’s	sexuality	
































and	 condom	 use	 section	 provide	 a	 good	 starting	 point	 for	 future	 PrEP	 policies,	 as	
condom	use	must	be	promoted	as	essential	for	PrEP-users.		
	 There	are	numerous	limitations	to	this	survey.	Firstly,	as	discussed	throughout	
Chapter	 3,	 the	 use	 of	 non-probability	 sampling	 reduces	 the	 external	 validity	 of	 the	
results.	This	 sample	 is	not	 representative	of	 the	LGBTI	population;	while	 the	sample	
size	of	forty-two	is	technically	a	large	statistical	sample,	it	is	clear	that	this	is	a	minute	
proportion	 of	 the	 New	 Zealand’s	 LGBTI	 population.	 During	 one	 interview,	 the	
researcher	 was	 told	 by	 a	 prominent	 HIV	 researcher	 that	 if	 you	 “get	 50	 or	 30	
respondents…	 you	 can’t	 do	 an	 awful	 lot	 with	 that.”531	Because	 the	 survey	 was	 only	








	 Similarly,	 the	 use	 of	 a	 Likert	 scale	 provides	 a	 quick	 overview	 of	 general	
attitudes	 towards	 certain	 statements	 but	 it	 does	 not	 provide	 any	 context	 to	 the	
answers.	 The	 researcher	 could	 only	 infer	 why	 certain	 options	 had	 been	 picked,	
particularly	with	questions	where	it	was	assumed	that	the	answers	should	be	similar.	








would	 enable	 the	 researcher	 to	 gain	 a	 better	 understanding	 of	 what	 aspects	 may	
persuade	or	deter	potential	PrEP-users	from	using	this	medication.		
	 Despite	 the	 limited	 generalisability,	 the	 small	 sample	 size	 compared	 to	 other	








an	 empirical	 policy	 for	 PrEP.	 With	 appropriate	 resources,	 further	 evidence-based	
research	 initiatives	 could	 broaden	 the	 sample	 beyond	 the	 Canterbury	 region	 with	
alternate	methods	 of	 sampling,	 such	 as	 online	 advertisements.	 This	 would	 gather	 a	
bigger	 and	 more	 diverse	 sample,	 which	 offers	 a	 better	 understanding	 of	 attitudes	
towards	PrEP,	HIV,	and	health	behaviour	among	at-risk	groups	in	New	Zealand.	More	
data	could	also	provide	better	quality	evidence	to	use	when	designing	health	policies.	
The	 subsequent	 chapter	 collates	 the	 results	 from	 the	 multiple,	 mixed-methods	
research	and	presents	a	case	for	PrEP	policy	in	New	Zealand,	including	a	Base	Case	to	









PrEP	 for	MSM	 in	New	Zealand.	The	 chapter	uses	 a	Base	Case	 to	 analyse	 the	 current	
situation	and	explore	the	impact	of	using	the	existing	HIV	prevention	policy	compared	
to	an	alternative	recommendation,	such	as	a	new	policy.	The	Base	Case	suggests	that	
the	 government	 needs	 to	 prioritise	HIV	prevention	 efforts	 over	 increased	 access	 for	
treatment	 for	 HIV-positive	 individuals.	 The	 conclusion	 of	 the	 Base	 Case	 is	 to	





undertaken	 is	 a	 result	 of	 a	 ‘policy	 problem,’	which	 is	 described	 as	 certain	 “tensions,	
barriers,	 and	 challenges”	 that	 are	 linked	 to	 a	 particular	 policy	 or	 situation.533	As	
problems	obviously	differ,	so	do	the	types	of	policies	that	are	used	to	solve	such	issues.	
The	policy	presented	 in	 this	chapter	 for	 the	 implementation	of	PrEP	 in	New	Zealand	
follows	Carol	H.	Weiss’s	problem-solving	model534	and	is	a	population-focused	health	
policy.535	The	policy	 is	 called	PrEPared	Against	HIV:	 2.0.	The	problem-solving	model	
uses	 “empirical	 evidence	 and	 conclusions	 to	 help	 solve	 a	 policy	 problem”	 that	
currently	 exists. 536 ,	 537 	Weiss’s	 model	 states	 that	 there	 is	 a	 level	 of	 uncertainty	
regarding	 each	 policy	 problem	 that	 requires	 further,	 high-quality	 research	 to	
formulate	an	effective	solution.538	The	model	suggests	that	it	does	not	matter	whether	
the	 research	 is	 primary	 or	 secondary,	 but	 primary	 research	 is	 more	 likely	 to	 have	
“direct	and	immediate	applicability	and	will	be	used	for	decision	making.”539	Through	
the	 multiple,	 mixed	 methods	 design	 of	 this	 thesis,	 the	 author	 has	 been	 able	 to	 use	


















analysis	 inform	 the	 final	 recommendation,	 PrEPared	 Against	 HIV:	 2.0.	 As	 this	 is	 a	
Master’s	 thesis,	 PrEPared	 Against	 HIV:	 2.0	 will	 not	 be	 implemented.	 However,	 this	
policy	may	 be	 useful	 to	 parties	 interested	 in	 developing	 a	 PrEP	 programme	 in	New	
Zealand	and	researchers	conducting	case	studies	in	other	national	contexts.		
	 Lavis	 et	 al.	 state	 that	 there	 are	 four	 defined	 policies:	 functional,	 intentional,	
population-focused,	 and	 programmatic.	 By	 this	 theory,	 this	 policy	 is	 deemed	 a	
population-focused	 policy,	 which	 is	 known	 to	 feature	 “statements	 and	 actions	 that	
benefit	 or	 harm	 specific	 groups.”541	As	 an	 HIV	 prevention	 method,	 PrEP	 has	 been	
recommended	 for	 numerous	 population	 groups	 that	 are	 considered	 at-risk	 of	
contracting	 the	 virus.	 This	 policy	 is	 solely	 focused	 on	 providing	 PrEP	 for	 MSM,	 as	
mentioned	multiple	 times,	 given	 their	high	prevalence	of	overall	HIV	 infections	each	
year	 (up	 to	 80%)	 in	 New	 Zealand.	 As	 a	 result,	 PrEPared	 Against	 HIV:	 2.0	 can	 be	








that	 is	 written	 does	 not	 come	 as	 a	 chapter	 of	 a	 Master’s	 thesis.	 The	 previous	 four	
chapters	of	 this	 thesis	have	 introduced	PrEP	as	an	HIV	prevention	tool,	explored	the	









The	Base	Case	 is	a	policy	method	 that	describes	 “the	current	 situation…	[and]	spells	













action	 should	 be	 evaluated.”546	The	 rationale	 behind	 documenting	 the	 Base	 Case	 is	
apparent:	 by	 clearly	 articulating	 “the	 Base	 Case	 (current	 situation)…	 the	 nature	
(dimensions)	 and	 the	 extent	 (quantity)	 of	 the	 problem”	 become	 clear	 for	 decision-
makers.547	In	this	context,	the	Base	Case	will	be	used	to	provide	justification	as	to	why	
continuing	 the	current	HIV	prevention	policies	 (not	doing	anything	new)	 is	 the	 least	
preferred	option	and	thus,	PrEP	implementation	is	crucial.		
	 In	September	2016,	Associate	Professor	Nigel	Dickson,	 former	Director	of	 the	












of	 HIV	were	 truly	 increasing	 in	 New	 Zealand.	 Dickson’s	 caution	was	 justified,	 as	 he	




2016,	 there	were	244	new	HIV	diagnoses	 (20	more	 infections	 than	2015).550,	551	The	
results	were	hugely	important,	as	the	number	of	diagnosed	HIV	infections	in	2016	was	








































and	 a	 further	 26%	 had	 a	 CD4	 cell	 count	 of	 350-499.556	Therefore,	 given	 that	 nearly	
75%	 of	 new	 infections	 are	 considered	 recent	 based	 on	 the	 CD4	 cell	 count,	 it	 is	
apparent	that	the	HIV	rates	in	New	Zealand	are	increasing.557	
	 With	a	general	consensus	that	the	rate	of	HIV	infections	is	definitely	increasing	
in	 New	 Zealand,	 it	 is	 important	 to	 consider	 the	 cost	 of	 treating	 an	 HIV-positive	
individual	 for	 the	 Base	 Case.	 It	 is	 well-known	 that	 antiretroviral	 therapy	 (ART)	 is	
expensive;	Peter	Saxton	from	the	Gay	Men’s	Sexual	Health	Research	Group	states	that	
“for	 every	 20	 year	 old	 infected	 with	 HIV,	 it’s	 going	 to	 cost	 the	 taxpayer	 around	
$800,000	 over	 their	 lifetime”558	(it	 is	 interesting	 to	 note	 that	 the	New	Zealand	AIDS	
Foundation	 (NZAF)	 estimates	 this	 lifetime	 cost	 at	 around	 $400,000	 per	 person559).	
Saxton	argues	 that	 it	 is	more	cost-effective	 to	 invest	money	 into	HIV	prevention	and	
surveys,	like	the	Gay	Auckland	Periodic	Sex	Survey	(GAPSS)	and	Gay	men’s	Online	Sex	
Survey	 (GOSS),	 rather	 than	 cutting	 the	 prevention	 budget	 to	 pay	 for	 ART	 for	 HIV-
positive	 individuals.560,	561	The	 cost	 of	HIV	 treatment	 in	New	Zealand	 has	 doubled	 in	




















It	 is	 evident	 that	 the	 current	 New	 Zealand	 government	 does	 not	 see	 HIV	
prevention	 as	 a	 priority,	 which	 is	 shown	 by	 the	 recent	 cease	 in	 funding	 for	 the	
GAPSS/GOSS	 behavioural	 studies	 and	 budget	 cuts	 for	 the	NZAF.564	Furthermore,	 the	
NZAF’s	 annual	 funding	 of	 $4.5	million	 from	 the	 government	 has	 never	 increased	 or	
been	adjusted	 for	 inflation.565	In	 June	2017,	 the	government’s	pharmaceutical	agency	
PHARMAC	 announced	 that	 the	 CD4	 cell	 threshold	 would	 be	 removed	 on	 July	 1st,	
meaning	that	HIV-positive	people	will	finally	be	able	to	access	ART	as	soon	as	they	are	
diagnosed. 566 	All	 those	 who	 campaigned	 for	 years	 welcomed	 this	 change	
enthusiastically	and	 it	 is	 important	 to	acknowledge	how	significant	 this	 is.	However,	




However,	 this	must	 change.	 This	 Base	 Case	model	 strongly	 suggests	 that	 the	
cost	of	doing	nothing	new	for	HIV	prevention	is	not	the	best	option.	In	June	2017,	the	
World	 Health	 Organization	 (WHO)	 announced	 PrEP	 on	 its	 Model	 List	 of	 Essential	
Medicines	2017.	This	 list	 is	published	as	 the	“guiding	principle”	 for	countries’	health	
policies.567 	PrEP	 can	 no	 longer	 be	 ignored	 as	 an	 HIV	 prevention	 tool,	 and	 it	 is	
imperative	 that	more	money	 is	 put	 into	 prevention,	 as	 it	 is	 undoubtedly	more	 cost-
effective	in	the	long	run.	More	importantly,	the	confirmation	that	HIV	rates	are	rising	
in	New	 Zealand	 and	 the	 record	 number	 of	 new	HIV	 diagnoses	 in	 2016	 suggest	 that	
current	prevention	efforts	are	not	working	 to	 their	maximum	capacity.	 It	 is	 time	 for	




the	most	 complicated	 and	 hardest	 to	 solve,568	but	 it	 is	 imperative	 that	 this	 does	 not	


























trends	 of	 HIV	 diagnoses	 where	 infection	 rates	 have	 risen	 consistently	 for	 five	
consecutive	years,	particularly	between	MSM.	
Furthermore,	PrEPared	Against	HIV:	2.0	is	an	innovative	and	forward-thinking	
policy.	 The	 Base	 Case	 shows	 that	 changes	 must	 be	 made	 to	 the	 country’s	 HIV	
prevention	plan,	and	“we	need	to	do	something	different	and	innovate,	in	discontinuity	
with	past	 and	 current	practice.”572	PrEPared	Against	HIV:	2.0	 is	 an	 innovative	policy	
that	has	been	designed	using	“diverse	forms	of	evidence,	weighed	for	their	strengths	
and	weaknesses	as	solutions	to	particular	policy	challenges	in	particular	contexts.”573	
These	 forms	 of	 evidence	 are	 the	multiple,	mixed-methods	 that	were	 used	 following	
Weiss’s	problem-solving	model.	This	model	has	utilised	research	to	reduce	uncertainty	














However,	 there	 is	 no	 way	 that	 New	 Zealand	 will	 achieve	 this	 historic	 milestone	














infections	 will	 drop	 and	 the	 government	 will	 be	 able	 to	 spend	 less	 money	 on	
treatment.	 The	 social	 and	mental	 benefits	 of	 having	 less	 people	 living	with	 HIV	 are	
undeniable,	 but	 the	 government	 has	 a	 very	 real	 opportunity	 to	 make	 a	 monetary	
investment	 in	 PrEP	 that	 could	 result	 in	 significant	 savings.	 For	 example,	 if	 PrEP	
prevents	one-third	of	the	224	HIV	infections	from	2015	in	one	year,	75	people	would	
remain	HIV-negative.	Using	 the	NZAF’s	 claim	 that	HIV	 treatment	 costs	 $400,000	per	





Additional	 information	 about	 the	 cost-benefit	 of	 PrEP	 will	 be	 discussed	 in	 the	 Cost	
section,	 but	 it	 is	 important	 to	 note	 that	 if	 a	 PrEP	 “price	 point	 was	 developed	 at	
$NZD1,000	per	year,	the	annual	cost	of	supplying	PrEP	to	5,000	gay	and	bisexual	men	
at	the	highest	risk	of	HIV	would	be	NZ	$5	million.”576	The	return	on	investment	(ROI)	
calculation	 can	 also	 show	 how	worthwhile	 an	 investment	 is	 based	 on	 the	 predicted	
return	 of	 money	 each	 year.	 See	 the	 ROI	 calculation	 below,	 which	 uses	 the	 yearly	






If	 the	 government	 invests	 $5	 million	 in	 PrEP	 annually	 and	 one-third	 of	 infections	


























The	 rest	 of	 this	 chapter	 will	 present	 PrEPared	 Against	 HIV:	 2.0.	 Policy	 options	 are	
made	 up	 of	 two	 parts:	 persuasive	 information,	 and	 explanatory	 information.	 The	
persuasive	 section	 is	 used	 to	 rationalise	 a	 policy	 recommendation,577	which	 was	





impossible	 to	 have	 all	 the	 information	 used	 to	 justify	 an	 option(s),	 so	 assumptions	






• Financial	 arrangements	 (i.e.,	 financing,	 funding,	 and	 remuneration	
arrangements	to	support	services);	








There	 are	 a	 number	 of	 stakeholders	who	will	 be	 involved	 in	 this	 policy	 or	 have	 an	
interest	in	how	it	plays	out.	Figure	28	includes	some	of	the	identified	stakeholders	that	
have	been	grouped	by	their	similarities.	This	diagram	is	not	exhaustive	of	all	potential	


















District	 Health	 Boards	 (DHBs),	 sexual	 health	 clinics,	 participating	 primary	 care	
doctors,	and	 the	NZAF.	The	MOH	“is	 the	best	sector	and	agency	 to	 lead	 this	project,”	
and	will	be	supported	by	the	DHBs	and	NZAF	to	“achieve	mutually	agreed	objectives”	
for	 the	successful	 implementation	of	PrEP.583	The	MOH	will	be	 the	primary	decision-
makers	 for	 the	policy,	which	 follows	 the	 “‘command-and-control’	approach,	 in	which	
the	 government	 attempts	 to	 increase	 access	 to	 and	 utilization	 of	 services	 largely	
through	deployment	of	its	own	resources	rather	than	through	working	with	others.”584	
All	 organisations	 and	 departments	 work	 differently, 585 	which	 is	 important	 to	
remember,	as	 the	three	phases	of	 implementing	PrEP	requires	multiple	stakeholders	
to	 work	 collaboratively.	 The	 PrEP	 providers	 will	 be	 released	 in	 three	 waves	 as	 the	
policy	becomes	more	widespread	and	the	number	of	MSM	using	PrEP	increases.	The	




discussing	 their	 sexuality	 with	 doctors,	 and	 17.5%	 are	 not	 comfortable	 asking	 for	
PrEP.	It	is	important	that	all	providers	create	an	environment	where	the	patients	feel	






2.0.	 It	 is	 recommended	 that	 the	 sexual	 health	 clinics	 be	 in	 charge	 of	 PrEP	when	 the	
nationwide	rollout	 first	occurs.	The	rationale	behind	this	decision	 is	based	on	advice	








around	 care	 and	 sexual	 health	 checks”	 that	 matches	 “international	 best	 practice,”	
which	is	necessary	when	prescribing	PrEP.586	These	experts	argued	that	sexual	health	
clinics	already	provide	similar	services	so	offering	PrEP	should	not	place	much	more	
demand	on	 their	 resources.587,	588,	589	The	similar	 services	 include	 regular	STI	 testing,	
counselling,	 and	 sexual	 health	 education.	 The	 sexual	 health	 doctors	 will	 discuss	 an	
individual’s	suitability	for	PrEP,	complete	the	necessary	pre-tests,	and	prescribe	PrEP.	
The	 nurses	 will	 be	 able	 to	 help	 with	 subsequent	 minor	 tests	 and	 provide	
supplementary	 information	 about	 PrEP,	 such	 as	 adherence	 strategies.	 Sexual	 health	
clinics	also	have	counsellors	who	may	be	also	used	to	provide	support	to	PrEP-users.	
All	 those	 involved	 in	 providing	 PrEP	 must	 follow	 the	 clinical	 guidelines	 (discussed	
later).		
	 The	NZAF’s	role	is	to	provide	support	for	the	DHBs	and	MOH	while	promoting	













sexual	health	clinics	around	the	country	(23	 in	 the	North	 Island	and	12	 in	 the	South	
Island).593	While	 potential	 PrEP-users	 in	 main	 centres	 may	 not	 be	 disadvantaged,	
individuals	 who	 do	 not	 live	 in	 such	 big	 towns	 or	 cities	 will	 be.	 For	 example,	 an	
individual	 from	 Kaitaia,	 Coromandel,	 Westport	 or	 Kurow	 would	 all	 have	 to	 travel	
multiple	hours	to	reach	their	nearest	sexual	health	clinic.	The	distance	that	potential	

















with	 the	 geographical	 spread	 of	 sexual	 health	 clinics	 across	 the	 country	 and	 the	
requirement	 of	 a	 referral.	 The	 recommendation	 is	 to	 move	 into	 phase	 two	 of	 PrEP	
implementation	as	soon	as	there	is	adequate	demand	for	more	PrEP	providers.	Phase	
two	 allows	 a	 group	 of	 doctors	 (Group	 A)	 to	 begin	 prescribing	 PrEP	 to	 their	 MSM	
patients.	The	doctors	who	qualify	 to	be	 in	Group	A	must	have	experience	with	or	an	
active	 interest	 in	HIV	prevention,	PrEP,	ART,	 and/or	LGBTI	patients.	This	 is	because	
prescribing	PrEP	 is	a	 large	commitment	 for	both	 the	doctor	and	user;	 the	user	must	
commit	to	regular	health	tests	and	the	doctor	must	have	a	very	good	understanding	of	
PrEP	 to	 ensure	 that	 the	 patient	 is	 provided	 with	 the	 highest	 standard	 of	 care.596	
Therefore,	 it	 is	 best	 that	 the	 first	 group	 of	 doctors	 (Group	 A)	 providing	 PrEP	 have	
sufficient	experience	with	LGBTI	patients	and	HIV	prevention.	There	were	only	three	
clinics	 around	 New	 Zealand	 who	 were	 registered	 having	 a	 sufficient	 interest	 or	
knowledge	 in	 PrEP	 in	mid-2017,597	but	 as	 at	 September	 2017,	 there	were	 20	 clinics	
registered.598	As	with	the	geographic	inequalities	regarding	sexual	health	clinics,	PrEP-
users	in	Taranaki,	Wairarapa,	West	Coast,	Marlborough	and	areas	of	the	Southland	and	
Canterbury	 regions	 will	 still	 be	 forced	 to	 travel	 long	 distances	 to	 see	 these	 current	
registered	doctors.	As	with	phase	one,	all	medical	professionals	involved	in	prescribing	
PrEP	 and	providing	 the	wider	 care	must	 follow	 the	 clinical	 guidelines	 to	 ensure	 the	
highest	standard	of	care.		















prescribe	PrEP	and	provide	 the	necessary	care	may	also	need	 to	 increase.	Figure	31	
shows	phase	 three,	which	 is	designed	to	accommodate	 large	numbers	of	PrEP-users.	
These	doctors	can	apply	on	an	individual	basis	or	as	an	entire	practice	to	provide	PrEP,	
and	will	be	required	to	follow	the	same	clinical	guidelines	as	the	sexual	health	clinics	




and	doctors	who	were	prescribing	PrEP	 in	phases	one	and	 two.	The	 conference	will	
discuss	the	clinical	guidelines	for	prescribing	PrEP	and	providing	adequate	healthcare	
for	LGBTI	for	HIV	prevention.	The	conference	should	also	contain	anecdotal	tips	from	
doctors	who	 are	 already	providing	 the	drug.	Attending	 the	 conference	 is	 essential	 if	
doctors	wish	to	become	part	of	the	Group	B	doctors.	Some	doctors	may	see	this	step	as	
unnecessary,	but	PrEP	is	a	complex	drug	and	patients	have	the	right	to	receive	the	best	
possible	 treatment	 from	 their	 healthcare	provider.	 Furthermore,	 PrEP	 is	 a	 relatively	
new	 HIV	 prevention	 technique	 so	 it	 is	 crucial	 that	 all	 doctors	 are	 aware	 of	 the	
complexities	of	 the	drug	before	they	can	prescribe	 it.	Conferences	can	be	held	as	the	
demand	requires.		
Throughout	phases	one	and	two,	 the	NZAF’s	only	 job	 is	 to	provide	support	 to	
the	MOH	and	DHBs.	However	once	more	MSM	are	using	PrEP	for	HIV	prevention,	the	
NZAF	 is	 encouraged	 to	 help	 set	 up	 a	 peer	 network.	 Body	 Positive	 has	 used	 a	 peer	
network	for	HIV-positive	men	in	New	Zealand	to	help	individuals	feel	more	supported,	







up	 for	 MSM	 currently	 using	 PrEP.	 The	 network	 will	 allow	 users	 to	 share	 stories,	
provide	 support	 to	 one	 another,	 encourage	 sensible	 choices,	 and	 facilitate	 open	
discussions	about	PrEP,	HIV	prevention	and	safe	sex.	Given	the	exposure	that	the	NZAF	











o After	 the	 development	 of	 this	 policy,	 the	 author	 became	 aware	 that	 a	
closed	PrEP	peer	 support	 group	had	 been	 set	 up	 on	 Facebook	 for	 this	
very	purpose.	This	group	promoted	open	discussion	about	PrEP.		
• Physical	peer	network:	PrEP-users	can	meet	up	with	other	PrEP-users.	Those	
interested	 in	 socialising	 with	 other	 PrEP-users	 can	 contact	 the	 NZAF	 to	 find	
others	nearby	who	are	also	part	of	 the	peer	network,	or	contact	 them	via	 the	
online	forum.		
o The	 NZAF	 has	 a	 strong	 community	 presence	 and	 hosts	 a	 number	 of	
events	 for	 MSM	 and	 other	 members	 of	 the	 LGBTI	 communities	 from	
around	the	country.	There	 is	potential	 for	 the	NZAF	and	the	PrEP	peer	
network	to	schedule	regular	social	events	for	PrEP-users.	
	
Once	the	third	phase	of	PrEP	 implementation	 is	underway,	 it	will	be	easier	 to	
see	 the	 impact	 that	 this	 policy	 will	 have	 on	 the	 healthcare	 system.	 There	 is	 the	
potential	 for	 strains	 to	 occur,	 as	 providing	 PrEP	 effectively	 requires	 cooperation	
between	multiple	stakeholder	groups.	For	example,	ensuring	that	all	PrEP-users	have	
an	STI	and	HIV	test	every	 three	months	when	they	go	 in	 to	get	a	new	script	of	PrEP	
may	 put	 additional	 stress	 on	 laboratory	 staff	 and	 nurses.	 Similarly,	 sexual	 health	
counsellors	may	see	an	influx	of	patients	wanting	advice	on	adherence	or	other	PrEP-
related	 topics.	 It	 is	 important	 that	 once	 phase	 three	 has	 been	 operating	 for	 a	
reasonable	length	of	time	(i.e.	12-18	months),	the	MOH,	DHBs,	and	NZAF	complete	an	
evaluation	 of	 the	 effect	 of	 PrEP	 on	 the	 healthcare	 system.	 The	 MOH	 should	 use	 an	
evaluation	of	 the	 three	phases	of	PrEP	 implementation	 to	 identify	 the	 strengths	 and	
weaknesses	 of	 the	 PrEP	 providers,	 and	 ensure	 resources	 are	 not	 stretched	 to	 an	
unreasonable	point.	Furthermore,	the	evaluation	will	also	provide	an	opportunity	for	




This	 research	 has	 repeatedly	 identified	 the	 medical,	 social,	 and	 behavioural	
complexities	associated	with	PrEP.	Thus,	it	is	crucial	that	doctors	follow	a	set	of	clinical	
guidelines	when	providing	PrEP	 to	 at-risk	 individuals	 to	 ensure	patients	 receive	 the	
highest	quality	healthcare.601	The	use	of	clinical	guidelines	is	supported	by	a	number	of	
the	 interviewees.	 The	 experts	 recommended	 that	 the	 guidelines	 contain	 criteria	
needed	 to	 guide	patient	 care.	Most	 importantly,	 these	 guidelines	will	 ensure	 that	 all	
PrEP-users	receive	the	same	high	standard	of	care,	regardless	of	what	PrEP	provider	
they	use.602,	603,	604		
One	 crucial	 aspect	 of	 the	 clinical	 guidelines	 is	 to	 ensure	 doctors	 follow	 the	
protocol	for	regular	health	tests.605	It	is	recommended	that	PrEP-users	have	quarterly	
HIV	 and	 STI	 tests,	 biannual	 bone	 density	 and	 kidney	 function	 tests,	 and	 yearly	
evaluations	to	assess	their	need	to	continue	PrEP.	These	recommendations	are	based	
on	the	Centers	for	Disease	Control	and	Prevention’s	(CDC)	Guidelines.	The	requirement	
for	 regular	 HIV	 tests	 should	 not	 be	 too	 much	 of	 a	 demand	 for	 MSM:	 97.5%	 of	
Canterbury	MSM	surveyed	agreed	that	it	is	important	to	get	regular	HIV	tests,	and	85%	
did	 not	 see	 the	 additional	 tests	 as	 a	 hassle.	 The	 researcher	 has	 not	 provided	 any	








should	 not	 be	 the	 only	 determinant	 of	 whether	 PrEP	 is	 deemed	 a	 worthwhile	
investment	 for	HIV	prevention.606	Nevertheless,	 the	WHO	also	 clearly	 states	 that	 the	
price	of	PrEP	is	not	the	only	cost	linked	to	its	implementation.	Other	associated	costs	
include	 “costs	 for	 clinical	 staff,	 laboratory	 testing,	 pharmacy	 services,	 community	

















decisions	 regarding	 funding	 will	 come	 from	 the	 New	 Zealand	 government.	 The	
Treasury	has	a	key	role	making	decisions	about	funding	for	our	healthcare	system:		
	
The	 Treasury	 provides	 advice	 to	 Ministers	 on	 the	 purchase	 and	 regulation	 of	
health	services.	This	advice	covers	areas	such	as	the	structure	and	management	of	
health	 spending,	 institutional	 and	 governance	 arrangements	 in	 the	health	 sector	
and	health	sector	strategies	and	policies.	The	Treasury	also	provides	advice	on	the	
Crown’s	 ownership	 interest	 in	 district	 health	 boards	 (DHBs).	 This	 includes	
monitoring	 the	performance	of	 the	DHBs	and	assessing	capital	 investments.	This	
work	is	carried	out	in	conjunction	with	the	Ministry	of	Health.609	
	
PHARMAC	 also	 has	 an	 influence	 on	 the	 funding	 decisions	 for	 PrEP.	 As	 reviewed	 in	
Chapter	 1,	 PHARMAC	 chooses	which	medicines	 to	 subsidise	 based	 on	 a	 “cost-utility	
analysis	 (CUA)	and	a	budget-impact	analysis	 (BIA).”610	PHARMAC’s	decision	whether	
to	 fund	PrEP	 is	 a	question	of	 “health	 economics,”	which	depends	 “on	 the	 cost	of	 the	
drugs	and	who	takes	it.”611		
Cost-benefit	 analyses	 (CBA)	 are	 also	 often	 used	 as	 a	 forecasting	 method	 to	





and	 by	 how	 much.	 However,	 it	 is	 crucial	 to	 remember	 that	 the	 benefit	 of	 a	 policy	
option	does	not	solely	rely	on	monetary	value,	as	stated	by	 the	WHO.	613	In	 fact,	CBA	
and	similar	methods	can	ignore	“non-quantifiable	costs	and	benefits	and	may	conflict	
with	 our	moral	 intuitions.”614	Furthermore,	 economic	 analyses	 of	 policy	 options	 can	
favour	 cost	 and	 efficiency	over	 “justice,	 liberty,	 democracy,	 the	 environment,”615	and	
health	 and	 wellbeing.616	Although	 the	 outcome	 of	 an	 economic	 analysis	 of	 PrEP	 is	
uncertain	in	a	real	world	policy	situation,	it	is	recommended	that	policy	advisors	look	
further	 than	 just	 economics	 and	 cost-benefits	 when	 considering	 the	 funding	 for	
PrEPared	 Against	 HIV:	 2.0.	 Therefore,	 this	 section	 will	 present	 multiple	 options	 for	
funding	PrEP	and	ways	to	measure	its	worth	as	a	medical	intervention.		
It	is	certain	that	any	case	put	forward	to	PHARMAC	to	subsidise	PrEP	needs	to	















opportunity	 costs, 617 	such	 as	 other	 behavioural	 prevention	 methods.	 One	 HIV	
researcher	 argues	 that	 persuading	 PHARMAC	 and	 the	 government	 comes	 down	 to	
acknowledging	that	while	funding	PrEP	is	a	“burden	to	the	state,”618	it	is	important	to	
critically	 evaluate	 how	 this	 new	 biomedical	 intervention	 could	 impact	 the	 current	
climate	of	HIV	in	New	Zealand.	The	researcher’s	argument	in	favour	of	implementing	a	
PrEP	policy	reinforces	the	result	of	the	Base	Case;	we	need	to	change	our	prevention	




month.621,	622,	623,	624	However,	 generic	 PrEP	 costs	 NZ	 $60-100	 per	 month	 and	 Mylan	
and	Actavis,	two	manufacturers	of	generic	PrEP,	have	both	been	approved	as	generic	
versions	of	Truvada	by	Medsafe.625	
Until	Gilead’s	patent	 for	Truvada	is	removed	in	2017,	 it	 is	highly	unlikely	that	
PHARMAC	 would	 choose	 to	 fund	 branded	 PrEP	 over	 the	 generic	 version.626	This	
decision	makes	 sense	 economically,	 and	 the	majority	 of	 countries	 around	 the	world	
that	provide	PrEP	will	also	use	the	generic	version.627	However,	this	may	change	once	
Gilead’s	 patent	 finishes	 because	 the	 pharmaceutical	 company	 will	 want	 to	 entice	
health	agencies	and	individuals	to	purchase	their	drug	over	generics.	Gilead	can	do	this	
in	 two	 ways:	 altering	 their	 drug	 to	 renew	 their	 patent	 (with	 proof	 that	 the	 new	
medication	works),	or	dropping	the	price	of	their	medication	to	just	above	the	generic	
so	 customers	 are	 persuaded	 to	 pay	 slightly	 more	 for	 a	 branded	 version.628	At	 this	
stage,	what	Gilead	decides	to	do	after	the	patent	for	Truvada	ends	is	uncertain,	so	the	




The	 recommended	 parameters	 are	 generic	 versus	 branded	 PrEP,	 the	 level	 of	
subsidisation,	 and	who	qualifies	 for	 this	 funding.	 It	has	been	assumed	 that	based	on	
the	price	of	branded	PrEP,	PHARMAC	will	only	subsidise	generic	versions.	The	level	of	
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	 Option	 B	 is	 partial	 subsidisation	 of	 generic	 PrEP.	 This	 would	mean	 an	 equal	













that	PrEP	 is	 available	 to	 all	 those	who	want	 it,	which	 follows	 the	WHO’s	 advice	 that	
PrEP	should	be	made	accessible	to	all	at-risk	individuals,	regardless	of	the	population	
group	 they	 identify	 with.631	This	 includes,	 but	 is	 not	 limited	 to,	 MSM,	 sex	 workers,	








men	 (TGM)	 and	 women	 (TGW).632	The	 number	 of	 potential	 users	 for	 PrEP	 could	
include	 more	 than	 5,000	 MSM	 who	 are	 deemed	 high-risk	 by	 the	 NZAF,633	plus	 any	





As	with	Option	1,	 it	was	not	possible	 to	provide	a	 clear	estimation	of	 the	number	of	
MSM	 who	 are	 not	 high-risk	 but	 would	 still	 be	 interested	 in	 PrEP.	 The	 NZAF	
approximates	 that	 gay	 and	 bisexual	men	make	 up	 2.5%	 of	 the	 population,	 which	 is	
nearly	120,000	people.634	It	is	almost	certain	that	not	all	gay	and	bisexual	men	would	
express	 a	 desire	 to	 use	 PrEP,	 but	 it	 is	 important	 to	 note	 that	 the	 number	 of	 MSM	
eligible	to	use	PrEP	through	Option	2	could	be	large.		




While	 there	 is	 uncertainty	 surrounding	 some	 the	 funding	 options	 presented	 above,	
they	 all	 point	 to	 the	 singular	 goal	 of	 facilitating	 the	 implementation	 of	 PrEP.636	This	
uncertainty	is	common	because	policy	recommendations	always	combine	a	mixture	of	
known	and	unknown	information.637	The	format	of	these	funding	options	means	that	




























































Figure	 32	 shows	 how	 the	 nine	 options	 are	 distributed	 regarding	 cost	 to	 the	
government	versus	cost	to	the	PrEP-user.	Please	note	that	the	costs	of	PrEP	have	not	
been	adjusted	for	inflation,	but	are	only	shown	at	this	point	in	time.	Figure	32	shows	
that	 options	A1,	A2,	 and	A3	 are	 the	 cheapest	 for	 the	PrEP-user	 ($5	per	month	 for	 a	
PrEP	prescription)	and	the	most	expensive	for	the	government	($55-95	per	month	per	
user).	Options	C1,	C2,	and	C3	are	the	most	expensive	for	the	PrEP-user	(who	will	pay	







uses	 option	 B3,	 partial	 subsidisation	 of	 generic	 PrEP	 for	 high-risk	 MSM.	 B3	 is	 the	









PrEP	 annually.	 These	 costs	 depend	 on	 which	 generic	 PrEP	 PHARMAC	 chooses	 to	
subsidise.	
B3	 is	 also	 preferable	 because	 it	 requires	 an	 equal	monetary	 investment	 from	
the	government	and	PrEP-user	each	month.	A	cost	of	$30-50	each	month	is	deemed	to	
be	 moderate	 and	 as	 one	 HIV	 expert	 puts	 it,	 “for	 gay	 men,	 sex	 is	 a	 recreation	 and	
actually	 to	 pay	 $80	 a	 month	 is	 like	 getting	 Sky	 TV.”638	Dickson’s	 quote	 comes	 from	
discussing	 MSM	 paying	 for	 generic	 PrEP	 with	 no	 government	 funding,	 so	 this	
argument	is	even	stronger	with	subsidisation;	if	HIV	prevention	is	important	to	MSM,	
the	small	monthly	cost	 for	PrEP	should	not	be	a	burden	to	 fit	 into	one’s	budget.	The	
average	New	Zealand	 salary	was	$74,965	 in	2015,639	so	with	a	50%	subsidisation	of	
PrEP	prescriptions	the	$360-600	cost	of	PrEP	would	be	0.005-0.008%	of	the	average	
annual	 earnings.	Furthermore,	 it	 is	 recommended	 that	 full	 funding	 is	not	offered	 for	
PrEP,	 as	 it	 is	 important	 that	MSM	 take	 a	proactive	 approach	 to	HIV	prevention.	The	
requirement	 for	 MSM	 to	 pay	 half	 of	 the	 medication	 cost	 should	 influence	 them	 to	
either	adhere	to	PrEP	correctly	or	not	use	it	at	all,	thus	encouraging	correct	adherence.	
However,	condoms	will	remain	fully	funded	(more	about	this	in	subsequent	sections).		
The	 rationale	 behind	 this	 recommendation	 is	 as	 follows:	 compared	 to	 option	
A3,	 where	 PrEP	 is	 ‘fully’	 funded	 by	 the	 government	 (minus	 prescription	 charges),	
option	 B3	 is	 significantly	 cheaper	 for	 the	 government.	 If	 the	 government	 were	 to	
choose	option	A3,	they	would	pay	between	$3.3-5.7	million	each	year	for	the	5,000	at-
risk	 MSM	 to	 have	 PrEP.	 It	 does	 not	 seem	 likely	 that	 the	 government	 or	 PHARMAC	



















that	PrEP	 is	 as	 cost-effective	 as	possible.	The	NZAF	 cited	 a	price	point	of	 $1000	per	
year	 for	each	PrEP	prescription,	which	would	require	an	 investment	of	$5	million	 to	
allow	 5,000	 high-risk	 MSM	 to	 access	 PrEP.640	However,	 based	 on	 the	 advice	 to	 use	
option	B3,	the	government	would	only	be	required	to	pay	$1.8-$3	million	each	year	for	
prescriptions	 for	 5,000	 MSM.	 This	 smaller	 investment	 gives	 the	 government	 an	
opportunity	 to	 evaluate	 how	 PrEP	 works	 on	 individual,	 community	 and	 population	
levels	without	investing	so	much	money.	Furthermore,	requiring	MSM	to	pay	50%	of	
the	monthly	PrEP	costs	(rather	than	the	 ‘full’	prescription	in	Option	A)	would	enable	
the	 government	 to	 consider	 investing	 more	 into	 alternative	 externalities641	of	 the	
policy	like	increased	staff,	wider	promotional	material,	and	more	education	resources.		
Whichever	subsidisation	method	the	government	uses,	it	is	imperative	that	the	




	 The	 analysis	 of	 funding	options	did	not	 consider	health	 insurance.	A	 study	of	
MSM	 from	 three	 PrEP	 clinics	 in	 the	United	 States	 of	 America	 found	 that	 individuals	
with	insurance	were	four	times	more	likely	to	use	PrEP	than	those	who	did	not	have	
insurance.642	Although	 the	 American	 public	 health	 and	 insurance	 systems	 are	 very	
different	 to	 New	 Zealand,	 it	 is	 important	 to	 note	 how	 much	 of	 an	 impact	 health	
insurance	 can	 have	 on	 PrEP	 use.	 The	 decision	 on	 whether	 to	 provide	 additional	
funding	for	PrEP	is	up	to	each	individual	insurance	company.	
Adherence	




The	 expert	 interviewees	 were	 divided	 on	 the	 value	 of	 intermittent	 PrEP	 use.	 The	
sexual	 health	doctor	would	only	 recommend	daily	PrEP	 to	patients,643	the	 infectious	
disease	 doctor	 Nigel	 Raymond	 acknowledges	 the	 freedom	 of	 customising	 the	 two	













said	 that	 remembering	 to	 take	 PrEP	 everyday	 would	 not	 be	 hard.	 This	 policy	
recognises	that	while	“it	is	a	burden	to	take	a	pill	everyday,”646	treating	one’s	self	with	
multiple	ARTs	 (polytherapy)	 each	day	 as	 an	HIV-positive	 individual	 is	much	harder.	




	 Adherence	 is	 not	 just	 about	 persuading	 PrEP-users	 to	 take	 their	 medication	
regularly	 to	 develop	 good	 habits;	 low	 adherence	 can	 cause	 an	 individual	 to	
seroconvert	and	develop	a	resistant	virus.	The	chances	of	antiretroviral	 resistance	 is	
incredibly	 low,	 as	 there	 have	 only	 been	 two	 confirmed	 cases	 and	 two	 unconfirmed	
cases	 of	 drug-resistant	 HIV	 infections	 despite	 hundreds	 of	 thousands	 of	 individuals	
using	 PrEP	 outside	 of	 the	 RCTs.648	Unsurprisingly,	 the	 confirmed	 cases	 of	 resistant	
infections	caused	concern	among	PrEP	communities,	so	it	is	important	that	adherence	
is	promoted	to	prevent	further	instances	of	antiretroviral	resistance.	
	 It	 is	 essential	 that	 strong	 messages	 promoting	 daily	 adherence	 come	 from	
multiple	 sources,	 such	 as	 the	MOH,	 PrEP	 providers,	 the	NZAF	 and	 their	 Ending	HIV	










• “Imparting	 knowledge”	 by	 providing	 the	 patient	 with	 enough	 information	
about	the	medication;	













• “Patient	 and	 family	 communication,”	 including	 regular	 text	 reminders	 and	
using	family	members	to	support	adherence;	
• “Leaving	 the	 bias”	 by	 removing	 the	 premise	 that	 certain	 demographic	
characteristics	are	linked	to	adherence,	and	tailoring	the	plan	to	each	individual	
patient;	and	
• “Evaluating	 adherence”	 using	 methods	 like	 pill	 counting	 and	 self-reported	
adherence.650	
	




advice	 for	 adherence	 when	 travelling,	 educational	 resources,	 and	 telephone	 or	 text	
reminders.653	
Education	and	promotion	campaigns	
There	 is	 a	 reasonable	 amount	 of	 misinformation	 about	 PrEP 654 	that	 could	 be	
detrimental	 to	 the	 policy’s	 effectiveness.	 Educational	 campaigns	 can	 correct	
misinformation	about	PrEP655	and	promotional	material	 can	promote	PrEP	 to	at-risk	
MSM.	The	education	and	promotion	campaigns	need	to	match	PrEPared	Against	HIV:	
2.0	 –	 these	 campaigns	 need	 to	 be	 innovative,	 strategic	 and	 forward-thinking.	
Furthermore,	 they	 need	 to	 capture	 the	 right	 target	 audiences	 through	 specific	
methods,	such	as	social	media	and	applications	(apps)	aimed	at	particular	community	
groups.656		
In	addition,	 it	 is	 important	 that	 the	education	and	promotional	 campaigns	 for	
PrEPared	Against	HIV:	2.0	reflect	the	HIV	virus	in	the	context	of	2017	and	onwards.657	
HIV	 should	 be	 promoted	 as	 a	manageable	 chronic	 condition	 that	 can	 affect	multiple	



























• A	 website	 solely	 for	 PrEP	 in	 New	 Zealand	 that	 includes	 educational	 and	
promotional	material	about	PrEP.		
o Young	 people,	 particularly	members	 of	 the	 LGBTI	 community,	 use	 the	
Internet	and	social	media	for	research,	to	inform	themselves,	and	make	




social	media	 and	dating	 apps	 commonly	 used	 by	MSM	 like	Grindr	 and	
Tinder.	If	MSM	are	interested	in	learning	more	about	PrEP,	they	can	click	
the	link	which	takes	them	to	the	PrEP	website.		













• Some	users	may	prefer	 to	 learn	 about	 PrEP	 through	 audio-visual	 educational	














	 The	authors	of	 the	educational	material	may	also	wish	 to	 include	 information	
about	HIV	in	New	Zealand,	such	as	rates	of	HIV	and	why	MSM	are	more	susceptible	to	
contracting	 HIV.	 Including	 this	 information	 is	 not	meant	 to	 frighten	 potential	 PrEP-
users	 into	 trying	 the	medication	but	should	remind	 them	that	HIV	 is	 still	an	 issue	 in	
New	Zealand.660	
Promotion	campaigns	
The	 promotion	 of	 PrEP	 could	 have	 an	 impact	 on	 its	 success	 as	 an	 HIV	 prevention	
method	and	the	overall	policy.	Promoting	PrEP	will	be	important	to	ensure	that	high-
risk	MSM	know	about	this	intervention	and	can	consider	whether	it	is	right	for	them.	
As	with	 the	 clinical	 guidelines,	 it	 is	 recommended	 that	 policy	 advisers	 look	 to	 other	
countries	 to	 see	 how	 they	 have	 successfully	 promoted	 PrEP.	 These	 campaigns	 can	





contracting	 HIV	 or	 are	 part	 of	 a	 high-risk	 community.	 The	 second	 option	 is	 a	 high-
exposure,	 blunt,	 and	 eye-catching	 campaign	 that	 utilises	 multiple	 sources	 of	 media.	
The	 first	 option	 has	 previously	 been	 used	 in	New	 Zealand,	 as	 the	HIV	 public	 health	
messages	were	 only	 designed	 to	 be	 seen	 by	 at-risk	 individuals	 and	 communities.661	
Clearly	 the	 previous	 promotional	 campaigns	 for	 HIV	 prevention	 have	 not	 been	
working,	 given	 the	 rising	 rates	 of	HIV	 and	prominence	of	 new	 infections	 (>500	CD4	
cell/ml3).	Therefore,	it	is	time	to	try	something	new,	innovative	and	strategic	that	will	
grab	 people’s	 attention.	 It	 is	 recommended	 that	 the	 MOH	 and	 NZAF	 collaborate	 to	
create	a	promotional	campaign	for	PrEP	that	gets	viewers	thinking	and	talking	about	
HIV	 prevention	 and	 PrEP.	 Two	 promotional	 campaigns,	 one	 American	 and	 one	
international,	are	analysed	below	which	may	provide	guidance	for	the	MOH.	
PrEP4Love		
PrEP4Love	 is	 a	 successful	 campaign	 from	 Chicago	 that	 has	 gained	 attention	 for	
exploring	 concepts	 of	 “intimacy	 and	 relationships	 and	 empowering	 people”	 while	
using	PrEP.662	PrEP4Love	is	a	very	visible	campaign	advertised	in	public	places,663	and	
features	 all	 different	 types	 of	 PrEP-users,	 not	 just	 stereotypical	 white	 MSM.664	The	
adverts	were	 designed	 to	 celebrate	 intimacy,	 safe	 sex,	 and	 love	 combined	with	 HIV	
prevention,	 rather	 than	 following	 the	 characteristic	 scaremongering	 public	 health	











implementation	 of	 PrEP	 for	MSM,	 some	 of	 the	 advertisement	 images	 for	 PrEP4Love	
may	not	be	applicable.	However,	 this	 should	not	deter	advisors	 from	 looking	at	how	
they	could	replicate	a	campaign	for	PrEP	for	MSM	that	is	also	attention	grabbing	and	
effective.	 The	 PrEP4Love	 slogan	 is	 ‘PrEP.	One	 Pill.	 Once	 a	Day.	 Protect	 Against	HIV.’	
PrEP4Love’s	 slogan	 clearly	describes	what	PrEP	 is	 and	what	 it	 does.	 It	 is	 catchy	but	
does	 not	 rely	 on	 graphic	 images	 or	 stereotypes	 to	 promote	 the	medication.	Another	
saying	 used	 by	 the	 Chicago	 campaign	 is	 ‘Love	 is	 contractible.	 Lust	 is	 transmittable.	
Touch	is	contagious.	Catch	feelings,	not	HIV.’	The	catchphrase	combines	words	linked	





countries.	 APCOM	 encourages	 the	 combination	 of	 PrEP	 and	 other	 methods	 for	 HIV	










• ‘PrEP	 is	 like	 taking	 oral	 contraception.	 Take	 it	 or	 leave	 it,	 the	 decision	 is	
yours.’667	
	






Direct-to-consumer	 advertising	 (DTCA)	 of	 pharmaceutical	 products	 is	 currently	
allowed	 in	 only	 two	developed	 countries,	 America	 and	New	Zealand.	 It	 is	 important	
that	 the	 MOH	 and	 other	 stakeholders	 are	 aware	 that	 Gilead	 Sciences	 and	 generic	
manufacturers	 of	 PrEP	may	 consider	 DTCA	 of	 PrEP.	 To	 summarise	 briefly,	 DTCA	 is	








condition,	 influencing	 them	 to	 approach	 their	 healthcare	 provider	 and	 request	 the	









PrEP	 is	not	 the	silver	bullet	 for	HIV.	Slip-ups	can	happen:	missed	PrEP	pills	result	 in	
less	active	components	 in	 the	body	 to	prevent	 the	virus	 from	taking	hold,	which	can	
lead	to	seroconversion	and	potential	antiretroviral	resistance.	Both	risk	compensation	
and	antiretroviral	 resistance	were	discussed	 in	Chapter	2	 from	provider	and	patient	
perspectives.	The	most	 likely	 instance	of	 risk	 compensation	between	MSM	would	be	
reduced	condom	use,	but	could	also	include	increased	sexual	partners.		
There	 is	 a	 general	 consensus	between	 the	HIV	experts	 that	were	 interviewed	
that	 risk	 compensation	 is	 a	 real	 problem	 associated	 with	 PrEP	 use.670,	671,	672,	673	For	
PrEP	to	be	most	effective,	and	for	this	policy	to	have	an	impact	on	HIV	infections,	it	is	
imperative	 that	 the	 potential	 for	 risk	 compensation	 is	 minimised	 and	 users	 are	
dissuaded	from	doing	so.	Infectious	disease	doctor	Nigel	Raymond,	who	has	extensive	
experience	 treating	HIV-positive	patients,	argues	 that	risk	compensation	needs	 to	be	
minimised	because	“you	can	have	a…	better	roll	cage	or	air	cushion	in	your	car	but	if	























Therefore,	 it	 is	 recommended	 that	 risk	 compensation	 be	minimised	 using	 an	
approach	with	multiple	 strategies	 including	 an	 emphasis	 on	 condom	 use,	 combined	
prescriptions,	 and	 utilising	 the	 education	 and	 promotion	 campaigns.	 Instead	 of	
presuming	 that	all	PrEP-users	will	engage	 in	risky	behaviour,	PrEPared	Against	HIV:	




to	 prevent	 STIs.	 As	 well	 as	 encouraging	 good	 habits,	 PrEP	 providers	 will	 promote	
multiple	 methods	 of	 HIV	 prevention	 to	 minimise	 the	 negative	 impacts	 if	 risk	
compensation	does	occur.	This	approach	acknowledges	that	mistakes	such	as	missed	
pills	 can	 happen	 but	 using	 multiple	 prevention	 methods	 increases	 one’s	 overall	
protection	against	HIV.		
Secondly,	 it	 is	 recommended	 that	 PrEP	 and	 condoms	 be	 prescribed	 together	
each	time	the	doctor	writes	a	new	script.	More	than	38%	of	the	Canterbury	MSM	said	
that	they	would	be	less	likely	to	use	condoms	if	they	took	PrEP	but	if	users	have	easy	
access	 to	 condoms,	 it	 is	possible	 that	 they	may	be	more	willing	 to	use	 them.	Pairing	
condoms	with	 the	PrEP	prescription	may	prevent	 the	30%	of	 Canterbury	MSM	who	
would	still	have	unprotected	anal	intercourse	if	they	did	not	have	access	to	condoms.	
Condoms	are	currently	subsidised	by	PHARMAC	so	twelve	boxes	(144	condoms)	costs	
$5.	 Depending	 on	 the	 government’s	 investment	 in	 PrEP,	 they	may	 consider	 offering	
free	condoms	to	PrEP-users	to	ensure	that	access	and	availability	of	condoms	remains	
as	 high	 as	 possible.	However	 even	 if	 the	 government	 does	 not	 remove	 the	 cost	 of	 a	
condom	prescription,	 an	additional	$5	 for	each	prescription	should	not	be	 too	much	
for	MSM	to	pay.	Furthermore,	MSM	can	always	get	free	condoms	from	the	NZAF.678		
The	third	recommendation	to	reduce	risk	compensation	is	increased	STI	testing	
for	MSM.	 Doctors	 and	 nurses	 should	 require	 regular	HIV	 and	 STI	 tests	 at	 least	 four	
times	 each	 year	 as	 recommended	 in	 the	 clinical	 guidelines	 for	 PrEP.	 An	 American	
modelling	 study	 estimates	 that	 if	 40%	 of	 at-risk	 MSM	 used	 PrEP,	 twice	 yearly	 STI	
screenings	would	 prevent	 “42%	 of	 [gonorrhoea]	 infections	 and	 40%	 of	 [chlamydia]	





Finally,	 the	educational	and	promotional	 campaigns	 for	PrEP	should	highlight	
the	 importance	of	 condoms	as	a	 companion	 to	PrEP.	Promoting	common	prevention	








important	 but	 wearing	 a	 sunhat	 and	 sunglasses,	 and	 sitting	 in	 the	 shade	 are	 all	
additional	 methods	 to	 avoid	 sunburn.	 The	 MOH	 and	 PrEP	 providers	 will	 need	 to	
reinforce	the	messages	shown	in	the	education	and	promotion	campaigns	by	offering	
condoms	and	regular	STI	and	HIV	tests.	However,	it	is	imperative	to	remember	that	for	
some	MSM	who	 never	 use	 condoms,	 using	 PrEP	 as	 one	 protection	method	 is	 better	
than	using	nothing	at	all.			
Stigmatisation	
Stigmatisation	 related	 to	PrEP	 is	widely	known,	 and	potential	PrEP-users	 factor	 this	
into	 their	 decision	 to	 use	 the	 medication.	 No	 one	 wants	 to	 be	 labelled	 a	 ‘Truvada	
whore’ 681 ,	 682 	or	 mistaken	 to	 be	 HIV-positive	 when	 taking	 PrEP. 683 	The	 stigma	
associated	 with	 PrEP	 comes	 in	 three	 main	 forms:	 misinformation	 about	 PrEP,	
preconceived	 judgements	 from	 individuals	 who	 see	 PrEP	 as	 an	 excuse	 to	 be	
promiscuous,684	or	 out-dated	 knowledge	 of	 HIV.	 It	 is	 hard	 to	 dispel	 rumours	 and	







can	 emphasise	 to	 PrEP-users	 that	 the	 labels	 are	 not	 true.	 Furthermore,	 continual	
education	about	HIV	prevention	is	important	for	all	individuals,	not	just	those	who	are	
statistically	 more	 likely	 to	 acquire	 the	 infection.	 This	 may	 start	 with	 better	 sexual	
health	education	in	schools	to	remove	stigmatisation,	including	more	about	same-sex	
relationships	and	LGBTI	 topics	 in	 the	curriculum.685	The	NZAF	can	support	 the	MOH	
and	Ministry	of	Education	to	facilitate	better	education	about	HIV.		
The	 bottom-up	 approach	 will	 be	 supported	 by	 the	 NZAF	 but	 begins	 at	 the	
individual	level,	as	confident	PrEP-users	and	members	of	the	peer	network	can	show	
that	 the	 labels	are	not	 true.	Some	of	 the	stigma	towards	PrEP	comes	 from	inside	the	
gay	community.686	For	example,	one	 in	 five	Canterbury	MSM	from	the	survey	agreed	

















shame	 him	 by	 saying	 “Oh	 you’re	 on	 PrEP,	 you	 must	 be	 a	 slut.	 You	 must	 be	
irresponsible.	You	must	make	 really	bad	 choices	 to	 think	you	need	 to	be	on	 this.”687	
Thus,	 it	 is	 important	 that	 this	 bottom-up	 method	 tries	 to	 change	 the	 way	 people	
perceive	PrEP.	Anecdotal	 stories	may	prove	effective	at	 reducing	stigmatisation	as	 it	
provides	a	relatable	story.	The	NZAF	did	this	recently	with	HIV-positive	individuals	to	
remove	the	stigma	from	HIV	so	it	may	work	with	PrEP	too.		
The	 UNAIDS	 recommends	 that	 campaigns	 to	 reduce	 HIV	 stigmatisation	 are	
paired	 with	 other	 HIV	 policies, 688 	which	 is	 why	 the	 bottom-up	 and	 top-down	
approaches	to	reduce	PrEP	discrimination	are	part	of	PrEPared	Against	HIV:	2.0.	It	is	
possible	 that	 as	 PrEP	 gains	 more	 attention	 and	more	MSM	 use	 the	medication,	 the	
stigma	 associated	 with	 the	 drug	 will	 reduce.	 The	 MOH’s	 strategy	 to	 remove	 labels	
related	to	PrEP	and	PrEP-users	will	need	to	be	monitored	and	evaluated	to	ensure	it	is	
effective.	Similarly,	 the	strategy	may	need	refreshing	regularly	 to	match	 the	 levels	of	
stigmatisation	or	types	of	 labels	associated	with	PrEP.	The	ideas	discussed	above	are	
not	concrete	or	the	only	methods	to	reduce	discrimination	towards	PrEP-users.		






solution,	 but	 as	 with	 the	 majority	 of	 policy	 recommendations,	 the	 design	 of	 the	
programme	 is	 incomplete	 and	 there	 are	 risks. 689 	HIV	 prevention	 has	 remained	
relatively	unchanged	since	the	emergence	of	the	virus	in	the	1980s	with	the	promotion	
of	behavioural	methods.	This	 lack	of	 change	was	not	 an	 issue	because	up	until	now,	
there	was	no	option	 to	 try	new	prevention	 techniques.	But	now	policy	 advisors	 and	
health	 officials	 have	 the	 option	 to	make	 a	 change	 and	 switch	 up	New	Zealand’s	HIV	
prevention	 policies.	 Changing	 tack	 is	 not	 as	 simple	 as	 reallocating	 funding	 and	
designing	a	policy	because	new,	 innovative	options	can	be	riskier	 than	not	changing.	
As	 a	 result,	 it	 is	 common	practice	 for	 policy	 advisors	 to	 engage	 in	 risk	management	
strategies	 when	 developing	 and	 implementing	 policy.690	Risk	 management	 follows	













their	 predicted	harm,	 and	plans	 are	put	 in	place	 to	minimise	 the	negative	 outcomes	
should	these	risks	occur.691,	692	Unfortunately,	this	research	had	little	room	left	to	delve	
into	 risk	management	 for	 PrEPared	Against	HIV:	 2.0,	which	 is	 a	 disadvantage	 if	 this	
research	 is	 used	 for	 further	 development	 of	 policies.	 The	 policy	 did	 discuss	 briefly	
risks	 identified	 through	 the	 literature	 review,	 such	 as	 stigmatisation,	 risk	
compensation	 leading	 to	 increased	 STIs,	 and	 antiretroviral	 resistance.	 However,	
highlighting	these	risks	is	not	enough;	there	is	great	potential	that	risks	may	occur	that	
the	 researcher	 did	 not	 identify,	 which	 could	 result	 in	 the	 policy	 being	 poorly	
implemented.	 If	 there	 was	 room	 for	 more	 detail,	 it	 is	 recommended	 that	 PrEPared	
Against	HIV:	2.0	 is	 presented	 to	healthcare	professionals,	 policy	 advisors,	 politicians	
and	 other	 key	 stakeholders	 with	 an	 adequate	 risk	 management	 section.	 This	 risk	
analysis	should	include	techniques	to	plan	against	risks	and	stop	them	from	impacting	
further	 sections	 of	 the	 policy.	 The	 risk	management	 should	 include	 risks	 associated	
with	the	overall	policy,	not	just	with	using	the	medication.		
Exclusivity	
PrEPared	Against	HIV:	2.0	provides	a	 framework	 for	 the	 implementation	of	PrEP	 for	
MSM,	thus	excluding	all	other	potentially	at-risk	users.	Due	to	research	constraints,	it	
was	more	beneficial	 that	 the	 researcher	 focused	on	one	at-risk	population	group.	As	
discussed	earlier,	MSM	were	chosen	because	 they	make	up	 the	vast	majority	of	new	
HIV	diagnoses	each	year,	therefore	offering	the	greatest	potential	impact.	However,	the	
exclusivity	 of	 PrEPared	 Against	 HIV:	 2.0	 is	 undeniable	 and	 a	 clear	 limitation	 of	 the	
overall	 policy.	 The	 statistical	 profiles	 of	 high-risk	HIV	 users	 are	well-known	 but	 the	
most	 recent	 recommendation	 from	 the	WHO	 is	 that	 PrEP	 should	 be	 provided	 to	 all	
high-risk	 individuals,	 regardless	 of	 what	 cohort	 they	 fit	 into.693	The	 researcher	 is	









Citizen	 Participation,	 both	 the	 focus	 group	 and	 attitude	 scaling	 survey	 fit	 on	 the	








are	 collected.694 	Unfortunately,	 the	 cancellation	 of	 the	 focus	 group	 meant	 a	 lost	
opportunity	 to	 engage	with	 potential	 PrEP-users	 in	 a	meaningful	way.	 If	 there	were	





of	 PrEP	 for	 MSM	 in	 New	 Zealand	 as	 a	 HIV	 prevention	 technique.	 This	 policy	 was	
informed	 by	 Weiss’s	 problem-solving	 model,	 which	 utilises	 research	 to	 reduce	
uncertainty	 about	 a	 problem	 and	 inform	 the	 design	 of	 a	 policy	 recommendation.	 A	
Base	Case	was	presented	that	highlighted	that	the	current	HIV	prevention	methods	are	
not	working	 based	 on	 increasing	 infections	 and	 record	HIV	 diagnoses	 in	 2016.	 As	 a	











a	monetary	 investment	 from	 the	government	 and	who	 could	access	 the	drug.	 It	was	
recommended	that	the	policy	uses	option	B3,	partial	subsidisation	of	generic	PrEP	for	
high-risk	MSM.	This	would	allow	an	estimated	5,000	high-risk	MSM	to	access	partially	
funded	 PrEP.	 The	 government	 could	 be	 expected	 to	 pay	 between	 $1.8-3	 million	
annually	 for	 5,000	 prescriptions,	 and	 PrEP-users	 would	 pay	 $360-600	 for	 a	 year’s	
worth	 of	 PrEP.	 This	 investment	 does	 not	 include	 the	 additional	 costs	 to	 the	
government,	 including	 funding	 the	 other	 components	 of	 this	 policy	 and	 increased	
strain	 on	 the	 healthcare	 system.	 PrEPared	 Against	 HIV:	 2.0	 also	 favours	 strong	
educational	and	promotional	campaigns.	These	campaigns	will	help	promote	PrEP	as	
an	 HIV	 prevention	method,	 educate	 users	 about	 the	 drug,	 and	 provide	 current	 and	
potential	users	with	resources	to	guide	PrEP	use.	The	promotional	campaigns	will	also	
serve	to	remove	any	negative	labels	or	stigma	associated	with	PrEP	and	PrEP-users.		
As	with	 any	 policy,	 there	 are	 a	 number	 of	 limitations	with	 PrEPared	 Against	
HIV:	 2.0.	 Firstly,	 no	 risk	 analysis	 was	 completed	 for	 the	 policy.	 This	 would	 have	
identified	potential	risks	and	the	suitable	actions	that	could	be	taken	to	minimise	these	











in	PrEP	among	other	at-risk	 individuals	was	to	 increase,	 there	 is	potential	 to	expand	
PrEPared	Against	HIV:	2.0.	Finally,	the	cancellation	of	the	focus	group	meant	there	was	
a	missed	opportunity	 for	 community	engagement	 for	 the	policy.	Consulting	with	 the	
MSM	and	HIV	 experts	 in	 a	 focus	 group	 setting	would	have	 provided	 the	 policy	with	
grassroots	insights	and	offered	information	about	HIV	prevention	that	the	researcher	
may	not	have	thought	of.		
Regardless	 of	 the	 limitations,	 PrEPared	Against	HIV:	 2.0	 is	 an	 evidence-based	
policy	 that	 includes	 insights	 from	 potential	 PrEP-users	 and	 HIV	 experts	 through	
Weiss’s	 problem-solving	 model.	 The	 primary	 data	 collected	 from	 the	 survey	 and	
interviews	was	complimented	by	document	analysis.	PrEPared	Against	HIV:	2.0	is	not	
complete,	but	 it	highlights	one	way	that	PrEP	could	be	 implemented	 in	New	Zealand	
using	the	MOH	and	NZAF	with	support	from	other	key	stakeholders.	While	this	policy	
is	 theoretical,	 there	 is	 potential	 that	 it	 could	 aid	 future	 PrEP	 policies	 that	 are	
established	in	New	Zealand,	such	as	the	one	currently	being	developed	by	the	MOH.	At	
the	 very	 least,	 PrEPared	Against	HIV:	 2.0	proves	 that	 there	 is	 a	 very	 real	 need	 for	 a	
change	 in	New	Zealand’s	HIV	prevention	methods	 and	PrEP	 is	 a	worthwhile	 option.	
























HIV	as	an	 illness,	analysed	trends	of	HIV	 infections	 in	New	Zealand	among	men	who	
have	sex	with	men	(MSM),	and	introduced	PrEP	as	a	medication.	Chapter	2	provided	
an	 in-depth	 literature	 review	 focusing	 on	 three	 key	 topics:	 the	 first-generation	
randomised	 controlled	 trials	 (RCTs)	 for	 PrEP,	 PrEP	providers’	 attitudes	 towards	 the	
new	 drug,	 and	 the	 opinions	 of	 MSM	who	 could	 use	 PrEP.	 Chapters	 1	 and	 2	 clearly	
showed	that	while	PrEP	could	have	a	positive	 impact	on	HIV	prevention	when	taken	
correctly,	 the	 drug	 is	 not	without	 its	 complications.	 For	 example,	 some	 complexities	
are	potential	antiretroviral	resistance,	side	effects,	cost,	and	adherence.	The	first	 two	
chapters	 provided	 the	 necessary	 background	 information	 for	 Chapter	 3	 where	 the	
research	 design,	 questions,	 and	 aims	 were	 all	 discussed.	 Chapter	 3	 also	 introduced	
Carol	 H.	Weiss’s	 problem-solving	model,	 which	 uses	 research	 to	 reduce	 uncertainty	
regarding	 a	 particular	 problem	 that	 subsequently	 informs	 a	 solution.	 This	 research	
asked	if	MSM	from	Canterbury	felt	that	PrEP	has	a	place	in	New	Zealand’s	public	health	
system	and	Chapter	4	answered	 this	question.	100%	of	participants	 from	 the	online	
survey	agreed	that	PrEP	is	a	worthwhile	HIV	prevention	method	for	MSM,	and	100%	
agreed	 that	 PrEP	 is	 a	 good	 method	 to	 reduce	 the	 chance	 of	 HIV	 transmission.	 The	
research	 also	 questioned	 how	 an	 effective	 policy	 could	 be	 designed	 for	 PrEP	 that	
minimises	the	complexities	linked	to	the	medication	cited	in	Chapters	1	and	2.	Chapter	
5	 presented	 an	 evidence-based,	 grassroots	 policy	 for	 PrEP	 for	MSM	 in	New	Zealand	
called	 PrEPared	 Against	 HIV:	 2.0.	 This	 policy	 tackles	 issues	 such	 as	 PrEP	 providers,	
funding	options,	and	the	stigmatisation	of	PrEP.			























was	 initially	 noticed,	 AIDS	 was	 drastically	 overrepresented	 in	 groups	 that	 were	
“politically	disadvantaged,	 socially	marginalized,	 and	partially	hidden.”701,	702	Gay	and	



































HIV	 by	 2025,	 which	 includes	 the	 implementation	 of	 PrEP.708	Prime	 Minister	 and	
National	party	leader	Bill	English	has	not	made	any	open	statements	about	PrEP,	but	
was	briefed	about	the	demonstration	project	in	Auckland	while	attending	the	Big	Gay	
Out	 in	 February	 2017.	 When	 asked	 about	 the	 National	 government’s	 lack	 of	
prioritisation	 of	 HIV	 funding	 for	 treatment	 and	 prevention,	 English	 said,	 “If	we	 saw	
some	 significant	 uplift	 in	 some	 of	 these	 debilitating	 health	 problems,	 then	 I	 would	
expect	 that	 the	 Minister	 of	 Health	 and	 the	 Ministry	 are	 answering	 questions	 about	
what	action	can	be	taken.”709	The	researcher	notes	that	after	the	Prime	Minister	made	
these	 comments,	 the	 AIDS	 Epidemiology	 Group	 confirmed	 that	 HIV	 rates	 are	
increasing	and	the	Ministry	of	Health	(MOH)	has	begun	researching	a	policy	for	PrEP.	
In	 August	 2017,	 the	 Minister	 of	 Health	 Dr	 Jonathan	 Coleman	 said	 that	 National	





to	what	 the	 current	 government	 budgeted.	 The	 support	 from	 the	 Labour	 and	Green	
parties	 is	 further	 justified	 given	 the	 recent	 cuts	 to	 the	 Gay	 Auckland	 Periodic	 Sex	
Survey	 (GAPSS)	 and	 Gay	 men’s	 Online	 Sex	 Survey	 (GOSS)	 under	 the	 National	
government.	However,	 the	promise	of	 funding	certain	medication	 is	not	new	to	New	
Zealand	politics,	 as	 these	promises	are	used	 to	potentially	 sway	voters	who	have	an	
interest	 in	 a	 health	 issue.	 In	 2008,	 former	 Prime	 Minister	 John	 Key,	 who	 was	 the	
Leader	of	the	Opposition	at	the	time,	made	a	promise	to	fund	breast	cancer	treatment	





the	 GAPSS/GOSS	 studies,	 the	 absence	 of	 a	 national	 HIV	 strategy	 since	 2003,712	and	
until	very	recently,	the	CD4	threshold	for	antiretroviral	therapy	(ART)	for	HIV-positive	
people.	 Mark	 Fisher,	 the	 Director	 of	 Body	 Positive,	 argues	 that	 HIV	 has	 limited	
exposure	in	the	media	and	from	the	ministries,	which	has	lead	to	an	attitude	that	HIV	
is	“normalised”	and	a	“non-issue.”713	It	is	highly	likely	that	HIV	will	remain	politicised	

















stakeholders	 and	 key	 factors:	 the	 results	 of	 the	 2017	 general	 election;	 the	 MOH’s	
upcoming	PrEP	policy;	PHARMAC’s	decision	regarding	subsidisation	of	PrEP;	and	the	
success	 of	 PrEP	 policies	 overseas.	 At	 this	 stage,	 it	 seems	 that	 HIV	 prevention	 and	
treatment	will	remain	politicised,	just	as	it	has	always	been.		
Each	to	their	own	interpretation	
When	 it	 comes	 to	 incidences	 of	 infection,	 the	 data	 cannot	 be	 taken	 at	 face	 value.715	




HIV	 infections	 were	 increasing	 but	 argued	 that	 the	 increased	 testing	 meant	 it	 was	
inevitable	 that	 there	 would	 be	 more	 positive	 results	 from	 individuals	 who	 had	 not	
been	 tested	 before.717	Kelly	 said	 that	 the	 increased	 testing	 would	 uncover	 a	 large	
number	 of	 infections	 quickly	 and	 then	 plateau	 out	 because	 HIV	 rates	 were	 not	
increasing	 overall.	 However,	 an	 HIV	 researcher	 argued	 that	 Kelly’s	 prediction	 of	 a	




in	 HIV	 infections.719	Infectious	 disease	 doctor	 Nigel	 Raymond	 agreed	 with	 the	 HIV	
researcher,	 stating	 that	 the	 increase	 in	 infection	 rates	 is	 a	 combination	 of	 increased	
testing	 uncovering	 old	 infections	 and	 lower	 condom	 use	 contributing	 to	 new	
infections. 720 	Similarly,	 the	 Director	 of	 Body	 Positive	 attributed	 the	 increased	
incidence	of	HIV	to	new	infections	based	on	high	CD4	cell	counts	reported	when	the	
virus	 was	 diagnosed. 721 	These	 five	 HIV	 experts	 who	 come	 from	 very	 different	
backgrounds	all	had	differing	 interpretations	of	HIV	trends	 in	New	Zealand.	This	has	


















results	 and	 their	 experience	 of	 the	 topic.	 By	 talking	 to	 multiple	 interviewees	 from	
different	 sectors,	 the	 researcher	 was	 able	 to	 gain	 a	 better	 understanding	 of	 how	
different	 interpretations	 of	 the	 same	 data	 can	 be.	 Furthermore,	 it	 shows	 how	 data	





PrEP	 nationally	 and	 internationally.	 Since	 the	 beginning	 of	 this	 research,	 huge	












the	MOH	was	 formulating	a	policy	 for	PrEP	 in	 late-March	2017.	PrEP	was	constantly	
evolving,	both	nationally	and	internationally,	which	left	the	researcher	with	the	never-





There	 is	 no	 doubt	 that	 there	will	 be	 implications	 associated	with	 using	 PrEP	 in	 the	























at-risk	 individuals	 who	 wish	 to	 use	 PrEP	 without	 an	 official	 health	 policy	 will	 be	
required	to	parallel	import	the	medication	regularly.	While	this	is	what	current	PrEP-
users	 are	 doing,	 as	 PrEP	 gains	 more	 attention,	 there	 is	 potential	 for	 considerable	
numbers	of	at-risk	 individuals	 to	use	 this	method.	Parallel	 importing	 is	 legal,	 though	
there	is	no	guarantee	that	the	medication	sent	from	overseas	is	safe,	which	is	a	risk	for	
both	 doctors	who	 authorise	 the	 prescription	 and	 PrEP-users.726	In	 addition,	 doctors	
may	be	 required	 to	provide	adequate	healthcare	 for	PrEP	 importers	without	 clinical	
guidelines	 that	 would	 be	 required	 for	 a	 PrEP	 policy.	 Without	 ministry	 support	 for	
PrEP,	healthcare	professionals	may	be	put	under	unnecessary	pressure,	which	could	
negatively	 impact	 the	 PrEP-users.	 Furthermore,	 the	 NZAF	 and	 other	 similar	








will	perform	in	a	real-world	situation	free	 from	the	control	of	a	 trial.727,	728,	729	This	 is	
known	as	the	efficacy-effectiveness	gap,	which	was	discussed	in	Chapter	2.	However,	if	
the	 current	 pilot	 studies	 and	 demonstration	 projects	 show	 PrEP	 reduces	 HIV	
acquisition	 without	 the	 controlled	 circumstances	 of	 trials,	 PrEP	 should	 become	












of	 new	 HIV	 infections730	and	 HIV	 affects	 more	 than	 15%	 of	 the	 total	 population	 in	
Swaziland,	 Botswana,	 Lesotho,	 South	 Africa,	 Zimbabwe,	 and	 Namibia.731	PrEP	 could	
have	 a	 significant	 impact	 on	 the	 HIV	 epidemic	 in	 third-world	 countries.	 This	
impression	 could	 be	 especially	 noticeable	 in	 nations	 where	 condom	 use	 is	 low,	 as	
individuals	will	have	a	layer	of	protection	that	was	not	available	before.	Furthermore,	









Therefore,	 if	 the	 efficacy-effectiveness	 gap	 has	 limited	 influence	 on	 PrEP,	 there	 is	 a	




prevention	kit.	When	 interviewed,	 Sean	Kelly	 and	Akira	Le	Fevre	 said	 sex	 education	
that	 incorporates	 HIV	 and	 LGBTI	 topics	 is	 currently	 limited	 in	 New	 Zealand.	 Many	
“principals	and	school	board	members”	do	not	want	to	include	HIV	and	LGBTI	subjects	
as	 part	 of	 their	 sexual	 education	 classes. 732 	These	 decisions	 may	 encourage	
stigmatisation	of	HIV	and	can	negatively	impact	students	who	would	benefit	from	HIV	
education.	 Without	 teaching	 future	 generations	 about	 safe	 sex	 and	 HIV	 prevention,	
many	teenagers	may	make	unwise	decisions	or	be	under	the	impression	that	HIV	is	not	
an	 issue	 anymore.733	It	 is	 recommended	 that	 if	 PrEP	 becomes	 a	 mainstream	 HIV	
prevention	method	 it	 is	added	to	 the	curriculum	for	sexual	health	classes	 in	schools,	
just	as	condoms	and	oral	 contraceptive	methods	currently	are.	This	will	help	ensure	
that	 young,	 impressionable	 New	 Zealanders	 have	 the	 knowledge	 to	 make	 the	 right	
decisions	 based	 on	 their	 behaviour.	 Having	 correct	 information	 about	 PrEP,	 HIV	















Research	 on	 PrEP	 is	 only	 just	 beginning,	 as	 academics,	 scientists,	 and	 policymakers	
alike	have	 the	opportunity	 to	 explore	 the	 impact	of	 this	new	biomedical	 technology.	
This	thesis	has	only	skimmed	the	surface	in	terms	of	PrEP-related	topics,	particularly	
regarding	attitudes	towards	the	medication	and	its	potential	as	a	health	policy	in	New	









Medicalisation	 emerged	 slowly	 in	 the	 1940s	 as	 a	 political-sociological	 phenomenon	
influenced	 by	 psychiatry	 and	 public	 health. 734 	Medicalisation,	 as	 an	 exploratory	
framework,	 explains	 the	 expansion	 of	 medicine	 where	 problems	 that	 were	 once	
considered	“moral,	social,	or	legal”	became	medicalised.735	Since	1985,	medicalisation	
shifted	into	biomedicalisation.	This	transition	was	greatly	influenced	by	the	launch	of	
the	 Human	 Genome	 Project	 in	 1990,	 which	 aimed	 to	 map	 the	 genetic	 make-up	 of	
human	 beings.	 Biomedicalisation	 theorises	 the	 use	 of	 technology	 and	 science	 in	 the	
spheres	of	health	and	medicine	to	improve	the	current	and	future	lives	of	humans.736	
Examples	 of	 biomedicalisation	 include	 plastic	 and	 cosmetic	 surgery,	 personalised	
medicine,	anti-love	medicine	to	cure	 ‘bad’	 loves,737	and	identifying	health	risks	at	 the	
gene,	 molecule,	 and	 protein	 level.	 Thus,	 biomedicalisation	 provides	 a	 scientific,	
technological,	and	medical	tool	that	can	correct	what	is	‘wrong’	or	not	good	enough.		
PrEP	fits	within	the	lens	of	biomedicalisation,	as	it	uses	a	prophylactic	to	reduce	
the	 risk	 of	 HIV	 acquisition,	 thus	 improving	 the	 users’	 lives.	 However,	 the	
biomedicalisation	 of	 HIV	 prevention	 has	 been	 continually	 cited	 as	 a	 problem	 with	
PrEP,	as	some	doctors	believe	that	non-biomedical	HIV	prevention	methods	are	more	
effective	 and	 safer	 than	 PrEP.738,	739	Furthermore,	 many	 doctors	 agreed	 that	 giving	




















of	 unwanted	 health	 problems	 have	 been	 medicalised	 long	 before	 PrEP.	 Dickson’s	
argument	is	invalid,	given	that	the	oral	contraceptive	pill	for	women	is	a	clear	example	
of	 medicalised	 sex	 that	 enables	 healthy	 women	 to	 take	 a	 medication	 to	 prevent	 an	




wearing	 long	 sleeves, 749 	or	 pay	 to	 use	 PrEP,	 a	 biomedical	 prevention	 method.	
Furthermore,	 the	 argument	 against	 prescribing	 healthy	 individuals	with	 toxic	 drugs	
can	also	be	compared	to	antimalarials,	as	doxycycline	is	also	a	strong	medication	with	
potentially	 long-term	 side	 effects.750	The	 decision	 to	 use	 biomedicalised	 prevention	
interventions	is	weighed	against	the	option	to	take	drugs	rather	than	contract	a	nasty	
illness,751	and	in	the	case	of	HIV,	a	permanent	infection.		
	 There	 is	 no	 doubt	 that	 the	 arguments	 against	 biomedicalisation	 of	 HIV	
prevention	have	merit,	but	 it	cannot	be	said	 that	PrEP	 is	 the	 first	drug	 to	medicalise	
sex	 or	 be	 given	 to	 healthy	 individuals.	 Due	 to	 the	 empirical	 focus	 of	 this	 research	
driven	 by	 Weiss’s	 problem-solving	 model	 there	 was	 little	 room	 to	 use	
biomedicalisation	 to	 examine	 PrEP,	 although	 it	 is	 clear	 that	 PrEP	 fits	 within	 this	
academic	 theory.	 Furthermore,	 theories	 are	 useful	 for	 explaining	 why	 things	 have	
happened	 in	 the	 past,	 discussing	 current	 trends,	 and	making	 assumptions	 about	 the	

























MSM	 are	 disproportionately	 represented	 in	 the	 HIV	 epidemic	 nationally	 and	
internationally,	 there	 are	many	 at-risk	 groups	 and	 individuals	 that	 do	 not	 fit	within	
this	 category	 that	 could	 benefit	 from	 PrEP.	 Due	 to	 the	 focus	 on	 MSM,	 little	 was	
discovered	about	 the	proportion	of	other	at-risk	 individuals,	 but	 it	 is	 important	 that	




of	 PrEP	 against	 HIV.	 Furthermore,	 if	 non-MSM	 use	 PrEP,	 they	 may	 need	 to	 receive	
different	 types	 of	 healthcare	 when	 they	 visit	 their	 doctor.	 Similarly,	 non-MSM	






an	overall	PrEP	policy	 that	are	unique	to	 these	non-MSM.	Future	research	 into	 these	






Policy	 case	 studies	 allow	 the	 researcher	 to	 become	 an	 expert	 on	 a	 policy	 topic.	 The	
information	gathered	in	a	policy	case	study	can	encourage	discussion	and	be	used	to	
help	 make	 decisions	 for	 the	 future	 policies	 in	 development.753	For	 example,	 case	
studies	may	be	used	 to	 explore	why	 a	policy	was	 so	 successful.	As	 a	 contrast,	 failed	
policies	 can	also	be	 analysed	by	extracting	valuable	 lessons	because	policies	 that	do	
not	succeed	are	often	just	as	helpful	for	policymakers.	It	is	important	that	the	MOH	and	
other	key	stakeholders	monitor	 the	current	and	 future	PrEP	demonstration	projects,	
pilot	 studies,	 and	 health	 policies	 worldwide.	 Observing	 what	 methods	 are	 used	
















intimate	 behaviour	 of	 individuals.	 The	 medical	 evidence	 of	 PrEP’s	 efficacy	 is	 clear:	
when	 taken	 once	 daily,	 PrEP	 is	 92%	 effective	 of	 preventing	 HIV	 transmission.	
However,	 the	social,	economic,	and	emotional	aspects	of	PrEP	are	more	complicated.	
Branded	 PrEP,	 Truvada,	 is	 currently	 too	 expensive	 at	 around	 $900-1,200	 per	




resistant	 to	 the	 active	 components	 in	PrEP.	PrEP-users	 are	 required	 to	have	 regular	
HIV	 and	STIs	 tests,	 as	well	 as	monitoring	of	 their	 kidney	 function	 and	bone	density,	
which	may	be	a	hassle.	Unlike	condoms,	PrEP	does	not	prevent	against	STIs,	so	there	is	
a	chance	that	STI	rates	may	increase	among	PrEP-users	if	they	do	not	continue	to	use	
condoms.	 Furthermore,	 PrEP-users	 currently	 face	 stigmatisation	 for	 using	 the	 drug	
and	are	often	labelled	as	promiscuous.		
	 Given	 the	 complexities	 associated	 with	 PrEP,	 and	 slow	 uptake	 of	 the	 drug	
overseas,	 this	 thesis	 used	 Weiss’s	 problem-solving	 model	 to	 answer	 the	 following	
questions:		do	MSM	from	Canterbury	feel	that	PrEP	has	a	place	in	New	Zealand’s	public	
health	system,	and	how	could	a	policy	be	developed	to	minimise	the	difficulties	faced	
overseas?	 It	was	 important	 that	 the	 first	research	question	was	answered	before	the	
second	because	if	Canterbury	MSM	did	not	see	a	role	for	PrEP	in	HIV	prevention	then	
there	might	 have	 been	 no	 need	 for	 a	 policy.	 However,	 the	 results	 from	 the	 attitude	
scaling	survey	of	Canterbury	MSM	found	undeniable	support	for	PrEP.	While	attitudes	
towards	 certain	 aspects	 of	 PrEP	 varied,	 all	 of	 the	 participants	 believe	 that	 PrEP	 is	 a	
















	 Therefore,	 it	 can	be	 seen	 that	both	 research	questions	were	 answered	 in	 this	
thesis	through	the	multiple,	mixed-methods	design:	MSM	from	Canterbury	do	support	
the	 use	 of	 PrEP	 for	HIV	 prevention,	 and	 a	 policy	 can	 be	 developed	 that	 attempts	 to	
minimise	 the	 issues	 faced	 overseas	 with	 other	 PrEP	 programmes.	 Whether	 the	
government	 and	MOH	 decide	 to	 also	 support	 PrEP	 is	 up	 to	 them,	 and	 as	 discussed	
earlier	 in	 the	 chapter,	 it	 is	 very	 possible	 that	 this	 decision	 will	 be	 impacted	 by	 the	
politicisation	 of	 HIV.	 However,	 it	 is	 important	 to	 put	 politics	 aside	 and	 look	 at	 the	
bigger	 picture:	 PrEP,	 when	 implemented	 correctly	 and	 successfully,	 can	 offer	
extremely	high	levels	of	protection	against	HIV.	As	one	sexual	health	doctor	argues,		
	




It	 is	 time	 to	 take	 a	 risk	 by	 trying	 something	 new759	and	 embrace	 an	 innovative,	
strategic,	 and	 forward-thinking	 policy	 for	 HIV	 prevention.	 PrEP	 is	 undoubtedly	 an	
investment	for	the	future,	which	could	help	eradicate	all	 future	HIV	diagnoses	within	

































































Pre-exposure	prophylaxis	(PrEP)	 is	a	drug	given	to	 individuals	 that	are	HIV-negative	
but	are	at	a	high	risk	of	contracting	HIV.	PrEP	is	a	once-daily,	oral	pill	and	when	taken	




other	 men	 (MSM)/gay	 and	 bisexual	 males.	 It	 has	 also	 been	 recommended	 for	




















 -	 Strongly	 agree				  -	 Agree	 			 -	 Disagree				  -	 Strongly	 disagree	 	 		 	 You	 are	 not	
required	to	explain	or	justify	your	answer.	There	is	no	right	or	wrong	answer.	
	
The	 results	 from	 this	 survey	 are	 anonymous,	 but	will	 be	 used	 for	 data	 analysis	 in	 a	
University	 of	 Canterbury	Master's	 thesis.	 Once	 you	 have	 submitted	 your	 answers	 to	
this	 survey,	 you	 cannot	 remove	 your	 results.	 If	 you	 wish	 to	 stop	 the	 survey	 at	 any	
point,	you	can	exit	using	the	tab	on	your	Internet	browser	and	your	answers	will	not	













































































































































































If	 you	 are	 interested	 in	 participating	 in	 the	 Christchurch	 focus	 group	 about	 PrEP	 in	
New	 Zealand	 for	MSM/gay	 and	 bisexual	men,	 feel	 free	 to	 leave	 your	 contact	 details	






If	 you	 have	 any	 questions,	 comments	 or	 suggestions	 regarding	 this	 survey,	 pre-
exposure	prophylaxis	or	my	overall	research,	please	email	the	researcher	here.			Your	
questions	and	comments	will	remain	confidential	and	your	answers	to	the	survey	will	
remain	anonymous.	 	 	This	 research	project	has	been	approved	by	 the	Human	Ethics	
Committee	 of	 the	 University	 of	 Canterbury.	 You	 are	 also	 welcome	 to	 contact	 my	
supervisor,	 Dr.	 Amy	 Fletcher,	 if	 you	 have	 any	 questions	 or	 concerns	 about	 this	
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To whom it may concern, 
RE: Invitation to Participate  
 
HIV in the 21st century: Pandemic or apathetic? MSM tertiary students, HIV, and pre-
exposure prophylaxis (PrEP) 
 
Tēnā koe,  
 
I am a Master’s thesis student studying Political Science at the University of Canterbury. 
Currently I am conducting research into pre-exposure prophylaxis (PrEP), a once-daily pill 
given to individuals that are at a high risk of contracting HIV. As you may be aware, men 
who have sex with men (MSM)/gay and bisexual men are one of the recommended groups 
that use PrEP to decrease their chances of an HIV infection. My research is policy-based, 
as I would like to provide a policy recommendation for how PrEP could be implemented for 
MSM/gay and bisexual men in New Zealand. 
 
I am seeking participants for my research for one-on-one interviews; I wish to speak with 
you along side other experts in the HIV/AIDS field in New Zealand. I have three main aims 
for these interviews:  
- To gain an understanding of the history of HIV/AIDS in New Zealand; 
- To get more context regarding current HIV/AIDS rates in New Zealand; 
- And to hear opinions about how PrEP could be effectively implemented for gay and 
bisexual men/MSM in New Zealand. 
If you chose to take part in this study, your involvement in the project will be an interview 
conducted in Christchurch or Wellington, or over the phone or on Skype. The interviews 
should take between twenty and sixty minutes. Interviews will be audio recorded and 
participants will be provided with an interview transcription within five days of the interview 
to approve.  
 
Participation in the interview is voluntary and you have the right to withdraw at any stage 
without penalty. You are welcome to interview on or off the record, but the presumption is 
that all identities will remain confidential unless a request is made for the participant to be 
identified. Following the interview, you continue to own the data generated from our 
interaction. You may choose to withdraw your raw data at any time, without penalty. Please 
be assured that all raw data collected from the interview will be kept on a password-
protected private laptop and the University Server. If you wish any record of your 
involvement to be deleted, or immediately returned to you, this will always be possible. 
However, after the researcher has analysed all the data to draw conclusions and the 
Master’s thesis is published on the University of Canterbury Library website and made 
public, the researcher’s use of the data will be impossible to withdraw.  
 
This project is being carried out as a requirement for the Master’s of Arts in Political 
Science under the supervision of Dr. Amy Fletcher. Amy can be contacted on 
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amy.fletcher@canterbury.ac.nz and will be happy to discuss any concerns you may have 
about the project. 
 
This project has been reviewed and approved by the University of Canterbury Human 
Ethics Committee, and participants should address any complaints to The Chair, Human 
Ethics Committee, University of Canterbury, Private Bag 4800, Christchurch (human-
ethics@canterbury.ac.nz).   
 
If you are willing to be interviewed please complete the consent form attached and return to 
alice.hartley@pg.canterbury.ac.nz or send to 
Alice Hartley c/o Department of Political Science and International Relations 
College of Arts 




I look forward to hearing from you. 
 







University of Canterbury 
Department: Political Science 





RE: Project Consent Form 
 
HIV in the 21st century: Epidemic or endemic? MSM tertiary students, HIV, and pre-
exposure prophylaxis (PrEP) 
 
I have read and understood the description of the above-named project. On this basis I 
agree to participate as a subject in the project.  
I understood that my participation remains confidential to protect my identity unless I 
request to be identifiable.  
I consent to the publication of the results of the project with the understanding that if 
requested the information will remain confidential and my anonymity will be preserved.  
I understand that I may at any time withdraw from the project, including withdrawal of any 
information I have provided, without penalty. Withdrawal of participation will include the 
withdrawal of any information I have provided should this remain practically achievable. 
I understand that all data collected for the study will be kept in locked and secure facilities 
and /or in password protected electronic form and will be destroy after five years.  
I understand that the interviews will be audio recorded, which I will be given the opportunity 
to review and revise within five days from the interview date. 
I understand that I can contact the researcher or Amy Fletcher 
(amy.fletcher@canterbury.ac.nz) for further information.  
 
Please tick one or more of the following 
☐ I agree that I am to be identified and my notes of this interview will be on the  
record _______________ (signature required) 
☐  I am authorised to speak on behalf of my institution 
_______________ (signature required) 
Please tick one or more of the following 
☐ After 5 years, I would like the raw data destroyed  
☐  I would like a summary of any output produced from this research.  
(email ______________________________) 
 
NAME (please print): ......................................................................  
 
Signature: ______________________________ Date: __________________________	
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